<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002109.pub4" GROUP_ID="ARI" ID="838301022015421747" MERGED_FROM="" MODIFIED="2014-10-07 04:19:35 +0100" MODIFIED_BY="Liz Dooley" REVIEW_NO="A012" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2014-10-07 04:19:35 +0100" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2010-07-26 14:28:31 +1000" MODIFIED_BY="Liz Dooley">Antibiotics for community-acquired pneumonia in adult outpatients</TITLE>
<CONTACT MODIFIED="2014-10-07 04:19:35 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="79267652133578674999110511192611" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Smita</FIRST_NAME><LAST_NAME>Pakhale</LAST_NAME><POSITION>Assistant Professor and Associate Scientist</POSITION><EMAIL_1>spakhale@ohri.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>The Ottawa Hospital, Ottawa Hospital Research Institute and the University of Ottawa</ORGANISATION><ADDRESS_1>501 Smyth Road</ADDRESS_1><CITY>Ottawa</CITY><ZIP>K1H 8L6</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>613-737-8899 ex. 79428</PHONE_1><FAX_1>613-739-6807</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-10-07 04:19:35 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="79267652133578674999110511192611" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Smita</FIRST_NAME><LAST_NAME>Pakhale</LAST_NAME><POSITION>Assistant Professor and Associate Scientist</POSITION><EMAIL_1>spakhale@ohri.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>The Ottawa Hospital, Ottawa Hospital Research Institute and the University of Ottawa</ORGANISATION><ADDRESS_1>501 Smyth Road</ADDRESS_1><CITY>Ottawa</CITY><ZIP>K1H 8L6</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>613-737-8899 ex. 79428</PHONE_1><FAX_1>613-739-6807</FAX_1></ADDRESS></PERSON><PERSON ID="z1210190425088864430133412197591" ROLE="AUTHOR"><FIRST_NAME>Sunita</FIRST_NAME><LAST_NAME>Mulpuru</LAST_NAME><SUFFIX>MD, FRCPC</SUFFIX><POSITION>Clinical Scholar</POSITION><EMAIL_1>smulpuru@toh.on.ca</EMAIL_1><EMAIL_2>smulpuru@Ottawahospital.on.ca</EMAIL_2><ADDRESS><DEPARTMENT>Division of Respirology</DEPARTMENT><ORGANISATION>The Ottawa Hospital, General Campus</ORGANISATION><ADDRESS_1>501 Smyth Road</ADDRESS_1><ADDRESS_2>Box 211</ADDRESS_2><CITY>Ottawa</CITY><ZIP>K1H 8L6</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 613 737 8899 ext 73994</PHONE_1><FAX_1>+1 613 737 8537</FAX_1></ADDRESS></PERSON><PERSON ID="8543" ROLE="AUTHOR"><FIRST_NAME>Theo</FIRST_NAME><MIDDLE_INITIALS>JM</MIDDLE_INITIALS><LAST_NAME>Verheij</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Director</POSITION><EMAIL_1>t.j.m.verheij@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 30 253 8188</PHONE_1></ADDRESS></PERSON><PERSON ID="12289" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Michael</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Kochen</LAST_NAME><SUFFIX>MD, MPH, PhD, FRCGP</SUFFIX><POSITION>Emeritus Professor of General Practice/Family Medicine</POSITION><EMAIL_1>mkochen@gwdg.de</EMAIL_1><URL>www.allgemeinmedizin.med.uni-goettingen.de</URL><ADDRESS><DEPARTMENT>Department of General Practice/Family Medicine</DEPARTMENT><ORGANISATION>University of Göttingen Medical School</ORGANISATION><ADDRESS_1>Ludwigstrasse 37</ADDRESS_1><CITY>Freiburg</CITY><ZIP>D-79104</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 7611 513 566</PHONE_1><FAX_1>+49 1513 567</FAX_1></ADDRESS></PERSON><PERSON ID="69155329214877133743120328025730" ROLE="AUTHOR"><FIRST_NAME>Gernot</FIRST_NAME><MIDDLE_INITIALS>GU</MIDDLE_INITIALS><LAST_NAME>Rohde</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Associate Professor for Respiratory Medicine</POSITION><EMAIL_1>gernot.rohde@ruhr-uni-bochum.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Respiratory Medicine</DEPARTMENT><ORGANISATION>Maastricht University Medical Center</ORGANISATION><ADDRESS_1>PO box 5800</ADDRESS_1><CITY>Maastricht</CITY><ZIP>6202 AZ</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 43 387 5047</PHONE_1><FAX_1>+31 43 387 5051</FAX_1></ADDRESS></PERSON><PERSON ID="16954" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lise</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Bjerre</LAST_NAME><SUFFIX>MD, PhD, MCFP</SUFFIX><POSITION>Clinician-Investigator and Assistant Professor</POSITION><EMAIL_1>lbjerre@bruyere.org</EMAIL_1><EMAIL_2>lbjerre@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Family Medicine, Bruyere Research Institute</DEPARTMENT><ORGANISATION>University of Ottawa</ORGANISATION><ADDRESS_1>43 Bruyere St</ADDRESS_1><ADDRESS_2>Room 369Y</ADDRESS_2><CITY>Ottawa</CITY><ZIP>K1N 5C8</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>(613) 562-6262</PHONE_1><PHONE_2>Ext. 2926</PHONE_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-04-16 11:02:30 +1000" MODIFIED_BY="Liz Dooley">
<UP_TO_DATE>
<DATE DAY="28" MONTH="3" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="3" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="3" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-07-15 07:31:48 +1000" MODIFIED_BY="Liz  Dooley">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-07-15 07:31:48 +1000" MODIFIED_BY="Liz  Dooley">
<DATE DAY="28" MONTH="3" YEAR="2014"/>
<DESCRIPTION>
<P>Three new review authors joined the original team to update this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-07-15 07:31:41 +1000" MODIFIED_BY="Liz  Dooley">
<DATE DAY="28" MONTH="3" YEAR="2014"/>
<DESCRIPTION>
<P>Searches updated. We included five new trials (<LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>; <LINK REF="STD-Oldach-2013" TYPE="STUDY">Oldach 2013</LINK>; <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK>; <LINK REF="STD-Vacarezza-2010" TYPE="STUDY">Vacarezza 2010</LINK>; <LINK REF="STD-van-Rensburg-2010a" TYPE="STUDY">van Rensburg 2010a</LINK>; <LINK REF="STD-van-Rensburg-2010b" TYPE="STUDY">van Rensburg 2010b</LINK>) and excluded 43 new trials (<LINK REF="STD-Alcacer-1993" TYPE="STUDY">Alcacer 1993</LINK>; <LINK REF="STD-Arifin-2013" TYPE="STUDY">Arifin 2013</LINK>; <LINK REF="STD-Bai-2014" TYPE="STUDY">Bai 2014</LINK>; <LINK REF="STD-Blasi-2013" TYPE="STUDY">Blasi 2013</LINK>; <LINK REF="STD-Block-2006" TYPE="STUDY">Block 2006</LINK>; <LINK REF="STD-Bothra-2012" TYPE="STUDY">Bothra 2012</LINK>; <LINK REF="STD-Brittain_x002d_Long-2011" TYPE="STUDY">Brittain-Long 2011</LINK>; <LINK REF="STD-Casapao-2012" TYPE="STUDY">Casapao 2012</LINK>; <LINK REF="STD-Critchley-2010" TYPE="STUDY">Critchley 2010</LINK>; <LINK REF="STD-Daniel-1999a" TYPE="STUDY">Daniel 1999a</LINK>; <LINK REF="STD-Daniel-1999b" TYPE="STUDY">Daniel 1999b</LINK>; <LINK REF="STD-Dartois-2013" TYPE="STUDY">Dartois 2013</LINK>; <LINK REF="STD-Esposito-2012" TYPE="STUDY">Esposito 2012</LINK>; <LINK REF="STD-File-2012a" TYPE="STUDY">File 2012a</LINK>; <LINK REF="STD-File-2012b" TYPE="STUDY">File 2012b</LINK>; <LINK REF="STD-Fogarty-2004" TYPE="STUDY">Fogarty 2004</LINK>; <LINK REF="STD-Ghebremedhin-2012" TYPE="STUDY">Ghebremedhin 2012</LINK>; <LINK REF="STD-Kohno-2013" TYPE="STUDY">Kohno 2013</LINK>; <LINK REF="STD-Lagler-2012" TYPE="STUDY">Lagler 2012</LINK>; <LINK REF="STD-Lee-2012" TYPE="STUDY">Lee 2012</LINK>; <LINK REF="STD-Little-2012" TYPE="STUDY">Little 2012</LINK>; <LINK REF="STD-Long-2011" TYPE="STUDY">Long 2011</LINK>; <LINK REF="STD-Lopez_x002d_Vejar-2013" TYPE="STUDY">Lopez-Vejar 2013</LINK>; <LINK REF="STD-Matzneller-2013" TYPE="STUDY">Matzneller 2013</LINK>; <LINK REF="STD-Montassier-2013" TYPE="STUDY">Montassier 2013</LINK>; <LINK REF="STD-Naderer-2013" TYPE="STUDY">Naderer 2013</LINK>; <LINK REF="STD-Navarta-2010" TYPE="STUDY">Navarta 2010</LINK>; <LINK REF="STD-Nussenblatt-2013" TYPE="STUDY">Nussenblatt 2013</LINK>; <LINK REF="STD-Polverino-2013" TYPE="STUDY">Polverino 2013</LINK>; <LINK REF="STD-Rank-2011" TYPE="STUDY">Rank 2011</LINK>; <LINK REF="STD-Seki-2009" TYPE="STUDY">Seki 2009</LINK>; <LINK REF="STD-Shorr-2013" TYPE="STUDY">Shorr 2013</LINK>; <LINK REF="STD-Skalsky-2012" TYPE="STUDY">Skalsky 2012</LINK>; <LINK REF="STD-Smith-2013" TYPE="STUDY">Smith 2013</LINK>; <LINK REF="STD-Snyman-2009" TYPE="STUDY">Snyman 2009</LINK>; <LINK REF="STD-Stille-2000" TYPE="STUDY">Stille 2000</LINK>; <LINK REF="STD-Sun-2012" TYPE="STUDY">Sun 2012</LINK>; <LINK REF="STD-Viasusa-2013" TYPE="STUDY">Viasusa 2013</LINK>; <LINK REF="STD-Worrall-2010" TYPE="STUDY">Worrall 2010</LINK>; <LINK REF="STD-Wunderink-2011" TYPE="STUDY">Wunderink 2011</LINK>; <LINK REF="STD-Yamamoto-2013" TYPE="STUDY">Yamamoto 2013</LINK>; <LINK REF="STD-Yuan-2012" TYPE="STUDY">Yuan 2012</LINK>; <LINK REF="STD-Zhang-2012" TYPE="STUDY">Zhang 2012</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-02-27 10:30:55 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>Four new studies included.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="2" YEAR="2004"/>
<DESCRIPTION>
<P>Review first published, Issue 2, 2004.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-08-29 22:19:48 +1000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2014-08-29 22:19:48 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-08-29 22:19:48 +1000" MODIFIED_BY="[Empty name]">
<NAME>No external funding was received for this review. Dr. Smita Pakhale being a full-time staff respirologist and a clinician scientist receives support from the Department of Medicine, the Ottawa Hospital, and Ottawa Hospital Research Institute</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-04-03 18:40:43 +1000" MODIFIED_BY="Lise M Bjerre">
<SOURCE MODIFIED="2009-04-03 18:40:43 +1000" MODIFIED_BY="Lise M Bjerre">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-10-07 05:38:21 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-10-07 05:38:21 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-04-16 11:44:00 +1000" MODIFIED_BY="Liz Dooley">Antibiotics for community-acquired pneumonia in adolescent and adult outpatients</TITLE>
<SUMMARY_BODY MODIFIED="2014-10-07 05:38:21 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>This review studied the effects of antibiotics on adolescents and adults with pneumonia acquired and treated in the community (as opposed to acquiring pneumonia in hospital and/or being treated for pneumonia in hospital). The evidence is current to March 2014.</P>
<P>
<B>Background</B>
</P>
<P>Lower respiratory tract infection is the third leading cause of death worldwide and the first leading cause of death in low-income countries. Pneumonia, or infection of the lungs, is a common condition representing a significant disease burden for the community. Pneumonia is especially life-threatening in children younger than five years, in older people and in people with other illnesses that may affect their immune system (such as diabetes or HIV/AIDS, or solid organ transplant recipients). Antibiotics are the most common treatment for pneumonia and these can vary in their effectiveness and adverse effects.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We identified 11 trials (with 3352 participants older than 12 years with a diagnosis of community-acquired pneumonia), fully published in peer-reviewed journals, focused on treatment of pneumonia in adolescents and adults treated in the community in outpatient settings. This included five new trials included since our last review published in 2009. None of the trials included antibiotics versus placebo; all trials included one or more antibiotics. All participants were diagnosed with pneumonia based upon clinical diagnosis by the physician and chest X-ray.</P>
<P>
<B>Study funding sources</B>
</P>
<P>All included trials were well conducted; nine of the 11 trials were sponsored by bio-pharmaceutical companies manufacturing the antibiotics used in the study, or their authors were closely linked with the company.</P>
<P>
<B>Key results</B>
</P>
<P>Nine of the included trials compared different antibiotics and, hence, we could not combine the results of the individual trials to present our overall conclusion. There were some notable adverse events in seven studies: 1) erythromycin demonstrated significant gastrointestinal side effects compared to clarithromycin in two studies; 2) nemonoxacin demonstrated higher gastrointestinal (nausea, diarrhoea) and nervous system (dizziness, headache) adverse events compared to levofloxacin; 3) cethromycin demonstrated more side effects, especially a distortion of the sense of taste, than clarithromycin; 4) gastritis and diarrhoea were more common in the high-dose amoxicillin group (1 g three times a day) compared to the other three antibiotic groups (clarithromycin, azithromycin and levofloxacin).</P>
<P>
<B>Conclusion</B>
</P>
<P>Unfortunately, there were not enough trials to compare the effects of different antibiotics for pneumonia acquired and treated in the community.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Lower respiratory tract infection (LRTI) is the third leading cause of death worldwide and the first leading cause of death in low-income countries. Community-acquired pneumonia (CAP) is a common condition that causes a significant disease burden for the community, particularly in children younger than five years, the elderly and immunocompromised people. Antibiotics are the standard treatment for CAP. However, increasing antibiotic use is associated with the development of bacterial resistance and side effects for the patient. Several studies have been published regarding optimal antibiotic treatment for CAP but many of these data address treatments in hospitalised patients. This is an update of our 2009 Cochrane Review and addresses antibiotic therapies for CAP in outpatient settings.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-04-16 13:54:13 +1000" MODIFIED_BY="Liz Dooley">
<P>To compare the efficacy and safety of different antibiotic treatments for CAP in participants older than 12 years treated in outpatient settings with respect to clinical, radiological and bacteriological outcomes.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (2014, Issue 1), MEDLINE (January 1966 to March week 3, 2014), EMBASE (January 1974 to March 2014), CINAHL (2009 to March 2014), Web of Science (2009 to March 2014) and LILACS (2009 to March 2014).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>We looked for randomised controlled trials (RCTs), fully published in peer-reviewed journals, of antibiotics versus placebo as well as antibiotics versus another antibiotic for the treatment of CAP in outpatient settings in participants older than 12 years of age. However, we did not find any studies of antibiotics versus placebo. Therefore, this review includes RCTs of one or more antibiotics, which report the diagnostic criteria and describe the clinical outcomes considered for inclusion in this review.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (LMB, TJMV) independently assessed study reports in the first publication. In the 2009 update, LMB performed study selection, which was checked by TJMV and MMK. In this 2014 update, two review authors (SP, SM) independently performed and checked study selection. We contacted trial authors to resolve any ambiguities in the study reports. We compiled and analysed the data. We resolved differences between review authors by discussion and consensus.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>We included 11 RCTs in this review update (3352 participants older than 12 years with a diagnosis of CAP); 10 RCTs assessed nine antibiotic pairs (3321 participants) and one RCT assessed four antibiotics (31 participants) in people with CAP. The study quality was generally good, with some differences in the extent of the reporting. A variety of clinical, bacteriological and adverse events were reported. Overall, there was no significant difference in the efficacy of the various antibiotics. Studies evaluating clarithromycin and amoxicillin provided only descriptive data regarding the primary outcome. Though the majority of adverse events were similar between all antibiotics, nemonoxacin demonstrated higher gastrointestinal and nervous system adverse events when compared to levofloxacin, while cethromycin demonstrated significantly more nervous system side effects, especially dysgeusia, when compared to clarithromycin. Similarly, high-dose amoxicillin (1 g three times a day) was associated with higher incidence of gastritis and diarrhoea compared to clarithromycin, azithromycin and levofloxacin.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-07-15 07:45:47 +1000" MODIFIED_BY="Liz  Dooley">
<P>Available evidence from recent RCTs is insufficient to make new evidence-based recommendations for the choice of antibiotic to be used for the treatment of CAP in outpatient settings. Pooling of study data was limited by the very low number of studies assessing the same antibiotic pairs. Individual study results do not reveal significant differences in efficacy between various antibiotics and antibiotic groups. However, two studies did find significantly more adverse events with use of cethromycin as compared to clarithromycin and nemonoxacin when compared to levofloxacin. Multi-drug comparisons using similar administration schedules are needed to provide the evidence necessary for practice recommendations. Further studies focusing on diagnosis, management, cost-effectiveness and misuse of antibiotics in CAP and LRTI are warranted in high-, middle- and low-income countries.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-09-02 08:23:27 +1000" MODIFIED_BY="Liz  Dooley">
<BACKGROUND MODIFIED="2014-08-30 00:29:38 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-08-29 23:21:38 +1000" MODIFIED_BY="[Empty name]">
<P>Community-acquired pneumonia (CAP), which excludes cases acquired in hospital, nursing homes and long-term care facilities, is a common condition that carries a high burden of mortality and morbidity. This burden is carried particularly in children younger than five years, the elderly and immunocompromised people. Prospective studies conducted in the United Kingdom, Finland and the United States have estimated the annual incidence of CAP in community-dwelling adults at 5 to 11 cases per 1000 adult population; the incidence is known to vary markedly with age, being higher in the very young and the elderly (<LINK REF="REF-BTS-2009" TYPE="REFERENCE">BTS 2009</LINK>; <LINK REF="REF-Foy-1979" TYPE="REFERENCE">Foy 1979</LINK>; <LINK REF="REF-Jokinen-1993" TYPE="REFERENCE">Jokinen 1993</LINK>; <LINK REF="REF-Torres-1991" TYPE="REFERENCE">Torres 1991</LINK>; <LINK REF="REF-Woodhead-1987" TYPE="REFERENCE">Woodhead 1987</LINK>).</P>
<P>CAP is the most important cause of death from infectious causes in high-income countries and the seventh most important cause of death overall (<LINK REF="REF-IDSA_x002f_ATS-2007" TYPE="REFERENCE">IDSA/ATS 2007</LINK>; <LINK REF="REF-Mandell-2007" TYPE="REFERENCE">Mandell 2007</LINK>). CAP can be caused by a broad range of pathogens, including bacteria, atypical bacteria <I>Chlamydophila pneumoniae </I>(<I>C. pneumoniae</I>),<I> Mycoplasma pneumoniae </I>(<I>M. pneumoniae</I>), <I>Legionella pneumophila </I>(<I>L. pneumophila</I>) and viruses (<LINK REF="REF-IDSA_x002f_ATS-2007" TYPE="REFERENCE">IDSA/ATS 2007</LINK>; <LINK REF="REF-Mandell-2007" TYPE="REFERENCE">Mandell 2007</LINK>; <LINK REF="REF-Welte-2012" TYPE="REFERENCE">Welte 2012</LINK>). In fact, more than 100 different micro-organisms have been associated with CAP (<LINK REF="REF-Loeb-2002" TYPE="REFERENCE">Loeb 2002</LINK>). Furthermore, a patient with CAP can be infected with more than one microbe, as in the case of a bacterial superinfection of an underlying influenza infection. The most common pathogens in normal hosts include <I>Streptococcus pneumoniae </I>(<I>S. pneumoniae</I>) (usually by far the most common),<I> C. pneumoniae</I>,<I> Haemophilus influenzae </I>(<I>H. influenzae</I>),<I> M. pneumoniae</I> and influenza viruses (<LINK REF="REF-BTS-2009" TYPE="REFERENCE">BTS 2009</LINK>; <LINK REF="REF-IDSA_x002f_ATS-2007" TYPE="REFERENCE">IDSA/ATS 2007</LINK>; <LINK REF="REF-Loeb-2002" TYPE="REFERENCE">Loeb 2002</LINK>; <LINK REF="REF-Mandell-2007" TYPE="REFERENCE">Mandell 2007</LINK>; <LINK REF="REF-Welte-2012" TYPE="REFERENCE">Welte 2012</LINK>).</P>
<P>Significant costs are associated with the diagnosis and management of CAP. In the UK, 22% to 42% of adults with CAP are admitted to hospital (<LINK REF="REF-BTS-2009" TYPE="REFERENCE">BTS 2009</LINK>) and of those 1.2% to 10% need to be admitted to an intensive care unit (<LINK REF="REF-BTS-2009" TYPE="REFERENCE">BTS 2009</LINK>). In a recent European review, pneumonia accounted for 10.1 billion Euros annually (<LINK REF="REF-Welte-2012" TYPE="REFERENCE">Welte 2012</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Antibiotics are the mainstay of treatment for CAP and the causative organisms usually respond well. Consequently, CAP treatment is associated with the development of bacterial resistance. In treating patients with CAP, the choice of antibiotic is a difficult one. Factors that must be considered are the possible aetiologic pathogen, the efficacy of the substance, potential side effects, the treatment schedule, patient adherence to treatment, the particular regional resistance profile of the causative organism, common pathogens in particular age groups (children versus elderly), co-morbidities that might influence the range of potential pathogens (such as in cystic fibrosis or solid organ transplant recipients), the dosage of antibiotics (as in the case of renal insufficiency) and the clinical severity of CAP.</P>
</INTERVENTION>
<THEORY MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Bacterial pathogens remain the most common causative agents of CAP. Use of appropriate antibiotics is essential, otherwise the chosen antibiotic may not be effective and could pose a danger to the patient due to side effects. If a specific pathogen has been identified, antibiotic therapy should be directed at this pathogen, so that it is more effective and less harmful.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-08-30 00:29:38 +1000" MODIFIED_BY="[Empty name]">
<P>Many clinical trials have been performed to evaluate and compare the efficacy of antibiotics for CAP. However, the vast majority of them were conducted in hospitalised patients. These patients usually suffer from more severe manifestations of the disease and often have other co-morbid conditions that affect their response to treatment and their time to recovery. Consequently, it is unclear if results of therapy in hospitalised patients can be extrapolated to outpatients. Numerous guidelines exist to aid clinicians with the treatment of CAP: in recent years, guidelines have been published by the American Thoracic Society (<LINK REF="REF-ATS-2001" TYPE="REFERENCE">ATS 2001</LINK>), the Infectious Diseases Society of America (<LINK REF="REF-IDSA-2000" TYPE="REFERENCE">IDSA 2000</LINK>, updated December 2003 and later in 2007; <LINK REF="REF-IDSA-2003" TYPE="REFERENCE">IDSA 2003</LINK>; <LINK REF="REF-IDSA_x002f_ATS-2007" TYPE="REFERENCE">IDSA/ATS 2007</LINK>; <LINK REF="REF-Mandell-2007" TYPE="REFERENCE">Mandell 2007</LINK>), the British Thoracic Society (<LINK REF="REF-BTS-2004" TYPE="REFERENCE">BTS 2004</LINK>; update: <LINK REF="REF-BTS-2009" TYPE="REFERENCE">BTS 2009</LINK>), the Canadian Community-Acquired Pneumonia Working Group (<LINK REF="REF-CCAPWG-2000" TYPE="REFERENCE">CCAPWG 2000</LINK>), the European Respiratory Society (<LINK REF="REF-Woodhead-2011" TYPE="REFERENCE">Woodhead 2011</LINK>), a German Guidelines Group (<LINK REF="REF-H_x00f6_ffken-2010" TYPE="REFERENCE">Höffken 2010</LINK>), a Dutch CAP Guidelines group (<LINK REF="REF-Wiersinga-2011" TYPE="REFERENCE">Wiersinga 2011</LINK>), the Gulf Cooperation Council (<LINK REF="REF-Memish-2007" TYPE="REFERENCE">Memish 2007</LINK>), the Japanese Respiratory Society (<LINK REF="REF-JRS-2006" TYPE="REFERENCE">JRS 2006</LINK>), the Latin American Thoracic Association (<LINK REF="REF-ALAT-2001" TYPE="REFERENCE">ALAT 2001</LINK>, update: <LINK REF="REF-ALAT-2004" TYPE="REFERENCE">ALAT 2004</LINK>), the South African Thoracic Society (<LINK REF="REF-SATS-2007" TYPE="REFERENCE">SATS 2007</LINK>) and the Swedish Society of Infectious Diseases (<LINK REF="REF-Hedlund-2005" TYPE="REFERENCE">Hedlund 2005</LINK>; update: <LINK REF="REF-Str_x00e5_lin-2007" TYPE="REFERENCE">Strålin 2007</LINK>; <LINK REF="REF-Spindler-2012" TYPE="REFERENCE">Spindler 2012</LINK>). All these guidelines include recommendations for the choice of antibiotic treatment for CAP in outpatient settings. However, the evidence on which these recommendations are based is derived mainly from studies carried out almost exclusively in hospitalised patients. Although many studies have been published concerning CAP and its treatment, there is no concise summary of the available evidence concerning its treatment in unselected ambulatory outpatients.</P>
<P>This review is an update of our review (<LINK REF="REF-Bjerre-2004" TYPE="REFERENCE">Bjerre 2004</LINK>; <LINK REF="REF-Bjerre-2009" TYPE="REFERENCE">Bjerre 2009</LINK>), and addresses the comparative efficacy of new antibiotic treatments for CAP in outpatients above 12 years of age.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-04-16 12:06:05 +1000" MODIFIED_BY="Liz Dooley">
<P>To compare the efficacy and safety of different antibiotic treatments for CAP in participants older than 12 years treated in outpatient settings with respect to clinical, radiological and bacteriological outcomes.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-09-02 08:04:21 +1000" MODIFIED_BY="Liz  Dooley">
<SELECTION_CRITERIA MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>We looked for studies comparing antibiotics versus placebo, as well as antibiotics versus another antibiotic. However, we did not find studies comparing antibiotics versus placebo. Therefore, we included RCTs of one or more antibiotics in adolescent and adult outpatients with CAP, which reported on clinical outcome parameters, clinical cure rates or bacteriologic response, or both, and adverse events.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Participants older than 12 years of age in outpatient settings with the following.</P>
<OL>
<LI>Symptoms and signs consistent with an acute lower respiratory tract infection associated with new radiographic shadowing for which there is no other explanation (for example, not pulmonary oedema or infarction).</LI>
<LI>The illness is the primary clinical problem and is managed as pneumonia.</LI>
</OL>
<P>(Modified from the criteria for CAP as defined by the British Thoracic Society (<LINK REF="REF-BTS-2009" TYPE="REFERENCE">BTS 2009</LINK>)).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>We considered all double-blind RCTs comparing one antibiotic and a placebo or at least two antibiotics used to treat CAP. We did not include trials comparing two doses, two treatment durations or two different application methods (example: intravenous versus oral) of the same drug. However, we included trials comparing two different pharmacological formulations of the same substance (for example, microspheres versus pure substance), as they are likely to differ in their pharmacodynamic and pharmacokinetic properties and thus may differ in their efficacy.</P>
<P>Comparisons involving intravenous drugs are usually carried out in a hospital setting. However, as this might occasionally be performed in an ambulatory setting, we did not exclude studies dealing with intravenous drug applications a priori.</P>
<P>We included trials allowing concurrent use of other medications, such as antitussives, antipyretics, bronchodilators or mucolytics, if they allowed equal access to such medications for participants in both arms of the trial.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Test-of-clinical-cure: clinical response: improvement of signs and symptoms, usually at a pre-defined test-of-cure (TOC) visit. Where possible, we used duration of clinical signs and symptoms as outcome measures. We used a clinical definition of cure as the primary outcome since radiographic resolution lags behind clinical improvement (<LINK REF="REF-Macfarlane-1984" TYPE="REFERENCE">Macfarlane 1984</LINK>).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-07-15 07:57:12 +1000" MODIFIED_BY="Liz  Dooley">
<OL>
<LI>Radiologic response: resolution or improvement of a new finding on chest X-ray after antibiotic therapy.</LI>
<LI>Bacteriologic response: negative sputum culture in patients previously found to have had pathogens in their sputum.</LI>
<LI>Adverse events: adverse events related to the intervention were reported.</LI>
<LI>Hospitalisation.</LI>
<LI>Mortality.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-08-30 00:31:17 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-08-30 00:31:17 +1000" MODIFIED_BY="[Empty name]">
<P>For this 2014 update, to improve our comprehensiveness and coverage of the literature, we edited our search strategy and extended our searches of the electronic databases to include CINAHL, Web of Science and LILACS. Details of the previous search are in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 1) (accessed 28 March 2014), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (January 2009 to March week 3, 2014), EMBASE (February 2009 to March 2014), CINAHL (2009 to March 2014), Web of Science (2009 to March 2014) and LILACS (2009 to March 2014).</P>
<P>We searched MEDLINE and CENTRAL using the search strategy shown below. We combined the MEDLINE search strategy with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity-and precision-maximising version (2008 revision) (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We adapted the search strategy for EMBASE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), CINAHL (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), Web of Science (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>) and LILACS (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
<P>
<B>MEDLINE (Ovid)</B>
</P>
<P>1 exp Pneumonia/<BR/>2 pneumonia.tw.<BR/>3 1 or 2<BR/>4 Community-Acquired Infections/<BR/>5 community-acquired.tw.<BR/>6 Outpatients/ (7479)<BR/>7 (outpatient* or out-patient*).tw.<BR/>8 exp Ambulatory Care/<BR/>9 (ambulat* adj2 (care or patient*)).tw.<BR/>10 or/4-9<BR/>11 3 and 10<BR/>12 (community acquired pneumon* or cap).tw.<BR/>13 11 or 12<BR/>14 exp Anti-Bacterial Agents/<BR/>15 antibiotic*.tw.<BR/>16 exp Macrolides/<BR/>17 exp beta-Lactams/<BR/>18 exp Quinolones/<BR/>19 exp Tetracyclines/<BR/>20 (beta-lactam* or macrolide* or makrolide* or quinolone* or tetracycline* or aciclovir or amikacin or amoxicillin or amoxycillin or ampicillin or azithromycin or cefepim or cefotaxim* or ceftarolin or ceftazidim* or ceftibuten or ceftriaxon* or cefuroxim* or cethromycin or ciprofloxacin or clarithromycin or clavulanic acid or clindamycin or co-amoxiclav or co-trimoxacol or doxycyclin* or ertapenem or erythromycin or fluoroquinolon* or fluorchinolon* or gemifloxacin or gentamicin or imipenem or levofloxacin or linezolide or meropenem or moxifloxacin or penicillin* or piperacillin or roxithromycin or sultamicillin or tazobactam or telithromycin or tetracyclin* or ticarcillin or tobramycin).tw,nm.<BR/>21 or/14-20<BR/>22 13 and 21</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>We also identified studies by checking the bibliographies of studies and review articles retrieved and, if necessary, by contacting the first or corresponding authors of relevant studies. In our first review of this topic, published in 2004 (<LINK REF="REF-Bjerre-2004" TYPE="REFERENCE">Bjerre 2004</LINK>), we had contacted the following antibiotics manufacturers to identify any additional published or unpublished studies: Abbott, AstraZeneca, Aventis, Boehringer-Ingelheim, Bristol-Myers-Squibb, GlaxoSmithKline, Hoffmann-LaRoche, Lilly, Merck, Merck Sharp &amp; Dohme, Novartis, Pfizer, Pharmacia, Sanofi and Yamanouchi. This search yielded no new studies.</P>
<P>We decided not to contact pharmaceutical companies for future review updates. We made this decision for two reasons: first, because of the very low yield of this search strategy, compared to the significant amount of time it requires; and second, because this search strategy provides an unfair advantage to unpublished studies carried out by industry, as opposed to government or academia, where an equivalent search strategy is not readily available. For the same reason, we decided only to include studies that have been fully published in peer-reviewed journals. We applied no language restrictions to the search and selection process.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-09-02 08:04:21 +1000" MODIFIED_BY="Liz  Dooley">
<STUDY_SELECTION MODIFIED="2014-08-29 23:40:45 +1000" MODIFIED_BY="[Empty name]">
<P>Two or one review authors (SP and SM for this 2014 update; and LMB and TJMV for the 2004 update; and LMB for the 2009 update) used the titles and abstracts of the identified citations to exclude trials that clearly did not meet our inclusion criteria in the previous two publications of this review (<LINK REF="REF-Bjerre-2004" TYPE="REFERENCE">Bjerre 2004</LINK>; <LINK REF="REF-Bjerre-2009" TYPE="REFERENCE">Bjerre 2009</LINK>). If the review authors felt that a study might possibly fulfil the inclusion criteria, we obtained the full paper for further study.</P>
<P>Two review authors (LMB, TJMV in the first review, LMB in the second review and SP, SM in this updated review) independently reviewed articles having passed this initial screen to determine whether they met the inclusion criteria of the review.</P>
<P>Studies could be excluded for any one of the following reasons: if they were not randomised; if they were conducted exclusively in hospitalised patients; if they only compared two doses or two application forms of the same substance, if the indication for treatment consisted of a mix of diagnoses (most commonly: acute bronchitis, exacerbation of chronic bronchitis and pneumonia) and if the results were not reported separately for each diagnostic group.</P>
<P>Another reason for exclusion was that some studies included a mix of in- and outpatients without reporting the data separately for these two subgroups. Whenever this was the case, we contacted the trial authors to obtain separate data for outpatients only.</P>
<P>We also excluded studies including only bacteriologically evaluable patients, because these studies typically included only patients with positive cultures of pathogens susceptible to study antibiotics or excluded patients with serologic confirmation of infection with atypical agents (such as <I>M. pneumoniae</I> or <I>C. pneumoniae</I>). A priori exclusion of patients with resistant strains, as well as of patients with non-bacterial or atypical causes of CAP, would falsely increase the treatment success rate to levels that would be unrealistic in real practice. We chose to exclude these 'narrow-focus' studies because we are interested in the efficacy of treatment in patients as they present to their general practitioner (GP), that is, unselected and unfiltered. We consider this essential to the generalisability of our results.</P>
<P>We also excluded studies if the diagnosis of pneumonia was not confirmed by chest X-ray. This exclusion criterion was necessary to ensure that only participants with a very high likelihood of having pneumonia be included in the review, since this was the patient population in which the efficacy of various treatment alternatives was to be assessed.</P>
<P>Furthermore, we excluded studies if the total number of patients was fewer than 30, because below this limit the estimate of a binomial parameter (in this case, the proportion of patients cured or improved) becomes too unstable (<LINK REF="REF-Armitage-1994" TYPE="REFERENCE">Armitage 1994</LINK>).</P>
<P>Similar to the previous versions of this review (<LINK REF="REF-Bjerre-2004" TYPE="REFERENCE">Bjerre 2004</LINK>; <LINK REF="REF-Bjerre-2009" TYPE="REFERENCE">Bjerre 2009</LINK>), we excluded studies of antibiotics that have been withdrawn from the market or are no longer licensed for the treatment of outpatients with CAP, due to severe adverse effects. For example, we excluded studies assessing the following fluoroquinolones: gatifloxacin, grepafloxacin, sparfloxacin, temafloxacin and trovafloxacin (Black Box Warning: not recommended for CAP because of serious side effects). Consequently, we excluded a study that had been included in the first publication of this review from the present review and the previous update (<LINK REF="STD-Ramirez-1999" TYPE="STUDY">Ramirez 1999</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-08-29 23:41:52 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted the following data from each study, whenever possible:</P>
<UL>
<LI>description of participants, in particular: age range and gender of participants, smoking status, co-morbidities;</LI>
<LI>description of potential pathogens identified and their antimicrobial resistance profiles;</LI>
<LI>description of intervention;</LI>
<LI>description of control therapy;</LI>
<LI>total number of participants in each arm of the trial;</LI>
<LI>study setting;</LI>
<LI>mean duration of symptoms in each arm of the trial;</LI>
<LI>clinical, radiographic and bacteriologic cure rates in each arm of the trial;</LI>
<LI>number of patients lost to follow-up;</LI>
<LI>types of adverse effects experienced and number of patients experiencing adverse effects;</LI>
<LI>number of drop-outs due to adverse effects;</LI>
<LI>proportion of patients admitted to hospital in each arm of the trial;</LI>
<LI>mortality rates in each arm of the trial;</LI>
<LI>study sponsor/s and role of sponsor/s in study conception, design, implementation, analysis, manuscript writing and publication.</LI>
</UL>
<P>There were no irreconcilable disagreements. Review authors were not blinded to the identity and affiliation of the study authors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-08-29 23:42:12 +1000" MODIFIED_BY="[Empty name]">
<P>We used the Cochrane 'Risk of bias' tool to systematically assess the risk of bias in included studies (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). (See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-09-02 08:04:21 +1000" MODIFIED_BY="Liz  Dooley">
<P>We used the Mantel-Haenszel approach to estimate the common odds ratios (ORs) with approximate 95% confidence intervals (CIs). This was done using <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was the individual patient. All included studies were RCTs without any design particularities, such as cross-over design or multiple interventions, which would warrant special attention to the units of analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-08-30 00:34:08 +1000" MODIFIED_BY="[Empty name]">
<P>We were to deal with missing data arising, for example, from failure to report on outcomes such as radiological cure rates in some studies, by excluding the specific outcome from the 'Data and analysis' section for the study in question. As for data missing from individual studies (more specifically, patients lost to follow-up), whenever possible, we used data from the clinical per protocol population, because this excluded patients who had not been sufficiently exposed to the study drug to be able potentially to benefit from the drug.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-09-02 08:04:21 +1000" MODIFIED_BY="Liz  Dooley">
<P>We carried out the assessment of heterogeneity by means of the Chi<SUP>2</SUP> test for heterogeneity, available in <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>If applicable, we assessed reporting/publication bias using funnel plots.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-09-02 08:04:21 +1000" MODIFIED_BY="Liz  Dooley">
<P>Whenever possible, we synthesised data using a fixed-effect meta-analysis model (Mantel-Haenszel odds ratio, available in <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-02-15 02:50:49 +1000" MODIFIED_BY="[Empty name]">
<P>As all included studies compared different antibiotic pairs, a subgroup analysis was not possible.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>We did not include studies with fewer than 30 participants in the new review, so no sensitivity analysis was done.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-09-02 08:23:27 +1000" MODIFIED_BY="Liz  Dooley">
<STUDY_DESCRIPTION MODIFIED="2014-08-29 23:46:44 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>This search yielded a total of 1828 references in our first review (1966 to 2003) (<LINK REF="REF-Bjerre-2004" TYPE="REFERENCE">Bjerre 2004</LINK>), the second updated search (2003 to 2009) yielded an additional 1298 records and this current updated search (2009 to 2014) yielded 730 records, for a grand total of 3856 records. After independently reading all the selected full articles, we selected 11 studies for this review. Some records were double entries, due to the overlapping content of databases.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-08-29 23:46:44 +1000" MODIFIED_BY="[Empty name]">
<P>We included 11 RCTs involving a total of 3352 patients aged 12 years and older diagnosed with CAP (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK>; <LINK REF="STD-Drehobl-2005" TYPE="STUDY">Drehobl 2005</LINK>; <LINK REF="STD-D_x0027_Ignazio-2005" TYPE="STUDY">D'Ignazio 2005</LINK>; <LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>; <LINK REF="STD-Kohno-2003" TYPE="STUDY">Kohno 2003</LINK>; <LINK REF="STD-Mathers-Dunbar-2004" TYPE="STUDY">Mathers Dunbar 2004</LINK>; <LINK REF="STD-Oldach-2013" TYPE="STUDY">Oldach 2013</LINK>; <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK>; <LINK REF="STD-Vacarezza-2010" TYPE="STUDY">Vacarezza 2010</LINK>; <LINK REF="STD-van-Rensburg-2010a" TYPE="STUDY">van Rensburg 2010a</LINK>; <LINK REF="STD-van-Rensburg-2010b" TYPE="STUDY">van Rensburg 2010b</LINK>). None of the studies included antibiotics versus placebo; all studies included one or more antibiotics. The van Rensburg 2010 article is presented here as <LINK REF="STD-van-Rensburg-2010a" TYPE="STUDY">van Rensburg 2010a</LINK>; <LINK REF="STD-van-Rensburg-2010b" TYPE="STUDY">van Rensburg 2010b</LINK> for simplicity as in this article two doses of nemonoxacin were tested against levofloxacin (in 1:1:1 ratio randomisation). The trials included varying numbers of patients, the largest having 1025 participants (<LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>), which is comprised of two studies, the smallest 31 (<LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK>). The mean size of studies included in the analysis was 310 participants and the median size was 131 (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> is reproduced from the previous review depicting antibiotic pairs included in that review (<LINK REF="REF-Bjerre-2009" TYPE="REFERENCE">Bjerre 2009</LINK>).</P>
<P>All trials enrolled outpatients with CAP and the diagnosis was based on clinical signs and symptoms as well as radiographic findings in all participants. The signs and symptoms included fever, chills, recent onset of productive cough, pleuritic chest pain, shortness of breath, tachypnoea, dullness to percussion, egophony, rales, localised reduced breath sounds and bronchial breath sounds. In all included trials, participants were treated exclusively as outpatients.</P>
<SUBSECTION>
<HEADING LEVEL="4">Participant inclusion and exclusion criteria</HEADING>
<P>Eight trials included adult participants only, aged 18 years and older. Three trials included adolescents: <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK> included adolescents 12 years of age and older. <LINK REF="STD-Drehobl-2005" TYPE="STUDY">Drehobl 2005</LINK> and <LINK REF="STD-Kohno-2003" TYPE="STUDY">Kohno 2003</LINK> included adolescents 16 years of age and older. Three trials included participants aged 75 years and older (24% to 30% greater than 65 years age) (<LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>; <LINK REF="STD-Oldach-2013" TYPE="STUDY">Oldach 2013</LINK>), and two trials excluded older participants (<LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK> excluded participants aged 55 years and older and in <LINK REF="STD-Kohno-2003" TYPE="STUDY">Kohno 2003</LINK> participants up to 80 years were included). Inpatients and outpatients were studied in <LINK REF="STD-Vacarezza-2010" TYPE="STUDY">Vacarezza 2010</LINK>, however, results were presented separately for both groups. Overall, the trials excluded patients with conditions that could have affected the treatment or interfered with follow-up. Exclusion criteria were reported in sufficient detail in all study reports. The most common criteria reported were: pregnancy and lactation, women not using adequate contraception (usually oral contraceptives or a barrier method), history of allergic reaction to the study drugs, recent treatment with or concomitant use of an antimicrobial agent, concurrent medication with ergotamine, cyclosporin, antacids (except H2-antagonists) or digitalis, conditions affecting gastrointestinal (GI) absorption, severe renal or hepatic impairment, terminal illness or conditions precluding study completion, infectious mononucleosis, HIV/AIDS and prior participation in the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Antibiotics</HEADING>
<P>The trials varied with respect to the antibiotics studied (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Four trials studied the same antibiotic pair: <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK> and <LINK REF="STD-Vacarezza-2010" TYPE="STUDY">Vacarezza 2010</LINK> studied clarithromycin versus amoxicillin and <LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK> and <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK> studied erythromycin versus clarithromycin. However, <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK> also studied two additional antibiotics including azithromycin and levofloxacin. All other trials studied different antibiotic pairs, namely clarithromycin versus azithromycin microspheres (<LINK REF="STD-Drehobl-2005" TYPE="STUDY">Drehobl 2005</LINK>), clarithromycin versus telithromycin (<LINK REF="STD-Mathers-Dunbar-2004" TYPE="STUDY">Mathers Dunbar 2004</LINK>), azithromycin microspheres versus levofloxacin (<LINK REF="STD-D_x0027_Ignazio-2005" TYPE="STUDY">D'Ignazio 2005</LINK>), telithromycin versus levofloxacin (<LINK REF="STD-Kohno-2003" TYPE="STUDY">Kohno 2003</LINK>), cethromycin versus clarithromycin (<LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>), solithromycin versus levofloxacin (<LINK REF="STD-Oldach-2013" TYPE="STUDY">Oldach 2013</LINK>), and nemonoxacin versus levofloxacin (<LINK REF="STD-van-Rensburg-2010a" TYPE="STUDY">van Rensburg 2010a</LINK>; <LINK REF="STD-van-Rensburg-2010b" TYPE="STUDY">van Rensburg 2010b</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>We excluded 109 studies. A large number of studies were excluded because they were conducted exclusively in hospitalised participants. Furthermore, a number of studies reported including a mix of in- and outpatients without reporting data separately for these two subgroups. For these studies, we contacted the trial authors to try to obtain separate data on outpatients. Out of seven trial authors, only two responded and both were unable to provide us with the necessary data.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-09-02 08:04:21 +1000" MODIFIED_BY="Liz  Dooley">
<P>The extent of reporting was variable between studies but was generally good to very good. However, in <LINK REF="STD-Vacarezza-2010" TYPE="STUDY">Vacarezza 2010</LINK> and <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK>, overall frequency of signs and symptoms was presented rather than presentation and resolution of signs and symptoms in each treatment arm. Treatment adherence relied on self reporting in all except three studies where treatment adherence was explicitly assessed by pill count (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK>; <LINK REF="STD-Mathers-Dunbar-2004" TYPE="STUDY">Mathers Dunbar 2004</LINK>). None reported any difference in the number of pills remaining between the two groups. However, in the <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK> study, 40 participants were excluded because they received "less than the minimum therapy" (seven days) and these patients were distributed unevenly across the two groups (10 in the clarithromycin group and 30 in the erythromycin group). In the two studies using azithromycin microspheres (<LINK REF="STD-D_x0027_Ignazio-2005" TYPE="STUDY">D'Ignazio 2005</LINK>; <LINK REF="STD-Drehobl-2005" TYPE="STUDY">Drehobl 2005</LINK>), the treatment adherence in the azithromycin group was 100% in both studies, because the drug was administered in a single dose under directly observed therapy (DOT) at the initial treatment visit.</P>
<P>Regarding co-interventions with other medications, most studies excluded patients whose co-medication included certain drugs such as other antibiotics, chemotherapeutics or anti-retrovirals. Only one study reported how many patients were excluded because of forbidden co-medication (<LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK>).</P>
<P>The risk of bias in included studies was systematically assessed using 'Risk of bias' tables (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
<ALLOCATION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Only three of the included studies clearly stated the randomisation method used (using interactive voice response systems) and allocation using coded blister cards (<LINK REF="STD-Drehobl-2005" TYPE="STUDY">Drehobl 2005</LINK>; <LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>; <LINK REF="STD-Mathers-Dunbar-2004" TYPE="STUDY">Mathers Dunbar 2004</LINK>). More female participants and more participants with chronic obstructive pulmonary disease (COPD) or asthma (or both) received solithromycin as compared to levofloxacin in <LINK REF="STD-Oldach-2013" TYPE="STUDY">Oldach 2013</LINK>.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-07-15 07:43:42 +1000" MODIFIED_BY="Liz  Dooley">
<P>All trials were randomised, double-blind evaluations comparing two or more antibiotics. None of the trials reported any test of effectiveness of the blinding procedures used.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Withdrawals were generally reported in sufficient detail. However, three studies did not report a CONSORT diagram (<LINK REF="STD-Oldach-2013" TYPE="STUDY">Oldach 2013</LINK>; <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK>; <LINK REF="STD-Vacarezza-2010" TYPE="STUDY">Vacarezza 2010</LINK>). The number of patients lost to follow-up was reported in all studies. Losses to follow-up appeared to be minor, amounting to a maximum of 10% of the initially randomised participants. One study did not present intention-to-treat (ITT) analysis results (<LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK>).</P>
<P>Since only two studies addressed the efficacy of the same antibiotic pair and both studies provided the same information about outcomes (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK>), there were no missing data issues in the combined analysis of the data arising from these two studies (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-07-04 07:03:04 +1000" MODIFIED_BY="[Empty name]">
<P>There were no obvious concerns about the selective availability of data, or selective reporting of outcomes. </P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>The main concern about other potential sources of bias was that nine included studies were sponsored by bio-pharmaceutical companies manufacturing the antibiotics used in the study, or authors were closely linked with the company (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK>; <LINK REF="STD-D_x0027_Ignazio-2005" TYPE="STUDY">D'Ignazio 2005</LINK>; <LINK REF="STD-Drehobl-2005" TYPE="STUDY">Drehobl 2005</LINK>; <LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>; <LINK REF="STD-Kohno-2003" TYPE="STUDY">Kohno 2003</LINK>; <LINK REF="STD-Mathers-Dunbar-2004" TYPE="STUDY">Mathers Dunbar 2004</LINK>; <LINK REF="STD-Oldach-2013" TYPE="STUDY">Oldach 2013</LINK>, <LINK REF="STD-van-Rensburg-2010a" TYPE="STUDY">van Rensburg 2010a</LINK>; <LINK REF="STD-van-Rensburg-2010b" TYPE="STUDY">van Rensburg 2010b</LINK>). Funding sources were not described in two trials (<LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK>; <LINK REF="STD-Vacarezza-2010" TYPE="STUDY">Vacarezza 2010</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-09-02 08:23:27 +1000" MODIFIED_BY="Liz  Dooley">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Test-of-clinical-cure</HEADING>
<P>The success rates for each of the treatment arms of the 11 trials are shown in the <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK> section of this review. 'Success' was defined as cure or improvement, be it clinical or bacteriological, as assessed at a predefined follow-up visit ('test-of-cure' (TOC) visit). Overall, success rates were very high, usually ranging from 76% to 89% though they were similar in treatment and comparator arms in individual studies. Efficacy in the studies by <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK> and <LINK REF="STD-Vacarezza-2010" TYPE="STUDY">Vacarezza 2010</LINK> is difficult to determine because the data are not presented clearly for treatment groups, rather the frequency of signs and symptoms is presented. Neither clinical nor statistical significance was achieved when the results of the two studies of clarithromycin versus erythromycin were pooled together (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK>) (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>; <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>; <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>; <LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Radiological response</HEADING>
<P>Radiological response was reported only in two studies (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK>), where it was not significant despite pooling the data (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>; <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>; <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>; <LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Bacteriologic response</HEADING>
<P>In the study by <LINK REF="STD-Oldach-2013" TYPE="STUDY">Oldach 2013</LINK>, bacterial success rate was higher in the solithromycin group when compared to the levofloxacin group. In the <LINK REF="STD-Kohno-2003" TYPE="STUDY">Kohno 2003</LINK> study, bacteriological success favoured levofloxacin over telithromycin, while overall efficacy was not different in both these studies. In the studies by <LINK REF="STD-van-Rensburg-2010a" TYPE="STUDY">van Rensburg 2010a</LINK>, <LINK REF="STD-van-Rensburg-2010b" TYPE="STUDY">van Rensburg 2010b</LINK> and <LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>, bacteriological cure ranged from 48% to 89%.</P>
<P>Detailed bacteriological data are not presented in <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK> and <LINK REF="STD-Vacarezza-2010" TYPE="STUDY">Vacarezza 2010</LINK>, and only Gram stain identification was performed on sputum samples in <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK> at the baseline.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Adverse events</HEADING>
<P>Detailed descriptions of adverse events were presented in all included studies. In all studies, the most common side effects attributable to the study drugs were gastrointestinal side effects. Most side effects were minor and comparable in all treatment arms, except for seven studies (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK>; <LINK REF="STD-D_x0027_Ignazio-2005" TYPE="STUDY">D'Ignazio 2005</LINK>; <LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>; <LINK REF="STD-Mathers-Dunbar-2004" TYPE="STUDY">Mathers Dunbar 2004</LINK>, <LINK REF="STD-van-Rensburg-2010a" TYPE="STUDY">van Rensburg 2010a</LINK>; <LINK REF="STD-van-Rensburg-2010b" TYPE="STUDY">van Rensburg 2010b</LINK>; <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK>). In the two studies comparing clarithromycin with erythromycin (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK>), there were significantly more side effects in the erythromycin group, the majority being gastrointestinal side effects. However, this was not reflected in the rate of side effects leading to withdrawal from the study, which was not significantly different across treatment arms. However, as noted above, in the <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK> study, 40 patients were excluded because they received "less than the minimum therapy" (seven days) and these patients were distributed unevenly across the two groups (10 in the clarithromycin group and 30 in the erythromycin group). Although not listed as drop-outs due to side effects, it is quite plausible that these differences in pre-study drop-out rates were due to the unfavourable gastrointestinal side effects of erythromycin. In <LINK REF="STD-van-Rensburg-2010a" TYPE="STUDY">van Rensburg 2010a</LINK>; <LINK REF="STD-van-Rensburg-2010b" TYPE="STUDY">van Rensburg 2010b</LINK>, nemonoxacin demonstrated higher gastrointestinal (nausea, diarrhoea) and nervous system (dizziness, headache) adverse events compared to levofloxacin. In <LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>, cethromycin demonstrated more side effects, especially dysgeusia, than clarithromycin. In <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK>, gastritis and diarrhoea were higher in the high-dose amoxicillin group (1 g three times a day) compared to the other three antibiotic groups (clarithromycin, azithromycin and levofloxacin).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Hospitalisation</HEADING>
<P>Hospitalisation was not explicitly reported as an outcome in any study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Mortality</HEADING>
<P>Mortality was not explicitly reported as an outcome in any trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons across antibiotic groups</HEADING>
<P>Different antibiotic pairs were studied in nine studies (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Notably, though, <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK> and <LINK REF="STD-Vacarezza-2010" TYPE="STUDY">Vacarezza 2010</LINK> studied clarithromycin and amoxicillin (high-dose amoxicillin was studied in <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK> in addition to azithromycin and levofloxacin). There were no significant differences in clinical or bacteriological success, except in <LINK REF="STD-Oldach-2013" TYPE="STUDY">Oldach 2013</LINK> and <LINK REF="STD-Kohno-2003" TYPE="STUDY">Kohno 2003</LINK>. Radiological outcomes were not reported separately for the treatment arms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bacteriological pathogens</HEADING>
<P>Various pathogens were identified with varying frequency across studies. The proportion of samples yielding an identifiable pathogen ranged from 19% (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>) to 65% in <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK> (only Gram stain on sputum samples at the baseline). <I>H. influenzae</I> was the most common pathogen identified by <LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK> (62% of positive cultures) and <LINK REF="STD-Kohno-2003" TYPE="STUDY">Kohno 2003</LINK> (43% of positive cultures), whereas <I>S. pneumoniae</I> was the main causative organism in <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK> (56% of positive cultures) and <LINK REF="STD-Mathers-Dunbar-2004" TYPE="STUDY">Mathers Dunbar 2004</LINK> (52% of positive cultures). <LINK REF="STD-D_x0027_Ignazio-2005" TYPE="STUDY">D'Ignazio 2005</LINK> and <LINK REF="STD-Drehobl-2005" TYPE="STUDY">Drehobl 2005</LINK> reported <I>C. pneumoniae</I> as being the most common pathogen (20% and 23% of positive cultures, respectively). In <LINK REF="STD-Kohno-2003" TYPE="STUDY">Kohno 2003</LINK>, the bacteriological success rate (i.e. eradication of previously identified pathogen) significantly favoured levofloxacin (<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>; <LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>; <LINK REF="CMP-011.03" TYPE="ANALYSIS">Analysis 11.3</LINK>; <LINK REF="CMP-011.04" TYPE="ANALYSIS">Analysis 11.4</LINK>). Most failures were due to failure to eradicate <I>H. influenzae</I>, so the authors looked at the clinical success rate of patients with <I>H. influenzae</I> at baseline, which turned out to not be significantly different between levofloxacin and telithromycin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Serologically identified pathogens</HEADING>
<P>The most frequently identified pathogen was <I>M. pneumoniae</I>, which represented 22% (<LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>), 39% (<LINK REF="STD-D_x0027_Ignazio-2005" TYPE="STUDY">D'Ignazio 2005</LINK>), 52% (<LINK REF="STD-Kohno-2003" TYPE="STUDY">Kohno 2003</LINK>), 67% (<LINK REF="STD-van-Rensburg-2010a" TYPE="STUDY">van Rensburg 2010a</LINK>; <LINK REF="STD-van-Rensburg-2010b" TYPE="STUDY">van Rensburg 2010b</LINK>), 69% (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>) and 74% (<LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK>) of positive serology results. In addition, <I>C. pneumoniae</I> was identified in 17% of cases in the <LINK REF="STD-van-Rensburg-2010a" TYPE="STUDY">van Rensburg 2010a</LINK>; <LINK REF="STD-van-Rensburg-2010b" TYPE="STUDY">van Rensburg 2010b</LINK> study and 7% of cases in the <LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK> study. <I>Legionella pneumoniae </I>(<I>L. pneumoniae</I>) was identified in 4% and 6% in the microbiological evaluable population in the <LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>; <LINK REF="STD-van-Rensburg-2010a" TYPE="STUDY">van Rensburg 2010a</LINK>; <LINK REF="STD-van-Rensburg-2010b" TYPE="STUDY">van Rensburg 2010b</LINK> studies respectively. In the study by <LINK REF="STD-D_x0027_Ignazio-2005" TYPE="STUDY">D'Ignazio 2005</LINK>, <I>C. pneumoniae</I> was predominant, representing 61% of atypical pathogens. Likewise in the studies by <LINK REF="STD-Drehobl-2005" TYPE="STUDY">Drehobl 2005</LINK> and <LINK REF="STD-Mathers-Dunbar-2004" TYPE="STUDY">Mathers Dunbar 2004</LINK>, <I>C. pneumoniae</I> represented just over half of atypical pathogens (53% and 52%, respectively). Only one patient tested positive for <I>L. pneumoniae</I> in the <LINK REF="STD-Mathers-Dunbar-2004" TYPE="STUDY">Mathers Dunbar 2004</LINK> study and no samples were positive for <I>Chlamydia psittaci </I>(<I>C. psittaci</I>) in any of the studies.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-08-30 00:29:23 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>The overwhelming feature of this review update remains the paucity of relevant evidence that could be identified and included in the review. Nonetheless, in this update, five new studies were included (<LINK REF="STD-English-2012" TYPE="STUDY">English 2012</LINK>; <LINK REF="STD-Oldach-2013" TYPE="STUDY">Oldach 2013</LINK>; <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK>; <LINK REF="STD-Vacarezza-2010" TYPE="STUDY">Vacarezza 2010</LINK>; <LINK REF="STD-van-Rensburg-2010a" TYPE="STUDY">van Rensburg 2010a</LINK>; <LINK REF="STD-van-Rensburg-2010b" TYPE="STUDY">van Rensburg 2010b</LINK>). Inclusion of these studies did not alter the conclusions of our previous reviews conducted in 2004 and 2009 (<LINK REF="REF-Bjerre-2004" TYPE="REFERENCE">Bjerre 2004</LINK>; <LINK REF="REF-Bjerre-2009" TYPE="REFERENCE">Bjerre 2009</LINK>).</P>
<P>Unfortunately, only two of the 11 studies focused on the same antibiotic pairs (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Chien-1993" TYPE="STUDY">Chien 1993</LINK>), so that, once again, no formal meta-analysis of the data could be carried out. At most, it can be stated that individual study results did not reveal significant differences in efficacy between various antibiotics and antibiotic groups, but that there were some significant differences with respect to the frequency of side effects. Given this current state of affairs, it is not possible to make strong evidence-based recommendations regarding the choice of antibiotic to be used for the treatment of community-acquired pneumonia in ambulatory outpatients. Under such circumstances, other factors such as tolerability, duration and frequency of treatment and cost will take on more importance in determining the choice of treatment.</P>
<P>Importantly, the majority of the studies were conducted in high-income countries and, hence, the available evidence does not adequately address the issue of community-acquired pneumonia (CAP) or lower respiratory tract infection (LRTI) in low- and middle-income countries. Lastly, antibiotic misuse is a global threat, although the antibiotic stewardship programmes are gaining some momentum in a few academic centres (<LINK REF="STD-Nussenblatt-2013" TYPE="STUDY">Nussenblatt 2013</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>One important reason for this lack of evidence is that a large number of the trials originally identified were conducted in hospitalised patients and therefore are not necessarily relevant to the treatment of ambulatory patients. It could be argued that the inclusion/exclusion criteria for this review were too strict and that this is the reason why so few studies were retained. However, we do believe that the criteria we applied are necessary in order to address validly the question of the efficacy of treatment of CAP in ambulatory patients. In particular, it could be argued that the decision to exclude studies based on size is not desirable, since one aim of the review is to pool results and that each study therefore would contribute some information. However, we felt that this criterion was necessary to exclude studies where the number of patients with pneumonia was so small that randomisation could no longer be expected to achieve a balanced distribution of confounders, both known and unknown, across study groups.</P>
<P>As for the requirement that the diagnosis of CAP be confirmed by a chest radiograph, we felt that this was necessary to avoid diagnostic misclassification, which could, for example, have led to the inclusion of patients with bronchitis in this review. This could have biased the estimation of the efficacy of various antibiotic treatments, either differentially or non-differentially, depending on the distribution of non-CAP cases across treatment groups. Indeed, most recent clinical guidelines recommend the routine use of chest X-rays to confirm a suspected pneumonia (<LINK REF="REF-BTS-2009" TYPE="REFERENCE">BTS 2009</LINK>; <LINK REF="REF-IDSA_x002f_ATS-2007" TYPE="REFERENCE">IDSA/ATS 2007</LINK>; <LINK REF="REF-Woodhead-2011" TYPE="REFERENCE">Woodhead 2011</LINK>; <LINK REF="STD-Wunderink-2011" TYPE="STUDY">Wunderink 2011</LINK>). However, we are aware that this diagnostic test is often not used in practice and that patients are therefore treated empirically according to the clinical findings and the severity of the clinical picture. In such a situation, patients with an empirical diagnosis of pneumonia (i.e. diagnosis without chest X-ray) are probably, on average, less severely ill than the participants in the trials we reviewed.<BR/>
</P>
<P>The diversity of pathogens identified as the most common causative organisms in our present review underscores the need for conducting studies of CAP treatment in a variety of different geographical locations. This also points to a possible limitation of such studies, namely their questionable generalisability to different clinical and geographical situations than the ones included in the present studies. For example, studies conducted in low- and middle-income countries might have a different bacteriological profile than those conducted in high-income countries.</P>
<P>Finally, a lot of potentially useful information is lost because investigators often included a mix of in- and outpatients in their studies without reporting results separately for each of these subgroups. Investigators and journal editors should be strongly encouraged to report such data separately, as these patients have different co-morbidity profiles and, potentially, respond to treatment differently. Putting heterogeneous patient groups into the same analytic basket may reduce the generalisability and thus the usefulness of such study results. Contacting trial authors after publication to get additional data, sometimes years after a study was published, is a time-consuming process with a very low yield, as was our experience and that of other Cochrane review authors (<LINK REF="REF-Robenshtok-2008" TYPE="REFERENCE">Robenshtok 2008</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Overall, the quality of the included studies was relatively good, although there were some differences in the completeness of reporting. The fact that we chose to include only double-blind, controlled, prospective randomised controlled trials (RCTs) led to a priori exclusion of studies of lesser quality.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>By choosing to include only studies published in peer-reviewed journals and by choosing no longer to contact pharmaceutical companies for information on unpublished studies, we believe that we have contributed to increasing study quality and reducing bias in our review to a minimum. Furthermore, by excluding data from studies focusing on selected subgroups of ambulatory participants (such as participants with suspected bacterial pneumonia), we believe we have maximised the generalisability of our review results to unselected patients presenting to their physician.</P>
<P>It is noteworthy that, once again, nine studies meeting the inclusion criteria for our review were sponsored by bio-pharmaceutical companies. This could potentially introduce a publication bias, as it would be in the interest of manufacturers not to publish studies yielding unfavourable results about their products. We are of the opinion that there is an urgent need for industry-independent research into the treatment of CAP in ambulatory patients.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-08-30 00:29:23 +1000" MODIFIED_BY="[Empty name]">
<P>As mentioned above, we feel that our decision to exclude studies focusing only on a subset of outpatients (for example, "only bacteriologically evaluable patients" or "excluding patients with atypical pneumonia") is necessary to maintain the generalisability of our results to patients presenting to first-line physicians. In contrast, a recent meta-analysis we encountered in the process of searching the literature was more inclusive (<LINK REF="REF-Maimon-2008" TYPE="REFERENCE">Maimon 2008</LINK>). The object of this meta-analysis was different from that of our review. However, the target population (outpatients with CAP, treated as outpatients) was the same. Despite the authors' stated focus on "the inclusion of only randomised prospective double-blind studies using only oral therapy exclusively in outpatients" (p.1974), this work included a number of open-label (non-blinded) studies, studies including a mix of in- and outpatients (for which subgroup data were reportedly obtained from study authors) as well as narrow-focus studies (i.e. studies focusing exclusively on bacterial pneumonia, for example). Of the 13 studies included in this meta-analysis, none met the inclusion criteria for our review, which leads us to question the generalisability of the results of this meta-analysis to unselected patients presenting in general practice.</P>
<P>Finally, a recent RCT confirmed that patients with CAP of moderate severity (Fine Score II or III) can be treated as outpatients, just as safely and effectively as inpatients (<LINK REF="REF-Carratal_x00e0_-2005" TYPE="REFERENCE">Carratalà 2005</LINK>), at only a fraction of the cost. This further underscores the need for solid, evidence-based data on the treatment of patients with CAP in the ambulatory care setting.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Currently available evidence from randomised controlled trials (RCTs) is insufficient to make evidence-based recommendations for the choice of antibiotic to be used in the treatment of community-acquired pneumonia (CAP) in ambulatory patients. At most, it can be stated that individual study results do not reveal significant differences in efficacy between various antibiotics and antibiotic groups.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Multi-drug, multi-drug-group, double-blind comparisons conducted in various geographical settings are needed to provide the evidence necessary for practice recommendations if these are to be applicable in the ambulatory setting. Study conditions should ensure that diagnosis and management of patients with CAP is as similar as possible to real practice, while still ensuring that the study question is addressed in a valid way. In studies recruiting a mix of in- and outpatients, it is imperative that data be reported separately for these two subgroups. Finally, good quality studies are needed in high as well as low- and middle-income countries to address CAP and lower respiratory tract infection diagnosis, management, cost-effectiveness and misuse of antibiotics.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>We thank the authors we contacted during the second revision of this review (<LINK REF="REF-Bjerre-2009" TYPE="REFERENCE">Bjerre 2009</LINK>), who kindly replied to our requests for additional information: Dr. Lorenzo Aguilar, Dr. Claude Carbon, Dr. Lars Hagberg, Dr. Karen Higgins, Dr. Shigeru Kohno, Dr. Hartmut Lode, Dr. Lala Mathers Dunbar and Dr. Antoni Torres Martí. Many thanks to Dr. Frederike Behn for precious help with parts of the data extraction process in the first version of this review (<LINK REF="REF-Bjerre-2004" TYPE="REFERENCE">Bjerre 2004</LINK>). We also wish to thank the following people for commenting on drafts of this review: Clare Jeffrey, Anne Lyddiatt, Mary Baldwin, Deviprasad Mohapatra, Tina Tan, Balwinder Singh, William Cayley, Mark Jones, Robert Ware and Roger Damoiseaux. Last, but not least, we thank the Acute Respiratory Infections Group editorial team for enduring support and guidance, in particular Liz Dooley (Managing Editor), as well as Ruth Foxlee and Sarah Thorning (respectively, past and present Trials Search Co-ordinators).</P>
<P>In this current 2014 update, we wish to thank Dr. Rosendo Rodriguez, Dr. Gonzalo Alvarez, Dr. Mathieu Saint Pierre, Dr. Jacqueline Sandoz and Dr. Keiko Asakawa for their assistance with translation of Spanish, French and Japanese articles. We also acknowledge and thank Ms. Lara Bajar, administrative assistant for Dr. Smita Pakhale, for administrative assistance with management of the articles.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-08-30 00:23:32 +1000" MODIFIED_BY="[Empty name]">
<P>Smita Pakhale: no potential conflicts of interest to declare.<BR/>Sunita Mulpuru: no potential conflicts of interest to declare.<BR/>Theo JM Verheij: I participated in an RCT on the effects of pneumococcal vaccination, funded by Pfizer.<BR/>Michael M Kochen: no potential conflicts of interest to declare.<BR/>Gernot GU Rohde: Dr. Rohde received financial benefits for advisory board memberships from Pfizer and consultancy work for Novartis and Takeda as well as payments for lectures from Pfizer, Chiesi, Astra-Zeneca, GSK, Novartis and Grünenthal.<BR/>Lise M Bjerre: Dr. Bjerre currently holds operating foundation grants as principal investigator from the Canadian Institutes for Health Research (CIHR) and the Centre for Learning, Research and Innovation in Long-term care (CLRI) of the Ministry of Health of Ontario; she is also co-investigator on other CIHR grants. She has never accepted remuneration, gifts or research funds in any form from drug or device manufacturers, or other member of the pharmaceutical industry.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Smita Pakhale and Sunita Mulpuru independently screened abstracts and full articles for inclusion in this review. They decided, by mutual agreement, which articles to include, extracted the data from these articles, performed the quantitative analyses, wrote the text, tables and figures of this review and made modifications to this review based on the comments of peer and consumer referees.</P>
<P>Lise M Bjerre was the lead author on the first two iterations of this review (2004, 2009); as such, she made substantial contributions to study design and to data acquisition, analysis and interpretation; she also wrote the text of these two earlier reviews, which form the backbone of the present review, with editorial input from MMK and TJMV. For the present review, she provided background information and guidance to the new lead author (Smita Pakhale) with respect to the search criteria and the overall process of the Cochrane review; she critically reviewed the manuscript for important intellectual content and approved the final version for submission.</P>
<P>Michael M Kochen (MMK) co-wrote the protocol, defined the search strategy and did a preliminary screening of abstracts for inclusion into the 2004 and 2009 reviews. He also critically reviewed and edited the text of this review at various stages in its development.</P>
<P>Theo JM Verheij (TJMV) co-wrote the protocol, screened abstracts and full articles for inclusion in the study and decided, in agreement with LMB, which articles to include for 2004 and 2009 reviews. He also critically reviewed and edited the text of the review at various stages in its development for all three reviews.</P>
<P>Gernot GU Rohde critically reviewed the protocol and data extraction tool and contributed to the revision and critical review of this manuscript.</P>
<P>All authors agreed upon the final draft of this review prior to submission.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-09-02 08:04:21 +1000" MODIFIED_BY="Liz  Dooley">
<P>In our first review of this topic, published in 2004 (<LINK REF="REF-Bjerre-2004" TYPE="REFERENCE">Bjerre 2004</LINK>), as per protocol we contacted the following antibiotics manufacturers to identify any additional published or unpublished studies: Abbott, AstraZeneca, Aventis, Boehringer-Ingelheim, Bristol-Myers-Squibb, GlaxoSmithKline, Hoffmann-LaRoche, Lilly, Merck, Merck Sharp &amp; Dohme, Novartis, Pfizer, Pharmacia, Sanofi and Yamanouchi. This search yielded no new studies. Starting with this update, we decided to no longer contact pharmaceutical companies to ask about unpublished studies. This decision was made for two reasons: first, because of the very low yield of this search strategy, compared to the significant amount of time it requires; and second, because this search strategy provides an unfair advantage to unpublished studies carried out by industry, as opposed to government or academia, where an equivalent search strategy is not readily available.</P>
<P>In this review and the second update of this review (<LINK REF="REF-Bjerre-2009" TYPE="REFERENCE">Bjerre 2009</LINK>), we excluded studies of antibiotics that have been withdrawn from the market or are no longer licensed for the treatment of outpatients with CAP, due to severe adverse effects. For example, studies assessing the following fluoroquinolones were excluded: gatifloxacin, grepafloxacin, sparfloxacin, temafloxacin and trovafloxacin.</P>
<P>Finally, in the second update (<LINK REF="REF-Bjerre-2009" TYPE="REFERENCE">Bjerre 2009</LINK>), and in this 2014 update, we applied the new 'Risk of bias' tools (tables, summary figures and graphs) newly made available in <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>. These tools were not available at the time our protocol and our first review (<LINK REF="REF-Bjerre-2004" TYPE="REFERENCE">Bjerre 2004</LINK>) were written and published.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-04-15 05:36:20 +1000" MODIFIED_BY="Lise M Bjerre"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-10-07 05:40:44 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-10-07 05:40:44 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1991" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Anderson 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson G, Esmonde TS, Coles S, Macklin J, Carnegie C</AU>
<TI>A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1997</YR>
<VL>27</VL>
<NO>Suppl A</NO>
<PG>117-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chien-1993" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Chien 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chien SM, Pichotta P, Siepman N, Chan CK and the Canada-Sweden Clarithromycin-Pneumonia Group</AU>
<TI>Treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing clarithromycin with erythromycin</TI>
<SO>Chest</SO>
<YR>1993</YR>
<VL>103</VL>
<PG>697-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Ignazio-2005" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="D'Ignazio 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Ignazio J, Camere MA, Lewis DE, Jorgensen D, Breen JD</AU>
<TI>Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2005</YR>
<VL>49</VL>
<NO>10</NO>
<PG>4035-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drehobl-2005" MODIFIED="2014-03-14 04:26:45 +1000" MODIFIED_BY="[Empty name]" NAME="Drehobl 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-03-14 04:26:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drehobl MA, De Salvo MC, Lewis DE, Breen JD</AU>
<TI>Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults</TI>
<SO>Chest</SO>
<YR>128</YR>
<VL>4</VL>
<PG>2230-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-English-2012" MODIFIED="2014-08-29 21:22:57 +1000" MODIFIED_BY="[Empty name]" NAME="English 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-11 11:04:43 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>English ML, Fredericks CE, Milanesio NA, Rohowsky N, Xu Z-Q, Jenta TRJ, et al</AU>
<TI>Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2011</YR>
<VL>56</VL>
<NO>4</NO>
<PG>2037-47</PG>
<IDENTIFIERS MODIFIED="2014-03-09 13:40:46 +1000" MODIFIED_BY="Liz Dooley"/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-04 02:10:18 +1000" MODIFIED_BY="Sunita Mulpuru" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Welte T, Torres A, Nathwani D</AU>
<TI>Clinical and economic burden of community-acquired pneumonia among adults in Europe</TI>
<SO>Thorax</SO>
<YR>2012</YR>
<VL>67</VL>
<PG>71-9</PG>
<IDENTIFIERS MODIFIED="2014-02-27 06:43:49 +1000" MODIFIED_BY="Sunita Mulpuru">
<IDENTIFIER MODIFIED="2014-02-27 06:43:49 +1000" MODIFIED_BY="Sunita Mulpuru" TYPE="OTHER" VALUE="Welte 2012"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-08-29 21:22:57 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kohno-2003" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Kohno 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kohno S, Watanabe A, Aoki N, Niki Y</AU>
<TI>Clinical evaluation of telithromycin for community-acquired pneumonia - phase III double-blind comparative study of telithromycin versus levofloxacin [Japanese]</TI>
<SO>Japanese Journal of Chemotherapy</SO>
<YR>2003</YR>
<VL>51</VL>
<NO>Suppl 1</NO>
<PG>255-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathers-Dunbar-2004" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Mathers Dunbar 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathers Dunbar L, Hassman J, Tellier G</AU>
<TI>Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults</TI>
<SO>Clinical Therapeutics</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>1</NO>
<PG>48-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oldach-2013" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Oldach 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, et al</AU>
<TI>Randomized, double-blind, multicentre phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2013</YR>
<VL>57</VL>
<NO>6</NO>
<PG>2526-34</PG>
<IDENTIFIERS MODIFIED="2014-08-29 21:18:38 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-01-17 02:23:52 +1000" MODIFIED_BY="Smita Pakhale">
<IDENTIFIER MODIFIED="2014-01-17 02:23:52 +1000" MODIFIED_BY="Smita Pakhale" TYPE="CTG" VALUE="NCT01168713"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Udupa-2011" MODIFIED="2014-08-29 21:23:09 +1000" MODIFIED_BY="[Empty name]" NAME="Udupa 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-29 21:20:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Udupa A, Gupta P</AU>
<TI>Antibiotic therapy in pneumonia: a comparative study of oral antibiotics in a rural healthcare centre</TI>
<SO>International Journal of Pharmacy and Pharmaceutical Sciences</SO>
<YR>2011</YR>
<VL>3</VL>
<PG>156-8</PG>
<IDENTIFIERS MODIFIED="2014-08-29 21:20:12 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-08-29 21:23:09 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vacarezza-2010" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Vacarezza 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vacarezza M, Pedrouzo RV, Bartesaghi L, Sicca M, Lerena V, Perdomo J, et al</AU>
<TI>Community-acquired acute pneumonias in the adult. Controlled therapeutic study. Uruguay</TI>
<TO>Neumona aguda del adulto adquirida en la comunidad. Ensayo terapéutico controlado. Uruguay</TO>
<SO>Archivos de Medicina Interna</SO>
<YR>2010</YR>
<VL>XXXII</VL>
<NO>2-3</NO>
<PG>31-5</PG>
<IDENTIFIERS MODIFIED="2014-01-17 02:22:40 +1000" MODIFIED_BY="Smita Pakhale">
<IDENTIFIER MODIFIED="2014-01-17 02:22:40 +1000" MODIFIED_BY="Smita Pakhale" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-08-29 21:23:14 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Rensburg-2010a" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="van Rensburg 2010a" YEAR="2010">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Rensburg D, Perng R-P, Mitha IH, Bester AJ, Kasumba J, Wu R-G, et al</AU>
<TI>Efficacy and safety of nemonoxacin versus levofloxacin for community acquired pneumonia</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2010</YR>
<VL>54</VL>
<NO>10</NO>
<PG>4098-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-08-29 21:23:19 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Rensburg-2010b" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="van Rensburg 2010b" YEAR="2010">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Rensburg D, Perng R-P, Mitha IH, Bester AJ, Kasumba J, Wu R-G, et al</AU>
<TI>Efficacy and safety of nemonoxacin versus levofloxacin for community acquired pneumonia</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2010</YR>
<VL>54</VL>
<NO>10</NO>
<PG>4098-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-10-07 05:40:44 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alcacer-1993" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Alcacer 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alcacer F, Belda A, Custardoy J, Borras F, Redondo A, Borja J, et al</AU>
<TO>Estudio comparativo entre ofloxacino y eritromicina en el tratamiento de la neumonia de la comunidad</TO>
<SO>Revista Española de Quimioterapia</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>3</NO>
<PG>213-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arifin-2013" MODIFIED="2014-08-29 21:24:24 +1000" MODIFIED_BY="[Empty name]" NAME="Arifin 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-08-29 21:24:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arifin NM, Soepandi P, Burhan E, Isbaniah F, Arimah C, Kusumo D, et al</AU>
<TI>P319 Multicenter, comparative study of levofloxacin high-dose, IV oral sequential therapy for CAP with moxifloxacin in Indonesia</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2013</YR>
<VL>42</VL>
<NO>Suppl</NO>
<PG>S142</PG>
<PB>Elsevier Science Publishers,</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bai-2014" MODIFIED="2014-04-16 11:31:15 +1000" MODIFIED_BY="Liz Dooley" NAME="Bai 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-04-16 11:31:15 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bai N, Sun C, Wang J, Cai Y, Liang B, Zhang L, et al</AU>
<TI>Ertapenem versus ceftriaxone for the treatment of complicated infections: a meta-analysis of randomized controlled trials</TI>
<SO>Chinese Medical Journal</SO>
<YR>2014</YR>
<VL>127</VL>
<NO>6</NO>
<PG>1118-25</PG>
<IDENTIFIERS MODIFIED="2014-04-15 21:29:27 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="24622445"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-04-15 21:10:14 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balgos-1999" MODIFIED="2014-03-14 04:21:55 +1000" MODIFIED_BY="[Empty name]" NAME="Balgos 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-03-14 04:21:55 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balgos AA, Rodriguez-Gomez G, Nasnas R, Mahasur AA, Margono BP, Tinoco-Favila JC</AU>
<TI>Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>5</NO>
<PG>325-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ball-1994" MODIFIED="2014-03-14 04:23:37 +1000" MODIFIED_BY="[Empty name]" NAME="Ball 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-03-14 04:23:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ball P</AU>
<TI>Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>10</NO>
<PG>851-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balmes-1991" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Balmes 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balmes P, Clerc G, Dupont B, Labram C, Pariente P, Poirier R</AU>
<TI>Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>437-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bantz-1987" MODIFIED="2014-03-14 04:26:02 +1000" MODIFIED_BY="[Empty name]" NAME="Bantz 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-03-14 04:26:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bantz PM, Grote J, Peters-Haertel W, Stahmann J, Timm J, Kasten R, et al</AU>
<TI>Low-dose ciprofloxacin in respiratory tract infections: a randomized comparison with doxycycline in general practice</TI>
<SO>American Journal of Medicine</SO>
<YR>1987</YR>
<VL>82</VL>
<NO>Suppl 4A</NO>
<PG>208-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biermann-1988" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Biermann 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biermann C, Loken A, Riise R</AU>
<TI>Comparison of spiramycin and doxycycline in the treatment of lower respiratory infections in general practice</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1988</YR>
<VL>22</VL>
<NO>Suppl B</NO>
<PG>155-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blasi-2013" MODIFIED="2014-03-04 02:31:01 +1000" MODIFIED_BY="[Empty name]" NAME="Blasi 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-04 02:31:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blasi F, Tarsia P, Mantero M, Morlacchi LC, Piffer F</AU>
<TI>Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication</TI>
<SO>Journal of Therapeutics and Clinical Risk Management</SO>
<YR>2013</YR>
<VL>9</VL>
<PG>55-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Block-2006" MODIFIED="2014-03-11 11:06:25 +1000" MODIFIED_BY="Liz Dooley" NAME="Block 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-03-11 11:06:25 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Block SL</AU>
<TI>Comparative tolerability, safety and efficacy of tablet formulations of twice-daily clarithromycin 250 mg versus once-daily extended-release clarithromycin 500 mg in pediatric and adolescent patients</TI>
<SO>Clinical Pediatrics</SO>
<YR>2006</YR>
<VL>45</VL>
<NO>7</NO>
<PG>641-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonvehi-2003" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Bonvehi 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonvehi P, Weber K, Busman T, Shortridge D, Notario G</AU>
<TI>Comparison of clarithromycin and amoxicillin/clavulanic acid for community-acquired pneumonia in an era of drug-resistant streptococcus pneumoniae</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>8</NO>
<PG>491-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bothra-2012" MODIFIED="2014-08-29 21:26:29 +1000" MODIFIED_BY="[Empty name]" NAME="Bothra 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-29 21:26:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bothra M, Lodha R, Kabra SK</AU>
<TI>Tobramycin for the treatment of bacterial pneumonia in children</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2012</YR>
<VL>13</VL>
<NO>4</NO>
<PG>565-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brittain_x002d_Long-2011" MODIFIED="2014-03-18 06:12:02 +1000" MODIFIED_BY="Liz Dooley" NAME="Brittain-Long 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-03-18 06:12:02 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brittain-Long R, Westin J, Olofsson S, Lindh M, Andersson LM</AU>
<TI>Access to a polymerase chain reaction assay method targeting 13 respiratory viruses can reduce antibiotics: a randomised, controlled trial</TI>
<SO>BMC Medicine</SO>
<YR>2011</YR>
<VL>9</VL>
<PG>44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carbon-1999" MODIFIED="2014-03-11 11:07:07 +1000" MODIFIED_BY="Liz Dooley" NAME="Carbon 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-03-11 11:07:07 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carbon C, Ariza H, Rabie WJ, Salvarezza CR, Elkharrat D, Rangaraj M, et al</AU>
<TI>Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>1999</YR>
<VL>5</VL>
<PG>724-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casapao-2012" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Casapao 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casapao AM, Steed ME, Levine DP, Rybak MJ</AU>
<TI>Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2012</YR>
<VL>13</VL>
<NO>8</NO>
<PG>1177-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chodosh-1991" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Chodosh 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chodosh S</AU>
<TI>Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients</TI>
<SO>Chest</SO>
<YR>1991</YR>
<VL>100</VL>
<PG>1497-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Critchley-2010" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Critchley 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Critchley I, Friedland D, Eckburg P, Jandourek A, Han S, Thye D</AU>
<TI>Microbiological outcomes of 2 multicenter phase 3 clinical trials of ceftaroline in community-acquired bacterial pneumonia</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2010</YR>
<VL>181</VL>
<PG>A5481</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daniel-1999a" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Daniel 1999a" YEAR="1999">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniel R</AU>
<TI>Oral trovafloxacin compared with amoxicillin (plus optional erythromycin) for the treatment of mild to moderate community-acquired pneumonia</TI>
<SO>Drugs</SO>
<YR>1999</YR>
<VL>58</VL>
<NO>Suppl 2</NO>
<PG>320-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daniel-1999b" MODIFIED="2014-03-11 11:07:50 +1000" MODIFIED_BY="Liz Dooley" NAME="Daniel 1999b" YEAR="1999">
<REFERENCE MODIFIED="2014-03-11 11:07:50 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniel R</AU>
<TI>Trovafloxacin vs high dose amoxicillin in the treatment of community-acquired bacterial pneumonia</TI>
<SO>Drugs</SO>
<YR>1999</YR>
<VL>58</VL>
<NO>Suppl 2</NO>
<PG>304-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dark-1991" MODIFIED="2014-03-14 04:31:37 +1000" MODIFIED_BY="[Empty name]" NAME="Dark 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-03-14 04:31:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dark D</AU>
<TI>Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections</TI>
<SO>American Journal of Medicine</SO>
<YR>1991</YR>
<VL>91</VL>
<NO>Suppl 3A</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dartois-2013" MODIFIED="2014-08-29 21:27:52 +1000" MODIFIED_BY="[Empty name]" NAME="Dartois 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-08-29 21:27:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dartois N, Cooper CA, Castaing N, Gandjini H, Sarkozy D</AU>
<TI>Tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia: an analysis of risk factors</TI>
<SO>Open Respiratory Medicine Journal</SO>
<YR>2013</YR>
<VL>7</VL>
<PG>13-20</PG>
<IDENTIFIERS MODIFIED="2014-04-15 21:33:21 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="23526572"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dautzenberg-1992" MODIFIED="2014-03-14 04:32:40 +1000" MODIFIED_BY="[Empty name]" NAME="Dautzenberg 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-03-14 04:32:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dautzenberg B, Scheimberg A, Brambilla C, Camus P, Godard P, Guerin JC</AU>
<TI>Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections</TI>
<SO>Diagnostic Microbiology and Infectious Disease</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>Suppl</NO>
<PG>85-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dean-2006" MODIFIED="2014-03-14 04:34:26 +1000" MODIFIED_BY="[Empty name]" NAME="Dean 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-03-14 04:34:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dean NC, Sperry P, Wikler M, Suchyta MS, Hadlock C</AU>
<TI>Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2006</YR>
<VL>50</VL>
<NO>4</NO>
<PG>1164-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Cock-1988" MODIFIED="2014-03-14 04:33:31 +1000" MODIFIED_BY="[Empty name]" NAME="De Cock 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-03-14 04:33:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Cock L, Poels R</AU>
<TI>Comparison of spiramycin with erythromycin for lower respiratory tract infections</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1988</YR>
<VL>22</VL>
<NO>Suppl B</NO>
<PG>159-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donowitz-1997" MODIFIED="2014-03-14 04:35:32 +1000" MODIFIED_BY="[Empty name]" NAME="Donowitz 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-03-14 04:35:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donowitz GR, Brandon ML, Salisbury JP, Harman CP, Tipping DM, Urick AE, et al</AU>
<TI>Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study</TI>
<SO>Clinical Therapeutics</SO>
<YR>1997</YR>
<VL>19</VL>
<NO>5</NO>
<PG>936-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Esposito-2012" MODIFIED="2014-03-11 11:08:15 +1000" MODIFIED_BY="Liz Dooley" NAME="Esposito 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-11 11:08:15 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Esposito S, Esposito I, Leone S</AU>
<TI>Considerations of antibiotic therapy duration in community and hospital-acquired bacterial infections</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2012</YR>
<VL>67</VL>
<NO>11</NO>
<PG>2570-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-File-1997" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="File 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al</AU>
<TI>A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>9</NO>
<PG>1965-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-File-2001" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="File 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>File TM Jr, Schlemmer B, Garau J, Cupo M, Young C; 049 Clinical Study Group</AU>
<TI>Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2001</YR>
<VL>48</VL>
<NO>1</NO>
<PG>67-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-File-2004" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="File 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>File TM Jr, Lode H, Kurz H, Kozak R, Xie H, Berkowitz E, et al</AU>
<TI>Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced-amoxicillin clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2004</YR>
<VL>48</VL>
<NO>9</NO>
<PG>3323-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-File-2012a" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="File 2012a" YEAR="">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>File Jr T, Eckburg P, Low D, Talbot G, llorens L, Friedland HD</AU>
<TI>Assessment of outcomes at an entry time point may identify a differential effect of macrolide therapy on community-acquired pneumonia due to atypical pathogens</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2012</YR>
<VL>18</VL>
<NO>55</NO>
<PG>133-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-File-2012b" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="File 2012b" YEAR="2012">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>File Jr TM, Wilcox MH, Stein GE</AU>
<TI>Summary of ceftaroline fosamil clinical trial studies and clinical safety</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2012</YR>
<VL>55</VL>
<NO>Suppl 3</NO>
<PG>173-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fogarty-1999" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Fogarty 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fogarty C, Grossman C, Williams J, Haverstock D, Church D for the Community-Acquired Pneumonia Study Group</AU>
<TI>Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia</TI>
<SO>Infections in Medicine</SO>
<YR>1999</YR>
<VL>16</VL>
<PG>748-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fogarty-2002" MODIFIED="2014-03-14 07:49:35 +1000" MODIFIED_BY="[Empty name]" NAME="Fogarty 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-03-14 07:49:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA</AU>
<TI>A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>11</NO>
<PG>1854-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fogarty-2004" MODIFIED="2014-03-11 11:09:01 +1000" MODIFIED_BY="Liz Dooley" NAME="Fogarty 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-03-11 11:09:01 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fogarty C, Siami G, Kohler R, File Jr TM, Tennenberg AM, Olson WH, et al</AU>
<TI>Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>Suppl 1</NO>
<PG>16-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fong-1995" MODIFIED="2014-03-14 07:50:34 +1000" MODIFIED_BY="[Empty name]" NAME="Fong 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-03-14 07:50:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fong IW, Laforge J, Dubois J, Small D, Grossman R, Zakhari R, et al</AU>
<TI>Clarithromycin versus cefaclor in lower respiratory tract infections</TI>
<SO>Clinical and Investigative Medicine</SO>
<YR>1995</YR>
<VL>18</VL>
<PG>131-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fujita-2012" MODIFIED="2014-03-11 11:09:14 +1000" MODIFIED_BY="Liz Dooley" NAME="Fujita 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-11 11:09:14 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fujita J, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, et al</AU>
<TI>Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial</TI>
<SO>Journal of Infection and Chemotherapy (Official Journal of the Japan Society of Chemotherapy)</SO>
<YR>2013</YR>
<VL>19</VL>
<NO>3</NO>
<PG>472-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghebremedhin-2012" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Ghebremedhin 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghebremedhin B</AU>
<TI>Bacterial infections in the elderly patient: focus on sitafloxacin</TI>
<SO>Clinical Medicine Insights: Therapeutics</SO>
<YR>2012</YR>
<VL>4</VL>
<PG>185-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gotfried-2002" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Gotfried 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gotfried MH, Dattani D, Riffer E, Devcich KJ, Busman TA, Notario GF, et al</AU>
<TI>A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia</TI>
<SO>Clinical Therapeutics</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>5</NO>
<PG>736-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gris-1996" MODIFIED="2014-08-29 21:34:23 +1000" MODIFIED_BY="[Empty name]" NAME="Gris 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-08-29 21:34:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gris P</AU>
<TI>Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>Suppl C</NO>
<PG>93-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hagberg-2002" MODIFIED="2014-03-14 07:54:05 +1000" MODIFIED_BY="[Empty name]" NAME="Hagberg 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-03-14 07:54:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E</AU>
<TI>Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia</TI>
<SO>Infection</SO>
<YR>2002</YR>
<VL>30</VL>
<NO>6</NO>
<PG>378-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Higuera-1996" MODIFIED="2014-03-14 07:55:14 +1000" MODIFIED_BY="[Empty name]" NAME="Higuera 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-03-14 07:55:14 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Higuera F, Hidalgo H, Feris J, Giguere G, Collins JJ</AU>
<TI>Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1996</YR>
<VL>37</VL>
<PG>555-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoeffken-2001" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Hoeffken 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoeffken G, Meyer HP, Winter J, Verhoef L; CAP1 Study Group</AU>
<TI>The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia</TI>
<SO>Respiratory Medicine</SO>
<YR>2001</YR>
<VL>95</VL>
<NO>7</NO>
<PG>553-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoepelman-1993" MODIFIED="2014-03-14 07:57:42 +1000" MODIFIED_BY="[Empty name]" NAME="Hoepelman 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-03-14 07:57:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoepelman AIM, Sips AP, van Helmond JLM, van Barneveld PWC, Neve AJ, et al</AU>
<TI>A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1993</YR>
<VL>31</VL>
<NO>Suppl E</NO>
<PG>147-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoepelman-1998" MODIFIED="2014-03-14 07:58:50 +1000" MODIFIED_BY="[Empty name]" NAME="Hoepelman 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-03-14 07:58:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoepelman IM, Möllers MJ, van Schie MH, Greefhorst APM, Schlösser NJJ, Sinninghe Damsté EJ, et al</AU>
<TI>A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>1998</YR>
<VL>9</VL>
<PG>141-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kammer-1991" MODIFIED="2014-03-14 07:59:47 +1000" MODIFIED_BY="[Empty name]" NAME="Kammer 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-03-14 07:59:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kammer RB, Ress R</AU>
<TI>Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections</TI>
<SO>Diagnostic Microbiology and Infectious Disease</SO>
<YR>1991</YR>
<VL>14</VL>
<PG>101-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiani-1990" MODIFIED="2014-03-14 08:00:53 +1000" MODIFIED_BY="[Empty name]" NAME="Kiani 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-03-14 08:00:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiani R, Coulson L, Johnson D, Hammershaimb L</AU>
<TI>Comparison of once-daily and twice-daily cefixime regimens with amoxicillin in the treatment of acute lower respiratory tract infections</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1990</YR>
<VL>48</VL>
<NO>5</NO>
<PG>841-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinasewitz-1991" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Kinasewitz 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinasewitz G, Wood RG</AU>
<TI>Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>10</NO>
<PG>872-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kohno-2013" MODIFIED="2014-03-11 11:09:27 +1000" MODIFIED_BY="Liz Dooley" NAME="Kohno 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-11 11:09:27 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kohno S, Yanagihara K, Yamamoto Y, Tokimatsu I, Hiramatsu K, Higa F, et al</AU>
<TI>Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan</TI>
<SO>Journal of Infection and Chemotherapy (Official Journal of the Japan Society of Chemotherapy)</SO>
<YR>2013</YR>
<VL>19</VL>
<NO>6</NO>
<PG>1035-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacny-1972" MODIFIED="2014-03-14 08:02:40 +1000" MODIFIED_BY="[Empty name]" NAME="Lacny 1972" YEAR="1972">
<REFERENCE MODIFIED="2014-03-14 08:02:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacny J</AU>
<TI>A comparison of oral therapy with clindamycin and penicillin G in common gram-positive infections</TI>
<SO>Current Therapeutic Research</SO>
<YR>1972</YR>
<VL>14</VL>
<NO>1</NO>
<PG>26-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lagler-2012" MODIFIED="2014-03-04 02:53:34 +1000" MODIFIED_BY="Smita Pakhale" NAME="Lagler 2012" YEAR="">
<REFERENCE MODIFIED="2014-03-04 02:53:34 +1000" MODIFIED_BY="Smita Pakhale" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lagler H, Gattringer R, Derler V, Wlazny D, Graninger W, Burgmann H</AU>
<TI>Intravenous azithromycin - single dose 1.5 g vs. 500 mg once daily for 3 days in patients with community-acquired pneumonia: a prospective and randomized study</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2012</YR>
<VL>18</VL>
<NO>65</NO>
<PG>137-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laurent-1996" MODIFIED="2014-03-14 08:03:32 +1000" MODIFIED_BY="[Empty name]" NAME="Laurent 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-03-14 08:03:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laurent K</AU>
<TI>Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>Suppl C</NO>
<PG>115-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2012" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Lee 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee JH, Kim SW, Kim JH, Ryu YJ, Chang JH</AU>
<TI>High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2012</YR>
<VL>32</VL>
<NO>9</NO>
<PG>569-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leophonte-2004" MODIFIED="2014-03-14 08:04:36 +1000" MODIFIED_BY="[Empty name]" NAME="Leophonte 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-03-14 08:04:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Léophonte P, File T, Feldman C</AU>
<TI>Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin</TI>
<SO>Respiratory Medicine</SO>
<YR>2004</YR>
<VL>98</VL>
<NO>8</NO>
<PG>708-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liipo-1994" MODIFIED="2014-03-14 08:05:34 +1000" MODIFIED_BY="[Empty name]" NAME="Liipo 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-03-14 08:05:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liippo K, Tala E, Puolijoki H, Brückner OJ, Rodrig J, Smits JPH</AU>
<TI>A comparative study of dirithromycin and erythromycin in bacterial pneumonia</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1994</YR>
<VL>28</VL>
<PG>131-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Little-2012" MODIFIED="2014-03-11 11:09:53 +1000" MODIFIED_BY="Liz Dooley" NAME="Little 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-11 11:09:53 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Little P, Stuart B, Moore M, Coenen S, Butler CC, Godycki-Cwirko M, et al</AU>
<TI>Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2013</YR>
<VL>13</VL>
<NO>2</NO>
<PG>123-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lode-1995" MODIFIED="2014-03-14 08:06:41 +1000" MODIFIED_BY="[Empty name]" NAME="Lode 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-03-14 08:06:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, et al</AU>
<TI>Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin</TI>
<SO>European Respiratory Journal</SO>
<YR>1995</YR>
<VL>8</VL>
<PG>1999-2007</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lode-1998" MODIFIED="2014-03-14 08:18:43 +1000" MODIFIED_BY="[Empty name]" NAME="Lode 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-03-14 08:18:43 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lode H, Aubier M, Portier H, Ortqvist A and the Sparfloxacin Study Group</AU>
<TI>Sparfloxacin as alternative treatment to standard therapy for community-acquired bacteremic pneumococcal pneumonia</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>3</NO>
<PG>135-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lode-2004a" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Lode 2004a" YEAR="2004">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lode H, Magyar P, Muir JF, Loos U, Kleutgens K; International Gatifloxacin Study Group</AU>
<TI>Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>6</NO>
<PG>512-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lode-2004b" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Lode 2004b" YEAR="2004">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lode H, Aronkyto T, Chuchalin AG, Jaaskevi M, Kahnovskii I, Kleutgens K, et al</AU>
<TI>A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>5</NO>
<PG>403-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Long-2011" MODIFIED="2014-03-11 11:10:00 +1000" MODIFIED_BY="Liz Dooley" NAME="Long 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-03-11 11:10:00 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J</AU>
<TI>Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia</TI>
<SO>Respirology</SO>
<YR>2011</YR>
<VL>16</VL>
<NO>5</NO>
<PG>819-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez_x002d_Vejar-2013" MODIFIED="2014-10-07 05:40:44 +1000" MODIFIED_BY="[Empty name]" NAME="Lopez-Vejar 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>López-Véjar CE, Castellanos de la Cruz L, Meraz-Ortega R, Román- Flores A, Geuguer-Chávez L, Pedro-González A, et al</AU>
<TO>Eficacia del levofloxacino en el tratamiento de neumonía adquirida en la comunidad</TO>
<SO>Medicina Interna de México</SO>
<YR>2013</YR>
<VL>29</VL>
<NO>587</NO>
<PG>594</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-10-07 05:40:44 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-07 05:40:44 +1000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacFarlane-1996" MODIFIED="2014-08-30 00:28:19 +1000" MODIFIED_BY="[Empty name]" NAME="MacFarlane 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-03-14 08:22:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacFarlane JT, Prewitt J, Gard P, Guion A</AU>
<TI>Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections</TI>
<SO>British Journal of General Practice</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>407</NO>
<PG>357-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matzneller-2013" MODIFIED="2014-03-11 11:10:12 +1000" MODIFIED_BY="Liz Dooley" NAME="Matzneller 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-11 11:10:12 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matzneller P, Krasniqi S, Kinzig M, Sörgel F, Hüttner S, Lackner E, et al</AU>
<TI>Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2013</YR>
<VL>57</VL>
<NO>4</NO>
<PG>1736-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montassier-2013" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Montassier 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montassier E, Goffinet N, Potel G, Batard E</AU>
<TI>How to reduce antibiotic consumption for community-acquired pneumonia</TI>
<SO>Medicines et Maladies Infectieuses</SO>
<YR>2013</YR>
<VL>43</VL>
<NO>2</NO>
<PG>52-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moola-1999" MODIFIED="2014-03-14 08:24:35 +1000" MODIFIED_BY="[Empty name]" NAME="Moola 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-03-14 08:24:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moola S, Hagberg L, Churchyard GA, Dylewski JS, Sedani S, Staley H</AU>
<TI>A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia</TI>
<SO>Chest</SO>
<YR>1999</YR>
<VL>116</VL>
<NO>4</NO>
<PG>974-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00fc_ller-1992" MODIFIED="2014-03-14 08:25:29 +1000" MODIFIED_BY="[Empty name]" NAME="Müller 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-03-14 08:25:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Müller O, Wettich K</AU>
<TI>Comparison of loracarbef (LY 163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia</TI>
<SO>Infection</SO>
<YR>1992</YR>
<VL>20</VL>
<NO>3</NO>
<PG>176-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naderer-2013" MODIFIED="2014-03-11 11:10:26 +1000" MODIFIED_BY="Liz Dooley" NAME="Naderer 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-11 11:10:26 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS</AU>
<TI>Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2013</YR>
<VL>57</VL>
<NO>5</NO>
<PG>2005-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NAPSG-1997" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="NAPSG 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Nordic Atypical Pneumonia Study Group</AU>
<TI>Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1997</YR>
<VL>39</VL>
<PG>499-508</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navarta-2010" MODIFIED="2014-10-07 05:40:01 +1000" MODIFIED_BY="[Empty name]" NAME="Navarta 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-10-07 05:40:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navarta AC, Bocklet ML, Anzorena A, Cuello H, Carena JA</AU>
<TI>Not available</TI>
<TO>Eficacia clínica de los macrólidos como parte del tratamiento empírico en neumonía de la comunidad que se interna</TO>
<SO>Revista Americana de Medicina Respiratoria</SO>
<YR>2010</YR>
<VL>3</VL>
<PG>97-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-10-07 05:38:56 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-07 05:38:56 +1000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neu-1993" MODIFIED="2014-03-14 08:27:43 +1000" MODIFIED_BY="[Empty name]" NAME="Neu 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-03-14 08:27:43 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neu HC, Chick TW</AU>
<TI>Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections</TI>
<SO>Chest</SO>
<YR>1993</YR>
<VL>104</VL>
<PG>1393-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nussenblatt-2013" MODIFIED="2014-03-11 11:10:39 +1000" MODIFIED_BY="Liz Dooley" NAME="Nussenblatt 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-11 11:10:39 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nussenblatt V, Avdic E, Cosgrove S</AU>
<TI>What is the role of antimicrobial stewardship in improving outcomes of patients with CAP</TI>
<SO>Infectious Disease Clinics of North America</SO>
<YR>2013</YR>
<VL>27</VL>
<NO>1</NO>
<PG>211-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Doherty-1997" MODIFIED="2014-08-29 21:47:12 +1000" MODIFIED_BY="[Empty name]" NAME="O'Doherty 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-08-29 21:46:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Doherty B, Dutchman DA, Pettit R, Maroli A</AU>
<TI>Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1997</YR>
<VL>40</VL>
<NO>Suppl A</NO>
<PG>73-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Doherty-1998" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="O'Doherty 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Doherty B, Muller O and the Azithromycin Study Group</AU>
<TI>Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>828-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x00d6_rtqvist-1996" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Örtqvist 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Örtqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C, et al</AU>
<TI>Oral empiric treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<PG>1499-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavie-2005" MODIFIED="2014-08-29 21:47:50 +1000" MODIFIED_BY="[Empty name]" NAME="Pavie 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-29 21:47:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavie J, de la Prida JM, Diaz A, Saldias F</AU>
<TI>Assessment of the management of community-acquired pneumonia in adult outpatients</TI>
<TO>Manejo ambulatorio de la neumonía comunitaria del adulto en las unidades de emergencia. Servicio de Salud Vina del Mar&#8211;Quillota de la V Región</TO>
<SO>Revista Médica de Chile</SO>
<YR>2005</YR>
<VL>133</VL>
<PG>1322-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petitpretz-2001" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Petitpretz 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petitpretz P, Arvis P, Marel M, Moita J, Urueta J; CAP5 Moxifloxacin Study Group</AU>
<TI>Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<NO>1</NO>
<PG>185-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peugeot-1991" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Peugeot 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peugeot RL, Lipsky BA, Hooton TM, Pecoraro RE</AU>
<TI>Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin</TI>
<SO>Drugs in Experimental and Clinical Research</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>5</NO>
<PG>253-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polverino-2013" MODIFIED="2014-03-11 11:10:46 +1000" MODIFIED_BY="Liz Dooley" NAME="Polverino 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-11 11:10:46 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polverino E, Cilloniz C, Dambrava P, Gabarrus A, Ferrer M, Agusti C, et al</AU>
<TI>Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome</TI>
<SO>Respirology</SO>
<YR>2013</YR>
<VL>18</VL>
<NO>2</NO>
<PG>263-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pullman-2003" MODIFIED="2014-03-14 08:34:09 +1000" MODIFIED_BY="[Empty name]" NAME="Pullman 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-03-14 08:34:09 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pullman J, Champlin J, Vrooman PS Jr</AU>
<TI>Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults</TI>
<SO>Internation Journal of Clinical Practice</SO>
<YR>2003</YR>
<VL>57</VL>
<NO>5</NO>
<PG>377-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rahav-2004" MODIFIED="2014-03-14 08:35:06 +1000" MODIFIED_BY="[Empty name]" NAME="Rahav 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-03-14 08:35:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rahav G, Fidel J, Gibor Y, Shapiro M</AU>
<TI>Azithromycin versus comparative therapy for the treatment of community acquired pneumonia</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>2</NO>
<PG>181-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramirez-1999" MODIFIED="2014-03-14 08:36:00 +1000" MODIFIED_BY="[Empty name]" NAME="Ramirez 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-03-14 08:36:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L</AU>
<TI>Sparfloxacin vs clarithromycin in the treatment of community acquired pneumonia</TI>
<SO>Clinical Therapeutics</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>1</NO>
<PG>103-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rank-2011" MODIFIED="2014-03-04 03:05:49 +1000" MODIFIED_BY="[Empty name]" NAME="Rank 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-03-04 03:05:49 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rank DR, Friedland HD, Eckburg PB, Smith A, Thye D</AU>
<TI>Integrated safety summary of ceftaroline fosamil (cpt): safety in patients overall and for patients with community-acquired pneumonia (cap)</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2011</YR>
<VL>183</VL>
<PG>A3357</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rayman-1996" MODIFIED="2014-03-14 08:36:51 +1000" MODIFIED_BY="[Empty name]" NAME="Rayman 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-03-14 08:36:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rayman J, Krchnavý M, Balciar P, Duchon J, Fortuník J, Faith L, et al</AU>
<TI>Ofloxacin once daily versus twice daily in community-acquired pneumonia and acute exacerbation of chronic bronchitis</TI>
<SO>Chemotherapy</SO>
<YR>1996</YR>
<VL>42</VL>
<PG>227-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saito-2008" MODIFIED="2009-04-06 10:00:03 +1000" MODIFIED_BY="Liz Dooley" NAME="Saito 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-04-06 10:00:03 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saito A, Watanabe A, Aoki N, Niki Y, Kohno S, Kaku M, et al</AU>
<TI>Phase III double-blind comparative study of sitafloxacin versus tosufloxacin in patients with community-acquired pneumonia</TI>
<SO>Japanese Journal of Chemotherapy</SO>
<YR>2008</YR>
<VL>56</VL>
<NO>Suppl 1</NO>
<PG>49-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-03-20 20:51:30 +1000" MODIFIED_BY="Lise M Bjerre">
<IDENTIFIER MODIFIED="2009-03-20 20:51:30 +1000" MODIFIED_BY="Lise M Bjerre" TYPE="OTHER" VALUE="Kohno 2008"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salvarezza-1998" MODIFIED="2014-03-14 08:38:02 +1000" MODIFIED_BY="[Empty name]" NAME="Salvarezza 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-03-14 08:38:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salvarezza CR, Mingrone H, Fachinelli H, Kijanczuk S</AU>
<TI>Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>Suppl B</NO>
<PG>75-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schleupner-1988" MODIFIED="2014-03-14 08:39:00 +1000" MODIFIED_BY="[Empty name]" NAME="Schleupner 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-03-14 08:39:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schleupner CJ, Anthony WC, Tan J, File TM, Lifland P, Craig W, et al</AU>
<TI>Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1988</YR>
<VL>148</VL>
<PG>343-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seki-2009" MODIFIED="2014-03-04 03:06:44 +1000" MODIFIED_BY="[Empty name]" NAME="Seki 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-04 03:06:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seki M, Higashiyama Y, Imamura Y, Nakamura S, Kurihara S, Izumikawa K, et al</AU>
<TI>A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia</TI>
<SO>Internal Medicine</SO>
<YR>2009</YR>
<VL>48</VL>
<NO>1</NO>
<PG>49-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shorr-2013" MODIFIED="2014-03-11 11:11:08 +1000" MODIFIED_BY="Liz Dooley" NAME="Shorr 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-11 11:11:08 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shorr AF, Kollef M, Eckburg PB, Llorens L, Friedland HD</AU>
<TI>Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials</TI>
<SO>Diagnostic Microbiology and Infectious Disease</SO>
<YR>2013</YR>
<VL>75</VL>
<NO>3</NO>
<PG>298-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siquier-2006" MODIFIED="2014-03-14 08:41:00 +1000" MODIFIED_BY="[Empty name]" NAME="Siquier 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-03-14 08:41:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siquier B, Sánchez-Alvarez J, García-Mendez E, Sabriá M, Santos J, Pallarés R, et al</AU>
<TI>Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2006</YR>
<VL>57</VL>
<NO>3</NO>
<PG>536-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skalsky-2012" MODIFIED="2014-03-11 11:11:16 +1000" MODIFIED_BY="Liz Dooley" NAME="Skalsky 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-11 11:11:16 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skalsky K, Yahav D, Lador A, Eliakim-Raz N, Leibovici L, Paul M</AU>
<TI>Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2013</YR>
<VL>19</VL>
<NO>4</NO>
<PG>370-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2013" MODIFIED="2014-03-11 11:11:27 +1000" MODIFIED_BY="Liz Dooley" NAME="Smith 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-11 11:11:27 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith KJ, Wateska A, Nowalk MP, Raymund M, Lee BY, Zimmerman RK, et al</AU>
<TI>Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2013</YR>
<VL>28</VL>
<NO>9</NO>
<PG>1157-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Snyman-2009" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Snyman 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Snyman JR, Schoeman HS, Grobusch MP, Henning M, Rabie W, Hira M, et al</AU>
<TI>Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>4</NO>
<PG>265-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sokol-2002" MODIFIED="2014-03-14 08:41:57 +1000" MODIFIED_BY="[Empty name]" NAME="Sokol 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-03-14 08:41:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sokol WN Jr, Sullivan JG, Acampora MD, Busman TA, Notario GF</AU>
<TI>A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia</TI>
<SO>Clinical Therapeutics</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>4</NO>
<PG>605-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sopena-2004" MODIFIED="2014-03-14 08:42:56 +1000" MODIFIED_BY="[Empty name]" NAME="Sopena 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-03-14 08:42:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sopena N, Martínez-Vázquez C, Rodríguez-Suárez JR, Segura F, Valencia A, Sabrià M</AU>
<TI>Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults</TI>
<SO>Journal of Chemotherapy</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>1</NO>
<PG>102-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stille-2000" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Stille 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stille W, Sab R, Klinge R, Loos U, Althoff P-H, Kullmann K-H</AU>
<TI>Ceftriaxon i. v./ efetametpivoxil versus efuroxim i. v./ efuroximatxetil</TI>
<SO>Chemotherapie Journal</SO>
<YR>2000</YR>
<VL>9</VL>
<NO>2</NO>
<PG>87-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2012" MODIFIED="2014-08-29 21:56:42 +1000" MODIFIED_BY="[Empty name]" NAME="Sun 2012" YEAR="">
<REFERENCE MODIFIED="2014-08-29 21:56:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun H, Maitetta R, Machineni J, Praestgaard J, Kuemell A, Stein D, et al</AU>
<TI>A single-dose study to evaluate the pharmacokinetics, safety and tolerability of multiple formulations of PTK0796 in healthy subjects</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2012</YR>
<VL>18</VL>
<NO>94</NO>
<PG>374-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tellier-2004" MODIFIED="2014-03-14 08:43:52 +1000" MODIFIED_BY="[Empty name]" NAME="Tellier 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-03-14 08:43:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B</AU>
<TI>Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2004</YR>
<VL>54</VL>
<NO>2</NO>
<PG>515-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tilyard-1992" MODIFIED="2014-03-14 08:44:48 +1000" MODIFIED_BY="[Empty name]" NAME="Tilyard 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-03-14 08:44:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tilyard MW, Dovey SM</AU>
<TI>A randomized double-blind controlled trial of roxithromycin and cefaclor in the treatment of acute lower respiratory tract infections in general practice</TI>
<SO>Diagnostic Microbiology and Infectious Disease</SO>
<YR>1992</YR>
<VL>15</VL>
<PG>97-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torres-2003" MODIFIED="2014-03-14 08:45:45 +1000" MODIFIED_BY="[Empty name]" NAME="Torres 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-03-14 08:45:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torres A, Muir JF, Corris P, Kubin R, Duprat-Lomon I, Sagnier PP, et al</AU>
<TI>Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia</TI>
<SO>European Respiratory Journal</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>1</NO>
<PG>135-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tr_x00e9_moli_x00e8_res-1998" MODIFIED="2014-03-14 08:46:47 +1000" MODIFIED_BY="[Empty name]" NAME="Trémolières 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-03-14 08:46:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trémolières F, de Kock F, Pluck N, Daniel R</AU>
<TI>Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>6</NO>
<PG>447-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tr_x00e9_moli_x00e8_res-2005" MODIFIED="2014-03-14 08:47:56 +1000" MODIFIED_BY="[Empty name]" NAME="Trémolières 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-03-14 08:47:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trémolières F, Mayaud C, Mouton Y, Weber P, Dellatolas F, Caulin E</AU>
<TI>Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults</TI>
<TO>Essai comparatif de l&#8217;efficacité et de la tolérance de la pristinamycine vs amoxicilline dans le traitement des pneumonies aigues communautaires de l&#8217;adulte</TO>
<SO>Pathologie-Biologie</SO>
<YR>2005</YR>
<VL>53</VL>
<NO>8-9</NO>
<PG>503-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Zyl-2002" MODIFIED="2014-03-14 08:48:56 +1000" MODIFIED_BY="[Empty name]" NAME="van Zyl 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-03-14 08:48:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Zyl L, le Roux JG, LaFata JA, Volk RS, Palo WA, Flamm R, et al</AU>
<TI>Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>11</NO>
<PG>1840-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Viasusa-2013" MODIFIED="2014-03-11 11:12:12 +1000" MODIFIED_BY="Liz Dooley" NAME="Viasusa 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-11 11:12:12 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Viasusa D, Garcia-Vidala C, Carratala J</AU>
<TI>Advances in antibiotic therapy for community acquired pneumonia</TI>
<SO>Current Opinion in Pulmonary Medicine</SO>
<YR>2013</YR>
<VL>19</VL>
<NO>3</NO>
<PG>209-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Worrall-2010" MODIFIED="2014-03-11 11:12:21 +1000" MODIFIED_BY="Liz Dooley" NAME="Worrall 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-03-11 11:12:21 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Worrall G, Kettle A, Graham W, Hutchinson J</AU>
<TI>Postdated versus usual delayed antibiotic prescriptions in primary care: reduction in antibiotic use for acute respiratory infections</TI>
<SO>Canadian Family Physician</SO>
<YR>2010</YR>
<VL>56</VL>
<NO>10</NO>
<PG>1032-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wunderink-2011" MODIFIED="2014-03-11 11:12:30 +1000" MODIFIED_BY="Liz Dooley" NAME="Wunderink 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-03-11 11:12:30 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, et al</AU>
<TI>Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2011</YR>
<VL>183</VL>
<NO>11</NO>
<PG>1561-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamamoto-2013" MODIFIED="2014-03-11 11:12:38 +1000" MODIFIED_BY="Liz Dooley" NAME="Yamamoto 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-11 11:12:38 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamamoto Y, Izumikawa K, Morinaga Y, Nakamura S, Kurihara S, Imamura Y, et al</AU>
<TI>Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan</TI>
<SO>Journal of Infection and Chemotherapy (Official Journal of the Japan Society of Chemotherapy)</SO>
<YR>2013</YR>
<VL>19</VL>
<NO>2</NO>
<PG>291-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2012" MODIFIED="2014-03-11 11:12:45 +1000" MODIFIED_BY="Liz Dooley" NAME="Yuan 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-11 11:12:45 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan X, Liang B-B, Wang R, Liu Y-N, Sun C-G, Cai Y, et al</AU>
<TI>Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials</TI>
<SO>Journal of Chemotherapy</SO>
<YR>2012</YR>
<VL>24</VL>
<NO>5</NO>
<PG>257-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2012" MODIFIED="2014-03-11 11:13:01 +1000" MODIFIED_BY="Liz Dooley" NAME="Zhang 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-11 11:13:01 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Huang J, Xu T, Lin Y</AU>
<TI>Procalcitonin-guided algorithms of antibiotic therapy in community-acquired lower respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials</TI>
<SO>Chinese Journal of Tuberculosis and Respiratory Diseases</SO>
<YR>2010</YR>
<VL>35</VL>
<NO>4</NO>
<PG>275-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zuck-1990" MODIFIED="2014-03-14 08:49:55 +1000" MODIFIED_BY="[Empty name]" NAME="Zuck 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-03-14 08:49:55 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuck P, Rio Y, Ichou F</AU>
<TI>Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1990</YR>
<VL>26</VL>
<NO>Suppl E</NO>
<PG>71-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2014-01-17 02:23:07 +1000" MODIFIED_BY="Smita Pakhale"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-09-02 08:04:28 +1000" MODIFIED_BY="Liz  Dooley">
<ADDITIONAL_REFERENCES MODIFIED="2014-09-02 08:04:28 +1000" MODIFIED_BY="Liz  Dooley">
<REFERENCE ID="REF-ALAT-2001" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="ALAT 2001" TYPE="JOURNAL_ARTICLE">
<AU>Grupo de trabajo de la Asociación Latinoamericana del Tórax (ALAT)</AU>
<TI>Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia</TI>
<TO>Recomendaciones ALAT sobre la neumonía adquirida en la comunidad</TO>
<SO>Archivos de Bronconeumología</SO>
<YR>2001</YR>
<VL>37</VL>
<PG>340-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ALAT-2004" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="ALAT 2004" TYPE="JOURNAL_ARTICLE">
<AU>Grupo de trabajo de la Asociación Latinoamericana del Tórax (ALAT)</AU>
<TI>Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia</TI>
<SO>Archivos de Bronconeumología</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>8</NO>
<PG>364-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Armitage-1994" NAME="Armitage 1994" TYPE="BOOK">
<AU>Armitage P, Berry G</AU>
<SO>Statistical Methods in Medical Research</SO>
<YR>1994</YR>
<EN>3rd</EN>
<PB>Blackwell Scientific Publications</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ATS-2001" NAME="ATS 2001" TYPE="JOURNAL_ARTICLE">
<AU>American Thoracic Society</AU>
<TI>Guidelines for the management of adults with community-acquired pneumonia</TI>
<SO>American Journal of Critical Care</SO>
<YR>2001</YR>
<VL>163</VL>
<PG>1730-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS-2004" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="BTS 2004" TYPE="JOURNAL_ARTICLE">
<AU>Macfarlane JT, Boldy D</AU>
<TI>2004 update of BTS pneumonia guidelines: what's new?</TI>
<SO>Thorax</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>5</NO>
<PG>364-6</PG>
<IDENTIFIERS MODIFIED="2014-08-29 22:00:02 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-24 01:45:53 +1000" MODIFIED_BY="Lise M Bjerre" TYPE="OTHER" VALUE="Macfarlane 2004"/>
<IDENTIFIER MODIFIED="2014-08-29 22:00:02 +1000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="www.brit-thoracic.org.uk/guidelines"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-BTS-2009" MODIFIED="2014-03-18 06:16:06 +1000" MODIFIED_BY="Smita Pakhale" NAME="BTS 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lim WS, Baudoui SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al</AU>
<TI>BTS guidelines for the management of community acquired pneumonia in adults: update 2009</TI>
<SO>Thorax</SO>
<YR>2009</YR>
<VL>64</VL>
<NO>Suppl 3</NO>
<PG>iii1-iii55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carratal_x00e0_-2005" MODIFIED="2014-08-30 00:29:23 +1000" MODIFIED_BY="[Empty name]" NAME="Carratalà 2005" TYPE="JOURNAL_ARTICLE">
<AU>Carratalà J, Fernández-Sabé N, Ortega L, Castellsagué X, Rosón B, Dorca J, et al</AU>
<TI>Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2005</YR>
<VL>142</VL>
<NO>3</NO>
<PG>165-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CCAPWG-2000" NAME="CCAPWG 2000" TYPE="JOURNAL_ARTICLE">
<AU>Canadian Community-Acquired Pneumonia Working Group</AU>
<TI>Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>383-421</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foy-1979" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Foy 1979" TYPE="JOURNAL_ARTICLE">
<AU>Foy HM, Cooney MK, Allan I, Kenny GE</AU>
<TI>Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975</TI>
<SO>JAMA</SO>
<YR>1979</YR>
<VL>241</VL>
<PG>253-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hedlund-2005" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Hedlund 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hedlund J, Strålin K, Ortqvist A, Holmberg H; Community-Acquired Pneumonia Working Group of the Swedish Society of Infectious Diseases</AU>
<TI>Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>2005</YR>
<VL>37</VL>
<NO>11-2</NO>
<PG>791-805</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-H_x00f6_ffken-2010" MODIFIED="2014-08-30 00:29:38 +1000" MODIFIED_BY="[Empty name]" NAME="Höffken 2010" TYPE="JOURNAL_ARTICLE">
<AU>Höffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K, et al</AU>
<TI>Guidelines of the Paul-Ehrlich-Society of Chemotherapy, the German Respiratory Diseases Society, the German Infectious Diseases Society and of the Competence Network CAPNETZ for the Management of Lower Respiratory Tract Infections and Community Acquired Pneumonia: Summary of the Update 2009</TI>
<SO>Pneumologie</SO>
<YR>2010</YR>
<VL>64</VL>
<PG>149-54</PG>
<IDENTIFIERS MODIFIED="2014-02-27 06:26:35 +1000" MODIFIED_BY="Lise M Bjerre">
<IDENTIFIER MODIFIED="2014-02-27 06:26:35 +1000" MODIFIED_BY="Lise M Bjerre" TYPE="OTHER" VALUE="German guidelines 2009"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-IDSA-2000" MODIFIED="2014-08-29 22:03:21 +1000" MODIFIED_BY="[Empty name]" NAME="IDSA 2000" TYPE="JOURNAL_ARTICLE">
<AU>Infectious Diseases Society of America</AU>
<TI>Practice guidelines for the management of community-acquired pneumonia in adults</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>347-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IDSA-2003" MODIFIED="2014-03-04 04:53:06 +1000" MODIFIED_BY="[Empty name]" NAME="IDSA 2003" TYPE="JOURNAL_ARTICLE">
<AU>Infectious Diseases Society of America</AU>
<TI>Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>37</VL>
<PG>1405-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IDSA_x002f_ATS-2007" MODIFIED="2014-08-29 22:04:24 +1000" MODIFIED_BY="[Empty name]" NAME="IDSA/ATS 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al</AU>
<TI>Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2007</YR>
<VL>44</VL>
<NO>Suppl 2</NO>
<PG>27-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jokinen-1993" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Jokinen 1993" TYPE="JOURNAL_ARTICLE">
<AU>Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Karkola K, Korppi M, et al</AU>
<TI>Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1993</YR>
<VL>137</VL>
<PG>977-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-JRS-2006" MODIFIED="2014-08-29 22:05:34 +1000" MODIFIED_BY="[Empty name]" NAME="JRS 2006" TYPE="JOURNAL_ARTICLE">
<AU>Committee for The Japanese Respiratory Society guidelines for the management of respiratory infections</AU>
<TI>Guidelines for the management of community acquired pneumonia in adults, revised edition</TI>
<SO>Respirology</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>Suppl 3</NO>
<PG>79-133</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loeb-2002" NAME="Loeb 2002" TYPE="BOOK_SECTION">
<AU>Loeb M</AU>
<TI>Community-acquired pneumonia</TI>
<SO>Clinical Evidence</SO>
<YR>2002</YR>
<VL>8</VL>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macfarlane-1984" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Macfarlane 1984" TYPE="JOURNAL_ARTICLE">
<AU>Macfarlane JT, Miller AC, Roderick Smith WH, Morris AH, Rose DH</AU>
<TI>Comparative radiographic features of community-acquired legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia and psittacosis</TI>
<SO>Thorax</SO>
<YR>1984</YR>
<VL>39</VL>
<PG>28-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maimon-2008" MODIFIED="2009-04-09 18:55:23 +1000" MODIFIED_BY="Lise M Bjerre" NAME="Maimon 2008" TYPE="JOURNAL_ARTICLE">
<AU>Maimon N, Nopmaneejumruslers C, Marras TK</AU>
<TI>Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis</TI>
<SO>European Respiratory Journal</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>5</NO>
<PG>1068-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mandell-2007" MODIFIED="2014-03-11 11:15:34 +1000" MODIFIED_BY="Liz Dooley" NAME="Mandell 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al</AU>
<TI>Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2007</YR>
<VL>44</VL>
<NO>Suppl 2</NO>
<PG>27-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Memish-2007" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Memish 2007" TYPE="JOURNAL_ARTICLE">
<AU>Memish ZA, Arabi YM, Ahmed QA, Shibl AM, Niederman MS; GCC CAP Working Group</AU>
<TI>Executive summary of the Gulf Cooperation Council practice guidelines for the management of community-acquired pneumonia</TI>
<SO>Journal of Chemotherapy</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>Suppl 1</NO>
<PG>7-11</PG>
<IDENTIFIERS MODIFIED="2009-03-24 01:48:58 +1000" MODIFIED_BY="Lise M Bjerre">
<IDENTIFIER MODIFIED="2009-03-24 01:48:56 +1000" MODIFIED_BY="Lise M Bjerre" TYPE="OTHER" VALUE="Memish 2007"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2014-09-02 08:04:28 +1000" MODIFIED_BY="Liz  Dooley" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robenshtok-2008" MODIFIED="2009-04-06 10:11:14 +1000" MODIFIED_BY="Liz Dooley" NAME="Robenshtok 2008" TYPE="COCHRANE_REVIEW">
<AU>Robenshtok E, Shefet D, Gafter-Gvili A, Paul M, Vidal L, Leibovici L</AU>
<TI>Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-04-06 10:11:14 +1000" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2009-04-06 10:11:14 +1000" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD004418.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SATS-2007" MODIFIED="2009-04-09 18:57:28 +1000" MODIFIED_BY="Lise M Bjerre" NAME="SATS 2007" TYPE="JOURNAL_ARTICLE">
<AU>Working Group of the South African Thoracic Society</AU>
<TI>Management of community-acquired pneumonia in adults</TI>
<SO>South African Medical Journal</SO>
<YR>2007</YR>
<VL>97</VL>
<NO>12 Pt 2</NO>
<PG>1296-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spindler-2012" MODIFIED="2014-03-04 04:56:14 +1000" MODIFIED_BY="Smita Pakhale" NAME="Spindler 2012" TYPE="JOURNAL_ARTICLE">
<AU>Spindler C, Strålin K, Eriksson L, Hjerdt-Goscinski G, Holmberg H, Lidman C, et al</AU>
<TI>Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults--Swedish Society of Infectious Diseases 2012</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>2012</YR>
<VL>44</VL>
<NO>12</NO>
<PG>885-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Str_x00e5_lin-2007" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Strålin 2007" TYPE="JOURNAL_ARTICLE">
<AU>Strålin K, Goscinski G, Hedlund J, Lidman C, Spindler C, Ortqvist A, et al</AU>
<TI>Management of adult patients with community-acquired pneumonia. Evidence-based guidelines from the Swedish Infectious Diseases Association</TI>
<TO>Handläggning av samhälls-förvärvad pneumoni hos vuxna. Evidensbaserade riktlinjer från Svenska infektionsläkarföreningen. (Abridged version of the 2007 update; http://www.infektion.net/klinik/lunga/pneumoni/Vardprogram_Pneumoni_slutvers_2007.pdf (in Swedish) (accessed 23 March 2009)</TO>
<SO>Lakartidningen</SO>
<YR>2008</YR>
<VL>105</VL>
<NO>38</NO>
<PG>2582-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Torres-1991" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Torres 1991" TYPE="JOURNAL_ARTICLE">
<AU>Torres A, Serra-Batlles J, Ferrer A, Jiménez P, Celis R, Cobo E, et al</AU>
<TI>Severe community-acquired pneumonia. Epidemiology and prognostic factors</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1991</YR>
<VL>144</VL>
<PG>312-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Welte-2012" MODIFIED="2014-03-04 04:56:36 +1000" MODIFIED_BY="Sunita Mulpuru" NAME="Welte 2012" TYPE="JOURNAL_ARTICLE">
<AU>Welte T, Torres A, Nathwani D</AU>
<TI>Clinical and economic burden of community-acquired pneumonia among adults in Europe</TI>
<SO>Thorax</SO>
<YR>2012</YR>
<VL>67</VL>
<PG>71-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiersinga-2011" MODIFIED="2014-08-29 22:09:06 +1000" MODIFIED_BY="[Empty name]" NAME="Wiersinga 2011" TYPE="OTHER">
<AU>Wiersinga WJ, Bonten MJ, Boersma WG, Jonkers RE, Aleva RM, Kullberg BJ, et al</AU>
<TI>Dutch guidelines on the management of community-acquired pneumonia in adults</TI>
<SO>SWAB/NVALT Guidelines Community-acquired Pneumonia</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woodhead-1987" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Woodhead 1987" TYPE="JOURNAL_ARTICLE">
<AU>Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG</AU>
<TI>Prospective study of the aetiology and outcome of pneumonia in the community</TI>
<SO>Lancet</SO>
<YR>1987</YR>
<VL>i</VL>
<PG>671-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woodhead-2011" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Woodhead 2011" TYPE="JOURNAL_ARTICLE">
<AU>Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al</AU>
<TI>Guidelines for the management of adult lower respiratory tract infections--full version</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>Suppl 6</NO>
<PG>E1-59</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-08-30 00:31:43 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bjerre-2004" MODIFIED="2014-04-16 11:35:30 +1000" MODIFIED_BY="Liz Dooley" NAME="Bjerre 2004" TYPE="COCHRANE_REVIEW">
<AU>Bjerre LM, Verheij TJ, Kochen MM</AU>
<TI>Antibiotics for community acquired pneumonia in adult outpatients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-04-16 11:35:30 +1000" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2014-04-16 11:35:30 +1000" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD002109.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bjerre-2009" MODIFIED="2014-08-30 00:31:43 +1000" MODIFIED_BY="[Empty name]" NAME="Bjerre 2009" TYPE="COCHRANE_REVIEW">
<AU>Bjerre LM, Verheij TJ, Kochen MM</AU>
<TI>Antibiotics for community acquired pneumonia in adult outpatients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-03-09 13:45:13 +1000" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2014-03-09 13:45:12 +1000" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD002109.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-08-30 00:34:21 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-08-30 00:34:21 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-08-30 00:25:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1991">
<CHAR_METHODS MODIFIED="2014-07-15 08:11:35 +1000" MODIFIED_BY="Liz  Dooley">
<P>Date and duration of study: not specified. Follow-up: 6 to 8 weeks. Patients were included from 57 general practitioners in the UK. Double-blind, double-dummy technique, intention-to-treat results provided</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-15 07:59:28 +1000" MODIFIED_BY="Liz  Dooley">
<P>Patients with CAP older than 18 years. CAP diagnosis confirmed by 3 of the following features: pyrexia, dyspnoea, tachypnoea, rales, localised reduced breath sounds and cough. Diagnosis of CAP was later confirmed radiographically. Total: n = 208. Evaluable for efficacy: n = 108 (exclusion usually due to failure to confirm initial diagnosis on CXR), n = 64 (clarithromycin), n = 44 (erythromycin). Exclusion criteria clear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-30 00:25:49 +1000" MODIFIED_BY="[Empty name]">
<P>Clarithromycin 250 mg twice daily for 14 days or erythromycin 500 mg 4 times daily for 14 days, each given at least 1 hour before or 2 hours after meals, mean treatment duration: 13 days (clarithromycin), or 10 days (erythromycin). Compliance assessment: tablet count</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: clinical response at 2 weeks (test-of-cure visit): 98% (clarithromycin), 91% (erythromycin). Treatment-related adverse events: 16% (clarithromycin) versus 33% (erythromycin), P value = 0.004, mainly gastrointestinal side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-15 08:13:16 +1000" MODIFIED_BY="Liz  Dooley">
<P>3 of 5 authors from Abbott Laboratories, source of funding not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chien-1993">
<CHAR_METHODS MODIFIED="2014-07-15 08:13:27 +1000" MODIFIED_BY="Liz  Dooley">
<P>Date and duration of study: January 1989 to June 1990. Follow-up: 4 to 6 weeks. Multicentre study (15 centres of the Canada-Sweden Clarithromycin-Pneumonia Study Group, 11 in Canada, 4 in Sweden). Double-blind, double-dummy technique, no intention-to-treat results provided</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-16 13:59:10 +1000" MODIFIED_BY="Liz Dooley">
<P>Ambulatory patients older than 12 years with CAP. N = 268 all patients, after exclusions 173 "evaluable patients": n = 92 (clarithromycin), n = 81 (erythromycin). Patients with mild or moderate infection. Drop-outs: 35% (due to less than minimum therapy, premature discontinuation, unavailable for follow-up, misdiagnosis, inadequate data collection, concomitant medication, underlying condition). Exclusion criteria clear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-16 13:59:16 +1000" MODIFIED_BY="Liz Dooley">
<P>Clarithromycin: 250 mg every 12 hours, or erythromycin stearate: 500 mg every 6 hours. Mean treatment duration not specified (minimum duration: 7 days, intended duration: 7 to 14 days). Compliance assessment: tablet count</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: clinical success (cure and improvement) 97% clarithromycin, 96% erythromycin. Treatment-related adverse events: 31% clarithromycin, 59% erythromycin (P value &lt; 0.001)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-18 05:31:14 +1000" MODIFIED_BY="[Empty name]">
<P>Research supported by Abbott Laboratories, Chicago</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-30 00:34:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Ignazio-2005">
<CHAR_METHODS MODIFIED="2014-07-15 07:44:33 +1000" MODIFIED_BY="Liz  Dooley">
<P>Date and duration of study: April 2003 to April 2004. Double-blind, double-dummy, non-inferiority trial, patients were recruited from 56 centres worldwide (Canada, Chile, India, Lithuania, Mexico, Peru, Russia, United States)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-29 20:45:54 +1000" MODIFIED_BY="[Empty name]">
<P>427 outpatients, 18 years or older, 423 patients received the study medication. Patients were eligible for enrolment if they had a clinical diagnosis of mild to moderate CAP (signs and symptoms) and radiographic evidence of new pulmonary infiltrate. Patients also had to have a Fine Mortality risk class of I, II or III (&lt; 90 points). Exclusion criteria are clearly listed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Single, 2 g dose of azithromycin microspheres versus levofloxacin 500 mg once daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-30 00:34:16 +1000" MODIFIED_BY="[Empty name]">
<P>Primary endpoint: clinical response in the clinical per protocol population, on the basis of signs and symptoms of CAP, assessed at test-of-cure visit (TOC; day 13 to 21): azithromycin 89.7%, levofloxacin 93.7%, non-significant difference. Treatment-related adverse effects: azithromycin 19.9%, levofloxacin 12.3%, P value = 0.0063, mainly gastrointestinal side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-18 05:32:51 +1000" MODIFIED_BY="[Empty name]">
<P>Study funded by Pfizer Inc., 3 of 5 authors are employees of Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Drehobl-2005">
<CHAR_METHODS MODIFIED="2014-07-15 07:44:29 +1000" MODIFIED_BY="Liz  Dooley">
<P>Date and duration of study: not specified. Double-blind, double-dummy, phase III trial, conducted in 58 outpatient centres worldwide (United States, Canada, Argentina, Russia, India, Estonia, Lithuania)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-16 13:57:03 +1000" MODIFIED_BY="Liz Dooley">
<P>501 outpatients, 16 years or older. Patients were eligible for enrolment if they had a clinical diagnosis of mild to moderate CAP (signs and symptoms) and radiographic evidence of new pulmonary infiltrate. Patients also had to have a modified Fine risk score of I or II (&lt; 70 points)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Single 2 g dose of azithromycin microspheres administered as an oral suspension versus extended-release clarithromycin administered orally as 2 x 500 mg capsules once daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Primary endpoint: clinical response in the clinical per protocol population, on the basis of signs and symptoms of CAP, assessed at test-of-cure visit (TOC; day 14 to 21): azithromycin 91.8% versus clarithromycin 94.7% (non-significant difference). Treatment-related adverse effects: azithromycin 26.3% versus clarithromycin 24.6% (non-significant difference), mainly gastrointestinal side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-18 05:34:26 +1000" MODIFIED_BY="[Empty name]">
<P>Study funded by Pfizer Inc., 2 of 4 authors are employees of Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-15 08:15:18 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-English-2012">
<CHAR_METHODS MODIFIED="2014-07-15 08:15:18 +1000" MODIFIED_BY="Liz  Dooley">
<P>2 phase 3 prospective, double-blinded RCTs, parallel-group, multicentre, multinational studies</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-16 14:04:35 +1000" MODIFIED_BY="Liz Dooley">
<P>Male or female participants &gt; 18 years from outpatient clinics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-11 10:48:08 +1000" MODIFIED_BY="Liz Dooley">
<P>Oral cethromycin versus oral clarithromycin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-11 10:48:34 +1000" MODIFIED_BY="Liz Dooley">
<P>Primary: clinical and radiological response. Secondary: bacteriological response, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-11 11:02:30 +1000" MODIFIED_BY="Liz Dooley">
<P>This trial included results from 2 separate RCTs. However, results were pooled and the interventions were identical. The results of the 2 studies are reported as 1 in the article. Study setting was South Africa, USA, Canada, South America, Europe, Israel</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-30 00:34:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kohno-2003">
<CHAR_METHODS MODIFIED="2014-07-15 07:44:38 +1000" MODIFIED_BY="Liz  Dooley">
<P>Date and duration of study: December 2000 to June 2001. Double-blind, double dummy, randomised phase III trial, conducted in 117 centres in Japan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-16 14:01:02 +1000" MODIFIED_BY="Liz Dooley">
<P>270 patients (mix of in- and outpatients), aged 16 to 80 years. 123 outpatients were included. Exclusion criteria are clearly stated and patient selection flow chart is provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-16 14:04:19 +1000" MODIFIED_BY="Liz Dooley">
<P>Telithromycin 600 mg (= 2 x 300 mg) once daily after breakfast versus levofloxacin 100 mg 3 times daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-30 00:34:18 +1000" MODIFIED_BY="[Empty name]">
<P>Results are reported separately for in- and outpatients. Primary endpoint: clinical response in the clinical per protocol population, on the basis of signs and symptoms of CAP, assessed at end of treatment (EOT; 7 days after treatment initiation) telithromycin 95.7% versus clarithromycin 96.3% (non-significant difference). Treatment-related adverse effects: telithromycin 33.6% versus levofloxacin 33.9% (non-significant difference), mostly gastrointestinal side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-16 14:01:32 +1000" MODIFIED_BY="Liz Dooley">
<P>Study report is in Japanese, but extensive figures and tables are provided in English, so that most of the necessary information could be extracted. Missing information was kindly provided by the main author, Prof. Shigeru Kohno, MD, PhD, of Nagasaki University, Japan. Funding provided by Astellas (Fujisawa) Pharmaceutical Co. Ltd</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-30 00:34:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mathers-Dunbar-2004">
<CHAR_METHODS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Date and duration of study: May 1998 to September 1999. Double-blind, double-dummy, parallel-group clinical trial conducted at 54 centres in 4 countries (United States, Canada, Argentina and Chile)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-15 07:44:42 +1000" MODIFIED_BY="Liz  Dooley">
<P>493 outpatients aged 18 and over. Patients were eligible for enrolment if they had a clinical diagnosis of acute CAP (signs and symptoms) and chest radiographic findings supporting the clinical diagnosis of bacterial pneumonia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Telithromycin 800 mg (= 2 x 400 mg capsules) once daily in the morning versus clarithromycin 500 mg (= 2 x 250 mg capsules) twice daily for 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-30 00:34:21 +1000" MODIFIED_BY="[Empty name]">
<P>Primary endpoint: clinical response in the clinically assessable per protocol population, on the basis of signs and symptoms of CAP, assessed at test-of-cure visit (TOC; day 17 to 24): telithromycin 88.3% versus clarithromycin 88.5% (non-significant difference). Treatment-related adverse effects: telithromycin 38.5% versus clarithromycin 27.9%, mostly gastrointestinal side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-18 05:37:50 +1000" MODIFIED_BY="[Empty name]">
<P>Funded by an unrestricted educational grant from Aventis Pharmaceuticals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-30 00:25:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oldach-2013">
<CHAR_METHODS MODIFIED="2014-08-30 00:25:02 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, multicentre, phase 2 study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-11 10:50:47 +1000" MODIFIED_BY="Liz Dooley">
<P>Males and females &gt; 18 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-11 10:50:55 +1000" MODIFIED_BY="Liz Dooley">
<P>Oral solithromycin versus oral levofloxacin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-11 10:51:18 +1000" MODIFIED_BY="Liz Dooley">
<P>Primary: clinical response. Secondary: bacteriological response, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-11 11:23:05 +1000" MODIFIED_BY="Liz Dooley">
<P>Study done in USA and Canada. Did not explicitly state the setting in which patients were recruited</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Udupa-2011">
<CHAR_METHODS MODIFIED="2014-07-15 07:59:53 +1000" MODIFIED_BY="Liz  Dooley">
<P>Randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Males and females 18 to 55 years of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Oral clarithromycin/oral azithromycin or oral levofloxacin/oral high-dose amoxicillin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-11 10:53:15 +1000" MODIFIED_BY="Liz Dooley">
<P>Primary: clinical response. Secondary: adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-04 07:27:30 +1000" MODIFIED_BY="[Empty name]">
<P>Study conducted in Rural Health Training Centre in India</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vacarezza-2010">
<CHAR_METHODS MODIFIED="2014-07-15 07:59:54 +1000" MODIFIED_BY="Liz  Dooley">
<P>Randomised, double-blinded study (outpatients), single-blinded (inpatients)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-11 10:53:41 +1000" MODIFIED_BY="Liz Dooley">
<P>Adult males and females &gt; 18 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-29 20:52:33 +1000" MODIFIED_BY="[Empty name]">
<P>Oral clarithromycin versus oral amoxicillin for outpatients study arm</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-11 10:54:15 +1000" MODIFIED_BY="Liz Dooley">
<P>Primary: clinical response. Secondary: adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Article in Spanish; translation done by Dr. RA Rodriguez, Dr. Gonzalo Alvarez and Dr. Jacqueline Sandoz (Department of Medicine, University of Ottawa)</P>
<P>Hospitalised patients are included in the study but separate results for inpatients and outpatients are provided. Study conducted in Uruguay</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Rensburg-2010a">
<CHAR_METHODS MODIFIED="2014-07-15 08:17:39 +1000" MODIFIED_BY="Liz  Dooley">
<P>Randomised, double-blind, multicentre, multinational study, with 3 treatment arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-11 11:01:46 +1000" MODIFIED_BY="Liz Dooley">
<P>Adult males and females &gt; 18 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-11 11:23:28 +1000" MODIFIED_BY="Liz Dooley">
<P>Oral nemonoxacin 750 mg versus levofloxacin 500 mg daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-11 10:54:50 +1000" MODIFIED_BY="Liz Dooley">
<P>Primary: clinical response. Secondary: bacteriological response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Study was partially supported by grant from Government of Taiwan. Study conducted in Taiwan and South Africa</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Rensburg-2010b">
<CHAR_METHODS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, multicentre, multinational study, with 3 treatment arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-11 10:56:14 +1000" MODIFIED_BY="Liz Dooley">
<P>Adult males and females &gt; 18 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-11 10:56:27 +1000" MODIFIED_BY="Liz Dooley">
<P>Oral nemonoxacin 500 mg versus levofloxacin 500 mg daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-11 10:55:45 +1000" MODIFIED_BY="Liz Dooley">
<P>Primary: clinical response. Secondary: bacteriological response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Study was partially supported by grant from Government of Taiwan. Study conducted in Taiwan and South Africa</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CAP: community-acquired pneumonia<BR/>CXR: chest x-ray<BR/>EOT: end of treatment<BR/>IVRS: interactive voice response system<BR/>n: number<BR/>RCT: randomised controlled trial<BR/>TOC: test-of-cure</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-08-30 00:25:30 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:19:42 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Alcacer-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:19:42 +1000" MODIFIED_BY="Liz  Dooley">
<P>Hospitalised patients only included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-15 21:51:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arifin-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-15 21:51:40 +1000" MODIFIED_BY="[Empty name]">
<P>Conference abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 20:56:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bai-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 20:56:54 +1000" MODIFIED_BY="[Empty name]">
<P>Meta-analysis of RCTs on ertapenem and ceftriaxone: inpatients only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-30 00:25:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Balgos-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-30 00:25:30 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of in- and outpatients (unspecified proportions)<BR/>Mix of diagnoses (chronic bronchitis and CAP), only about 50% with CAP; results reported separately<BR/>Comparison of 2 dosage regimens of the same drug (amoxycillin/clavulanic acid 875/125 mg twice daily versus 500/125 mg 3 times daily)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ball-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Review of a series of unblinded trials<BR/>Mix of patients from different studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Balmes-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of diagnoses (acute bronchitis and pneumonia)<BR/>Only 8/110 patients (7%) had a diagnosis of pneumonia<BR/>Mix of in- and outpatients (unspecified proportions)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bantz-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of diagnoses (bronchitis and pneumonia)<BR/>Only 15/108 patients (14%) had a diagnosis of pneumonia<BR/>Data not reported separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:40:12 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biermann-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:40:12 +1000" MODIFIED_BY="[Empty name]">
<P>No chest X-ray for every patient with suspected pneumonia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-24 07:49:45 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Blasi-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-24 07:49:45 +1000" MODIFIED_BY="Smita Pakhale">
<P>Patients with chronic bronchitis were included, not CAP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Block-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Children with a mean age of 11; comparison of same antibiotic with different doses; indication for treatment consists of mix of diagnoses besides CAP; some diagnoses not confirmed by chest X-ray</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-19 01:14:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bonvehi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-19 01:14:15 +1000" MODIFIED_BY="[Empty name]">
<P>Focus on pneumococcal CAP; positive sputum cultures used as a selection criterion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:20:10 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Bothra-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:20:10 +1000" MODIFIED_BY="Liz  Dooley">
<P>Study not randomised, expert opinion only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-14 01:44:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brittain_x002d_Long-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-14 01:44:36 +1000" MODIFIED_BY="[Empty name]">
<P>Study did not address antibiotic treatment for CAP and URTIs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carbon-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of in- and outpatients, data not reported separately; authors did not respond, or separate data could not be provided by authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:20:16 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Casapao-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:20:16 +1000" MODIFIED_BY="Liz  Dooley">
<P>Study not randomised, expert opinion only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:40:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chodosh-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:40:41 +1000" MODIFIED_BY="[Empty name]">
<P>Only bacteriologically evaluable patients were included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:20:20 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Critchley-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:20:20 +1000" MODIFIED_BY="Liz  Dooley">
<P>Hospitalised patients only included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daniel-1999a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Hospitalised patients included; study uses trovafloxacin - not recommended for treatment of CAP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daniel-1999b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Hospitalised patients included; study uses trovafloxacin - not recommended for treatment of CAP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dark-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of diagnoses (bronchitis and pneumonia)<BR/>Only 23/272 patients (8%) had a diagnosis of pneumonia<BR/>Mix of in- and outpatients (unspecified proportions)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 21:00:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dartois-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 21:00:21 +1000" MODIFIED_BY="[Empty name]">
<P>Pooled analysis of 2 phase 3 studies on tigecycline versus levofloxacin iv - inpatients only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:41:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dautzenberg-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:41:04 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Cock-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of diagnoses (acute bronchitis, acute superinfection of chronic bronchitis, pneumonia) and results reported separately<BR/>Only 42/198 patients (21%) had a diagnosis of pneumonia (results not reported separately for each diagnostic group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:41:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dean-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:41:18 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-17 07:29:35 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Donowitz-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-17 07:29:35 +1000" MODIFIED_BY="Liz Dooley">
<P>Focus on bacterial pneumonia (acute onset, purulent sputum, Gram stain and chest X-ray consistent with bacterial pneumonia were required for inclusion into the study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-24 08:08:45 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Esposito-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-24 08:08:45 +1000" MODIFIED_BY="Smita Pakhale">
<P>Review article, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-File-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of in- and outpatients, data not reported separately; authors did not respond, or separate data could not be provided by authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-File-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of in- and outpatients, data not reported separately; authors did not respond, or separate data could not be provided by authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:41:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-File-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:41:57 +1000" MODIFIED_BY="[Empty name]">
<P>Focus on bacterial pneumonia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-File-2012a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Report on safety and efficacy of ceftaroline fosamil; not a RCT; hospitalised patients included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:21:13 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-File-2012b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:21:13 +1000" MODIFIED_BY="Liz  Dooley">
<P>Hospitalised patients included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fogarty-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of in- and outpatients, data not reported separately; authors did not respond, or separate data could not be provided by authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:21:26 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Fogarty-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:21:26 +1000" MODIFIED_BY="Liz  Dooley">
<P>Focus on bacterial pneumonia. Serologic evidence of <I>M. pneumoniae</I> or <I>C. pneumoniae</I> was an exclusion criterion; serologic testing was systematically carried out pre-treatment as well as twice after treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:21:31 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Fogarty-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:21:31 +1000" MODIFIED_BY="Liz  Dooley">
<P>Hospitalised patients only included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:42:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fong-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:42:45 +1000" MODIFIED_BY="[Empty name]">
<P>Too small (n &lt; 30)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-24 08:15:05 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Fujita-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-24 08:15:05 +1000" MODIFIED_BY="Smita Pakhale">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-24 08:16:07 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Ghebremedhin-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-24 08:16:07 +1000" MODIFIED_BY="Smita Pakhale">
<P>Study on pharmacokinetics and pharmacodynamics of sitafloxacin, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:42:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gotfried-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:42:53 +1000" MODIFIED_BY="[Empty name]">
<P>Culture confirmation of bacterial CAP required</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:43:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gris-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:43:01 +1000" MODIFIED_BY="[Empty name]">
<P>Too small (n &lt; 30)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hagberg-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of in and outpatients, data not reported separately; authors did not respond, or separate data could not be provided by authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:43:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Higuera-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:43:21 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:22:05 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Hoeffken-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:22:05 +1000" MODIFIED_BY="Liz  Dooley">
<P>Patients were recruited as outpatients. However, 30% were hospitalised in the course of the study, data for in- and outpatients are not reported separately, and hospitalisation was not considered treatment failure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoepelman-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of diagnoses (infective exacerbation of chronic obstructive pulmonary disease, purulent bronchitis and pneumonia) and results not reported separately<BR/>Only 9/99 patients (9%) had pneumonia. Pneumonia not necessarily community-acquired</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-17 07:27:43 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Hoepelman-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-17 07:27:43 +1000" MODIFIED_BY="Liz Dooley">
<P>Mix of diagnoses (infective exacerbation of chronic obstructive pulmonary disease, purulent bronchitis and pneumonia) and results not reported separately; only 3 of 144 patients had CAP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:44:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kammer-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:44:03 +1000" MODIFIED_BY="[Empty name]">
<P>Only bacteriologically evaluable patients were included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kiani-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of in and outpatients, data not reported separately<BR/>Mix of diagnoses (acute bronchitis, pneumonia, acute exacerbation of chronic bronchopulmonary infection) but data reported separately<BR/>Only 10/110 patients (9%) had a diagnosis of pneumonia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-17 07:27:25 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Kinasewitz-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-17 07:27:25 +1000" MODIFIED_BY="Liz Dooley">
<P>Focus on bacterial pneumonia (purulent sputum and leucocytosis were required for inclusion into study, patients without sputum pathogens were excluded from efficacy analysis, etc.)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:22:39 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Kohno-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:22:39 +1000" MODIFIED_BY="Liz  Dooley">
<P>Hospitalised patients only included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lacny-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of diagnoses (infection of soft tissue, infection of the upper respiratory tract, otitis, skin infection, conjunctivitis, pneumonia) and results not reported separately<BR/>Only 2/121 patients (2.6%) had a diagnosis of pneumonia<BR/>Completely institutionalised population<BR/>32.5% patients were younger than 16 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-24 08:20:14 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Lagler-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-24 08:20:14 +1000" MODIFIED_BY="Smita Pakhale">
<P>Comparison of same antibiotic with different doses (abstract only)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laurent-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of diagnoses (acute bronchitis, acute infectious exacerbations of chronic bronchitis or pneumonia) but results reported separately<BR/>Only 43/204 patients (21%) had a diagnosis of pneumonia<BR/>Mix of in- and outpatients (unclear in which proportions)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:23:02 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Lee-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:23:02 +1000" MODIFIED_BY="Liz  Dooley">
<P>Hospitalised patients only included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:44:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leophonte-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:44:49 +1000" MODIFIED_BY="[Empty name]">
<P>Focus on pneumococcal pneumonia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:44:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liipo-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:44:58 +1000" MODIFIED_BY="[Empty name]">
<P>Dirithromycin withdrawn from market</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-24 07:50:34 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Little-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-24 07:50:34 +1000" MODIFIED_BY="Smita Pakhale">
<P>Patients with CAP excluded, only patients with lower respiratory tract infection were included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lode-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Only inpatients (personal communication H. Lode), contrary to study report (patients reportedly treated as either in- or outpatients)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lode-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Combines patients from 4 other RCTs, including only those patients with <I>S. pneumoniae</I> pneumonia confirmed by blood culture, i.e. highly select subgroup, generalisability questionable. The data from the 4 studies can be obtained from the original reports (one of which is Örtqvist 1996, already excluded from this review because open-label)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:45:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lode-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:45:28 +1000" MODIFIED_BY="[Empty name]">
<P>Gatifloxacin withdrawn from market</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:45:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lode-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:45:31 +1000" MODIFIED_BY="[Empty name]">
<P>Gatifloxacin withdrawn from market</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-14 01:49:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Long-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-14 01:49:45 +1000" MODIFIED_BY="[Empty name]">
<P>Not comparing treatment looking at antibiotic reduction, not comparing antibiotic use</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 21:12:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lopez_x002d_Vejar-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 21:12:16 +1000" MODIFIED_BY="[Empty name]">
<P>Comparison levofloxacin versus ceftriaxone/clarithromycin iv - inpatients only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:45:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MacFarlane-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:45:43 +1000" MODIFIED_BY="[Empty name]">
<P>Single-blind study, no chest X-ray required</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-11 11:24:07 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Matzneller-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-11 11:24:07 +1000" MODIFIED_BY="Liz Dooley">
<P>A study about tissue pharmacokinetics and pharmacodynamics, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montassier-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>A critical and synthetic review of the literature, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:45:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moola-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:45:52 +1000" MODIFIED_BY="[Empty name]">
<P>Grepafloxacin withdrawn from market</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:46:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-M_x00fc_ller-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:46:00 +1000" MODIFIED_BY="[Empty name]">
<P>Only bacteriologically evaluable patients were included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-24 07:53:01 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Naderer-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-24 07:53:01 +1000" MODIFIED_BY="Smita Pakhale">
<P>A pharmacokinetic study on healthy volunteers, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:46:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NAPSG-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:46:08 +1000" MODIFIED_BY="[Empty name]">
<P>Fleroxacin withdrawn from market</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:24:09 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Navarta-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:24:09 +1000" MODIFIED_BY="Liz  Dooley">
<P>Hospitalised patients only included, not clear if diagnosis confirmed by chest X-ray</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-17 07:25:27 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Neu-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-17 07:25:27 +1000" MODIFIED_BY="Liz Dooley">
<P>Mix of diagnoses (acute bacterial exacerbation of chronic bronchitis or asthmatic bronchitis and bacterial pneumonia) and data not reported separately<BR/>Unclear whether in- or outpatients. Only 43/213 (20%) had a diagnosis of CAP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-24 07:53:53 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Nussenblatt-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-24 07:53:53 +1000" MODIFIED_BY="Smita Pakhale">
<P>A review of interventions to improve outcomes in CAP patients, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-17 07:25:11 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-O_x0027_Doherty-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-17 07:25:11 +1000" MODIFIED_BY="Liz Dooley">
<P>Grepafloxacin withdrawn from worldwide market in October 1999 due to risk of severe arrhythmias</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:46:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Doherty-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:46:37 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pavie-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Descriptive study, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:46:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petitpretz-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:46:52 +1000" MODIFIED_BY="[Empty name]">
<P>Focus on pneumococcal pneumonia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:46:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peugeot-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:46:58 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:24:39 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Polverino-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:24:39 +1000" MODIFIED_BY="Liz  Dooley">
<P>Hospitalised patients only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:24:45 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Pullman-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:24:45 +1000" MODIFIED_BY="Liz  Dooley">
<P>Excluded because trovafloxacin no longer available for outpatients due to severe hepatotoxicity. Study recruitment was terminated because FDA restricted use of trovafloxacin to hospitalised patients with severe life- or limb-threatening infections (1999)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:47:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rahav-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:47:17 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-17 07:24:45 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Ramirez-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-17 07:24:45 +1000" MODIFIED_BY="Liz Dooley">
<P>Sparfloxacin withdrawn from market due to increased risk of severe phototoxicity and rash, as well as rhabdomyolysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-24 08:42:28 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Rank-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-24 08:42:28 +1000" MODIFIED_BY="Smita Pakhale">
<P>Cohort of RCTs, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rayman-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Comparison of different dosage regimens of the same drug<BR/>Included patients with either CAP or acute exacerbation of chronic bronchitis (i.e. mixed indications)<BR/>Groups were not similar at baseline (more smokers and more failures of previous treatment in the "twice daily" group, for which more adverse reactions were reported)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saito-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of in- and outpatients, separate data for outpatients not available</P>
<P>Note: article in Japanese. However, tables and figures in English; additional information obtained through personal communication with one of the authors (Kohno S)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:47:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salvarezza-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:47:52 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schleupner-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of diagnoses (bronchitis, pneumonia)<BR/>Only 34/61 patients (56%) had a diagnosis of pneumonia<BR/>Mix of in- and outpatients (unspecified proportions)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:25:15 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Seki-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:25:15 +1000" MODIFIED_BY="Liz  Dooley">
<P>Hospitalised patients included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:25:21 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Shorr-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:25:21 +1000" MODIFIED_BY="Liz  Dooley">
<P>Hospitalised patients only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:48:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Siquier-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:48:10 +1000" MODIFIED_BY="[Empty name]">
<P>Focus on pneumococcal pneumonia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-17 07:24:04 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Skalsky-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-17 07:24:04 +1000" MODIFIED_BY="Liz Dooley">
<P>A systematic review and meta-analysis of RCTs for CAP. We searched the back references of this paper to check for any studies suitable for our review. Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-24 07:56:34 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Smith-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-24 07:56:34 +1000" MODIFIED_BY="Smita Pakhale">
<P>Cost-effectiveness analysis, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Snyman-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Comparison of same antibiotic; mix of diagnoses not just CAP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sokol-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Excluded because trovafloxacin no longer indicated for outpatients, later removed from market due to severe hepatotoxicity. Study recruitment was terminated because FDA restricted use of trovafloxacin to hospitalised patients with severe life- or limb-threatening infections (1999)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:48:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sopena-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:48:25 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:25:48 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Stille-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:25:48 +1000" MODIFIED_BY="Liz  Dooley">
<P>Hospitalised patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-17 07:23:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Sun-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-17 07:23:02 +1000" MODIFIED_BY="Liz Dooley">
<P>Healthy participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tellier-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of in- and outpatients, data not reported separately; authors did not respond, or separate data could not be provided by authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:48:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tilyard-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:48:44 +1000" MODIFIED_BY="[Empty name]">
<P>Too small (n &lt; 30)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Torres-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Mix of in- and outpatients, data not reported separately; authors did not respond, or separate data could not be provided by authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:49:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tr_x00e9_moli_x00e8_res-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:49:02 +1000" MODIFIED_BY="[Empty name]">
<P>Trovafloxacin withdrawn from market due to severe hepatotoxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:49:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tr_x00e9_moli_x00e8_res-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:49:08 +1000" MODIFIED_BY="[Empty name]">
<P>Focus on bacterial pneumonia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-17 07:22:32 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-van-Zyl-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-17 07:22:32 +1000" MODIFIED_BY="Liz Dooley">
<P>Focus on bacterial pneumonia; purulent sputum sample required; patients with serologic evidence of <I>Mycoplasma pneumoniae</I> or <I>Chlamydophila pneumoniae</I> were excluded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-24 07:57:32 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Viasusa-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-24 07:57:32 +1000" MODIFIED_BY="Smita Pakhale">
<P>A review of CAP treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-11 08:15:43 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Worrall-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-11 08:15:43 +1000" MODIFIED_BY="Smita Pakhale">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-11 08:15:22 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Wunderink-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-11 08:15:22 +1000" MODIFIED_BY="Smita Pakhale">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:26:19 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Yamamoto-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:26:19 +1000" MODIFIED_BY="Liz  Dooley">
<P>Hospitalised patients only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-24 08:37:01 +1000" MODIFIED_BY="Smita Pakhale" STUDY_ID="STD-Yuan-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-24 08:37:01 +1000" MODIFIED_BY="Smita Pakhale">
<P>Meta-analysis of RCTs, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-17 07:22:03 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Zhang-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-17 07:22:03 +1000" MODIFIED_BY="Liz Dooley">
<P>Systematic review and meta-analysis, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-15 08:26:33 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Zuck-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-15 08:26:33 +1000" MODIFIED_BY="Liz  Dooley">
<P>Open-label, unblinded study comparing oral administration twice daily versus intramuscular administration once daily. Included only high-risk patients; unclear whether treated as in- or outpatients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-18 05:49:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x00d6_rtqvist-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-18 05:49:34 +1000" MODIFIED_BY="[Empty name]">
<P>Patients had CAP but were treated exclusively as inpatients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CAP: community-acquired pneumonia<BR/>FDA: Food and Drug Administration<BR/>iv: intravenous<BR/>RCT: randomised controlled trial<BR/>URTIs: upper respiratory tract infections<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-01-17 02:23:07 +1000" MODIFIED_BY="Smita Pakhale" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-07-15 08:14:31 +1000" MODIFIED_BY="Liz  Dooley" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 07:59:30 +1000" MODIFIED_BY="Liz  Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1991">
<DESCRIPTION>
<P>Randomisation method not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 07:59:31 +1000" MODIFIED_BY="Liz  Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Chien-1993">
<DESCRIPTION>
<P>Randomisation method not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 07:59:42 +1000" MODIFIED_BY="Liz  Dooley" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Ignazio-2005">
<DESCRIPTION>
<P>Randomisation method not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 08:14:31 +1000" MODIFIED_BY="Liz  Dooley" RESULT="YES" STUDY_ID="STD-Drehobl-2005">
<DESCRIPTION>
<P>Quote: "Subjects were randomised according to computer-generated pseudo random code using the method of permutated blocks, balanced within investigational site"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 07:59:47 +1000" MODIFIED_BY="Liz  Dooley" RESULT="YES" STUDY_ID="STD-English-2012">
<DESCRIPTION>
<P>Randomisation done by interactive voice response system (IVRS)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 05:36:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kohno-2003">
<DESCRIPTION>
<P>Text in Japanese; tables and figures in English</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 07:44:42 +1000" MODIFIED_BY="Liz  Dooley" RESULT="YES" STUDY_ID="STD-Mathers-Dunbar-2004">
<DESCRIPTION>
<P>Quote: "Patients... were randomised according to a schedule generated by the sponsor for each centre. The schedule linked sequential treatment assignment number to treatment codes allocated at random."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 07:59:52 +1000" MODIFIED_BY="Liz  Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Oldach-2013">
<DESCRIPTION>
<P>Randomisation stratified by age and pneumonia severity index (PORT score), but method of randomisation not explicitly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 07:44:42 +1000" MODIFIED_BY="Liz  Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Udupa-2011">
<DESCRIPTION>
<P>No stated method of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 07:44:44 +1000" MODIFIED_BY="Liz  Dooley" RESULT="YES" STUDY_ID="STD-Vacarezza-2010">
<DESCRIPTION>
<P>Block randomisation by PORT score was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 07:44:44 +1000" MODIFIED_BY="Liz  Dooley" RESULT="UNKNOWN" STUDY_ID="STD-van-Rensburg-2010a">
<DESCRIPTION>
<P>No explicit mention of randomisation methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 07:44:44 +1000" MODIFIED_BY="Liz  Dooley" RESULT="UNKNOWN" STUDY_ID="STD-van-Rensburg-2010b">
<DESCRIPTION>
<P>No explicit mention of randomisation methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 08:12:22 +1000" MODIFIED_BY="Liz  Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1991">
<DESCRIPTION>
<P>Randomisation method not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 07:44:24 +1000" MODIFIED_BY="Liz  Dooley" RESULT="YES" STUDY_ID="STD-Chien-1993">
<DESCRIPTION>
<P>Quote: "The randomisation was blinded to both the investigators and the patients."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Ignazio-2005">
<DESCRIPTION>
<P>Randomisation method not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 08:14:36 +1000" MODIFIED_BY="Liz  Dooley" RESULT="YES" STUDY_ID="STD-Drehobl-2005">
<DESCRIPTION>
<P>Quote: "Randomization numbers were assigned by a central Web/telephone computer-based telerandomization system"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 10:49:51 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-English-2012">
<DESCRIPTION>
<P>IVRS assigned numerically coded blister cards to each participant containing either cethromycin or clarithromycin or placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 05:36:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kohno-2003">
<DESCRIPTION>
<P>Text in Japanese; tables and figures in English</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mathers-Dunbar-2004">
<DESCRIPTION>
<P>Quote: "Randomization schedules were held by the sponsor."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 02:56:51 +1000" MODIFIED_BY="Smita Pakhale" RESULT="UNKNOWN" STUDY_ID="STD-Oldach-2013">
<DESCRIPTION>
<P>Not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 11:23:07 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Udupa-2011">
<DESCRIPTION>
<P>Not explicitly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 11:23:10 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Vacarezza-2010">
<DESCRIPTION>
<P>Not explicitly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 03:27:47 +1000" MODIFIED_BY="Smita Pakhale" RESULT="UNKNOWN" STUDY_ID="STD-van-Rensburg-2010a">
<DESCRIPTION>
<P>No explicit mention of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-08 06:28:57 +1000" MODIFIED_BY="Smita Pakhale" RESULT="UNKNOWN" STUDY_ID="STD-van-Rensburg-2010b">
<DESCRIPTION>
<P>No explicit mention of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-04-16 14:02:13 +1000" MODIFIED_BY="Liz Dooley" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-18 05:28:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1991">
<DESCRIPTION>
<P>Double-blind, double-dummy technique</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-18 05:31:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chien-1993">
<DESCRIPTION>
<P>Double-blind, double-dummy technique</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-18 05:33:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Ignazio-2005">
<DESCRIPTION>
<P>Double-blind, double-dummy technique</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-18 05:34:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Drehobl-2005">
<DESCRIPTION>
<P>Double-blind, double-dummy technique</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-11 10:50:10 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-English-2012">
<DESCRIPTION>
<P>Participants and assessors were blinded to treatment and assessments. Study medications and placebos were over-encapsulated and appeared identical</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-18 05:36:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kohno-2003">
<DESCRIPTION>
<P>Double-blind, double-dummy technique</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-04-16 14:02:13 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Mathers-Dunbar-2004">
<DESCRIPTION>
<P>Double-blind, double-dummy technique. Quote: "Treatment blinding was ensured by encapsulation of both active study medication and placebo within identical opaque capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-17 02:57:56 +1000" MODIFIED_BY="Smita Pakhale" RESULT="UNKNOWN" STUDY_ID="STD-Oldach-2013">
<DESCRIPTION>
<P>Not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-11 11:23:07 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Udupa-2011">
<DESCRIPTION>
<P>Not explicitly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-24 07:45:44 +1000" MODIFIED_BY="Smita Pakhale" RESULT="UNKNOWN" STUDY_ID="STD-Vacarezza-2010">
<DESCRIPTION>
<P>No explicit mention of patient and assessor blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-24 07:44:21 +1000" MODIFIED_BY="Smita Pakhale" RESULT="UNKNOWN" STUDY_ID="STD-van-Rensburg-2010a">
<DESCRIPTION>
<P>No explicit mention of patient and assessor blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-08 06:29:04 +1000" MODIFIED_BY="Smita Pakhale" RESULT="UNKNOWN" STUDY_ID="STD-van-Rensburg-2010b">
<DESCRIPTION>
<P>No explicit mention of patient and assessor blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-16 13:58:34 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Anderson-1991">
<DESCRIPTION>
<P>Detailed list of reasons for exclusion from efficacy analyses, with number of patients affected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-16 13:59:26 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Chien-1993">
<DESCRIPTION>
<P>Detailed list of reasons for exclusion from efficacy analyses, with number of patients affected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-16 14:00:45 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-D_x0027_Ignazio-2005">
<DESCRIPTION>
<P>Detailed list of reasons for exclusion from efficacy analyses, with number of patients affected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-16 13:59:54 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Drehobl-2005">
<DESCRIPTION>
<P>Detailed list of reasons for exclusion from efficacy analyses, with number of patients affected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-English-2012">
<DESCRIPTION>
<P>All inclusions and exclusions were explicitly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-16 14:01:36 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Kohno-2003">
<DESCRIPTION>
<P>Detailed flow chart of reasons for exclusion from efficacy analyses, with number of patients affected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-16 14:02:15 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Mathers-Dunbar-2004">
<DESCRIPTION>
<P>Detailed list of reasons for exclusion from efficacy analyses, with number of patients affected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oldach-2013">
<DESCRIPTION>
<P>CONSORT diagram of patient inclusion and reasons for exclusion is not provided in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Udupa-2011">
<DESCRIPTION>
<P>No CONSORT diagram presented, therefore reasons for exclusion of patients at the entry level are unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vacarezza-2010">
<DESCRIPTION>
<P>No CONSORT diagram presented, therefore reasons for exclusion of patients at the entry level are unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-Rensburg-2010a">
<DESCRIPTION>
<P>CONSORT diagram presented and numbers of included and excluded patients stated. However, reasons for exclusions are not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-Rensburg-2010b">
<DESCRIPTION>
<P>CONSORT diagram presented and numbers of included and excluded patients stated. However, reasons for exclusions are not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 05:30:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1991">
<DESCRIPTION>
<P>Pre-specified outcomes appear to be fully reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 05:32:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chien-1993">
<DESCRIPTION>
<P>Pre-specified outcomes appear to be fully reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 05:33:36 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Ignazio-2005">
<DESCRIPTION>
<P>Pre-specified outcomes appear to be fully reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 05:35:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Drehobl-2005">
<DESCRIPTION>
<P>Pre-specified outcomes appear to be fully reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 10:50:25 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-English-2012">
<DESCRIPTION>
<P>All enrolled participants were accounted for. Reasons for participant exclusion from the final analysis were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 05:36:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kohno-2003">
<DESCRIPTION>
<P>Text in Japanese; tables and figures in English</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 05:38:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mathers-Dunbar-2004">
<DESCRIPTION>
<P>Pre-specified outcomes appear to be fully reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oldach-2013">
<DESCRIPTION>
<P>Since CONSORT diagram missing, we are unclear regarding the reasons patients were excluded from the outcome analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 03:10:55 +1000" MODIFIED_BY="Smita Pakhale" RESULT="YES" STUDY_ID="STD-Udupa-2011">
<DESCRIPTION>
<P>The study reported on every patient that was included in the trial (n = 31)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-24 07:47:22 +1000" MODIFIED_BY="Smita Pakhale" RESULT="YES" STUDY_ID="STD-Vacarezza-2010">
<DESCRIPTION>
<P>The study reported on every patient that was included in the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Rensburg-2010a">
<DESCRIPTION>
<P>No evidence of selective reporting; all outcomes are reported in the included study population</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-29 23:15:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Rensburg-2010b">
<DESCRIPTION>
<P>No evidence of selective reporting; all outcomes are reported in the included study population</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-07-15 08:12:31 +1000" MODIFIED_BY="Liz  Dooley" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-15 08:12:31 +1000" MODIFIED_BY="Liz  Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1991">
<DESCRIPTION>
<P>3 of 5 authors from Abbott Laboratories, source of funding not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 05:32:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chien-1993">
<DESCRIPTION>
<P>Research supported by Abbott Laboratories, Chicago</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 05:33:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Ignazio-2005">
<DESCRIPTION>
<P>Study funded by Pfizer Inc., 3 of 5 authors are employees of Pfizer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 05:35:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Drehobl-2005">
<DESCRIPTION>
<P>Study sponsored by Pfizer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 10:50:29 +1000" MODIFIED_BY="Liz Dooley" RESULT="NO" STUDY_ID="STD-English-2012">
<DESCRIPTION>
<P>All authors were members of Advanced Life Sciences Inc, a biopharmaceutical company (USA)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-18 05:36:50 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kohno-2003">
<DESCRIPTION>
<P>Study sponsored by Fujisawa</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-16 14:02:17 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Mathers-Dunbar-2004">
<DESCRIPTION>
<P>Funded by an unrestricted educational grant from Aventis Pharmaceuticals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 10:51:58 +1000" MODIFIED_BY="Liz Dooley" RESULT="NO" STUDY_ID="STD-Oldach-2013">
<DESCRIPTION>
<P>Study was funded by Cempra Inc., a pharmaceutical company. All investigators are member of Cempra Inc. USA, or InClin Inc. USA. InClin is a consulting firm for biotechnology and pharmaceutical companies</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 03:11:43 +1000" MODIFIED_BY="Smita Pakhale" RESULT="YES" STUDY_ID="STD-Udupa-2011">
<DESCRIPTION>
<P>No explicit mention of biopharmaceutical industry involvement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-24 07:47:36 +1000" MODIFIED_BY="Smita Pakhale" RESULT="YES" STUDY_ID="STD-Vacarezza-2010">
<DESCRIPTION>
<P>No financial conflicts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 03:32:06 +1000" MODIFIED_BY="Smita Pakhale" RESULT="NO" STUDY_ID="STD-van-Rensburg-2010a">
<DESCRIPTION>
<P> Several authors of the study are employees of TaiGen Biotechnology Co. Ltd.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-08 06:29:28 +1000" MODIFIED_BY="Smita Pakhale" RESULT="NO" STUDY_ID="STD-van-Rensburg-2010b">
<DESCRIPTION>
<P>Several authors of the study are employees of TaiGen Biotechnology Co. Ltd.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-10-07 13:16:35 +1000" MODIFIED_BY="Liz  Dooley">
<COMPARISON ID="CMP-001" MODIFIED="2014-08-29 22:11:23 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Solithromycin versus levofloxacin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2584874407552236" CI_START="0.32250520699303714" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.853448275862069" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.3538176798317194" LOG_CI_START="-0.49146326909045657" LOG_EFFECT_SIZE="-0.06882279462936856" METHOD="MH" MODIFIED="2014-08-29 22:11:16 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7496047124804978" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="67" WEIGHT="100.0" Z="0.3191606269157221">
<NAME>Test-of-clinical-cure</NAME>
<GROUP_LABEL_1>Solithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours solithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2584874407552236" CI_START="0.32250520699303714" EFFECT_SIZE="0.853448275862069" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="58" LOG_CI_END="0.3538176798317194" LOG_CI_START="-0.49146326909045657" LOG_EFFECT_SIZE="-0.06882279462936856" MODIFIED="2014-01-24 07:11:03 +1000" MODIFIED_BY="Smita Pakhale" ORDER="1" O_E="0.0" SE="0.4965222136050653" STUDY_ID="STD-Oldach-2013" TOTAL_1="65" TOTAL_2="67" VAR="0.24653430860327413" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.976039368781229" CI_START="0.28096171715590934" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.8436089228413975" LOG_CI_START="-0.5513528514849215" LOG_EFFECT_SIZE="0.146128035678238" METHOD="MH" MODIFIED="2014-04-16 12:23:37 +1000" MODIFIED_BY="Liz Dooley" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6813447988265221" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="14" WEIGHT="100.0" Z="0.4106287245028588">
<NAME>Bacteriological cure</NAME>
<GROUP_LABEL_1>Solithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours solithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.976039368781227" CI_START="0.28096171715590945" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.8436089228413974" LOG_CI_START="-0.5513528514849214" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2014-01-24 07:14:16 +1000" MODIFIED_BY="Smita Pakhale" ORDER="2" O_E="0.0" SE="0.8194074514114278" STUDY_ID="STD-Oldach-2013" TOTAL_1="18" TOTAL_2="14" VAR="0.6714285714285714" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3992792625033572" CI_START="0.19292150675016995" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5195681511470985" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.14590439788060755" LOG_CI_START="-0.7146193548222625" LOG_EFFECT_SIZE="-0.2843574784708275" METHOD="MH" MODIFIED="2014-08-29 22:11:23 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.19520697519123756" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="68" WEIGHT="99.99999999999999" Z="1.29532837364894">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Solithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Solithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Levofoxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.399279262503357" CI_START="0.19292150675016995" EFFECT_SIZE="0.5195681511470985" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.14590439788060747" LOG_CI_START="-0.7146193548222625" LOG_EFFECT_SIZE="-0.2843574784708275" MODIFIED="2014-01-24 07:15:48 +1000" MODIFIED_BY="Smita Pakhale" ORDER="3" O_E="0.0" SE="0.5054759119989406" STUDY_ID="STD-Oldach-2013" TOTAL_1="64" TOTAL_2="68" VAR="0.25550589761116077" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-08-29 22:12:25 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Nemonoxacin versus levofloxacin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5292451886122724" CI_START="0.5536346511925448" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1833333333333333" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.40299093250763557" LOG_CI_START="-0.2567767358367723" LOG_EFFECT_SIZE="0.07310709833543166" METHOD="MH" MODIFIED="2014-08-29 22:11:35 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6640293794725174" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="90" WEIGHT="99.99999999999999" Z="0.4343567792924228">
<NAME>Test-of-clinical-cure</NAME>
<GROUP_LABEL_1>Nemonoxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nemonoxacin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.529245188612273" CI_START="0.5536346511925447" EFFECT_SIZE="1.1833333333333333" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="72" LOG_CI_END="0.4029909325076357" LOG_CI_START="-0.25677673583677235" LOG_EFFECT_SIZE="0.07310709833543166" MODIFIED="2014-03-08 06:40:53 +1000" MODIFIED_BY="Smita Pakhale" ORDER="22" O_E="0.0" SE="0.3875507942881354" STUDY_ID="STD-van-Rensburg-2010a" TOTAL_1="86" TOTAL_2="90" VAR="0.15019561815336463" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.435606193684287" CI_START="0.18831478023300663" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8043478260869565" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.5360033770126639" LOG_CI_START="-0.725115592241822" LOG_EFFECT_SIZE="-0.09455610761457907" METHOD="MH" MODIFIED="2014-04-16 12:24:09 +1000" MODIFIED_BY="Liz Dooley" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.7688280980594526" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="50" WEIGHT="100.0" Z="0.2939081402485364">
<NAME>Bacteriological cure</NAME>
<GROUP_LABEL_1>Nemonoxacin 750mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin 500mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nemonoxacin 750mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours evofloxacin 500mg</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.435606193684287" CI_START="0.18831478023300663" EFFECT_SIZE="0.8043478260869565" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="46" LOG_CI_END="0.5360033770126639" LOG_CI_START="-0.725115592241822" LOG_EFFECT_SIZE="-0.09455610761457907" MODIFIED="2014-03-08 06:18:43 +1000" MODIFIED_BY="Smita Pakhale" ORDER="20" O_E="0.0" SE="0.7407875251796628" STUDY_ID="STD-van-Rensburg-2010a" TOTAL_1="41" TOTAL_2="50" VAR="0.5487661574618097" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3900388593649176" CI_START="0.7296601527223122" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3205741626794258" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.37840496214920777" LOG_CI_START="-0.13687937024088034" LOG_EFFECT_SIZE="0.12076279595416371" METHOD="MH" MODIFIED="2014-08-29 22:12:25 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.3582629327058725" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="90" WEIGHT="100.0" Z="0.9186800989840194">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Nemonoxacin 750 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin 500 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nemonoxacin 750 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin 500 mg</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3900388593649176" CI_START="0.7296601527223122" EFFECT_SIZE="1.3205741626794258" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="44" LOG_CI_END="0.37840496214920777" LOG_CI_START="-0.13687937024088034" LOG_EFFECT_SIZE="0.12076279595416371" MODIFIED="2014-03-08 06:19:53 +1000" MODIFIED_BY="Smita Pakhale" ORDER="21" O_E="0.0" SE="0.3026805675445202" STUDY_ID="STD-van-Rensburg-2010a" TOTAL_1="86" TOTAL_2="90" VAR="0.09161552596907287" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-10-07 13:16:35 +1000" MODIFIED_BY="Liz  Dooley" NO="3">
<NAME>Nemonoxacin versus levofloxacin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5427296232376544" CI_START="0.37574606596347293" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7613636363636364" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.18828981885314658" LOG_CI_START="-0.425105557751831" LOG_EFFECT_SIZE="-0.1184078694493422" METHOD="MH" MODIFIED="2014-10-07 13:16:35 +1000" MODIFIED_BY="Liz  Dooley" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.44923544570259055" Q="0.0" RANDOM="NO" SCALE="15.64357210041249" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="90" WEIGHT="100.0" Z="0.7566902799017544">
<NAME>Test-of-clinical-cure</NAME>
<GROUP_LABEL_1>Nemonoxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin]</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nemonoxacin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5427296232376544" CI_START="0.37574606596347293" EFFECT_SIZE="0.7613636363636364" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="72" LOG_CI_END="0.18828981885314658" LOG_CI_START="-0.425105557751831" LOG_EFFECT_SIZE="-0.1184078694493422" MODIFIED="2014-03-08 04:27:05 +1000" MODIFIED_BY="Smita Pakhale" ORDER="17" O_E="0.0" SE="0.36031148057384776" STUDY_ID="STD-van-Rensburg-2010b" TOTAL_1="89" TOTAL_2="90" VAR="0.12982436303331826" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7784603580974907" CI_START="0.13197548422241628" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.484472049689441" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.2500441892005251" LOG_CI_START="-0.8795067358832637" LOG_EFFECT_SIZE="-0.3147312733413693" METHOD="MH" MODIFIED="2014-10-07 05:37:24 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.274734170508548" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="50" WEIGHT="100.0" Z="1.092225143389187">
<NAME>Bacteriological cure</NAME>
<GROUP_LABEL_1>Nemonoxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin]</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nemonoxacin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7784603580974907" CI_START="0.13197548422241628" EFFECT_SIZE="0.484472049689441" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="46" LOG_CI_END="0.2500441892005251" LOG_CI_START="-0.8795067358832637" LOG_EFFECT_SIZE="-0.3147312733413693" MODIFIED="2014-03-08 05:57:21 +1000" MODIFIED_BY="Smita Pakhale" ORDER="18" O_E="0.0" SE="0.6635038047614732" STUDY_ID="STD-van-Rensburg-2010b" TOTAL_1="46" TOTAL_2="50" VAR="0.4402372989329511" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5358596071148418" CI_START="0.4742273685641632" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8534322820037106" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.18635151866297003" LOG_CI_START="-0.3240133856732993" LOG_EFFECT_SIZE="-0.06883093350516463" METHOD="MH" MODIFIED="2014-10-07 05:37:24 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5970375378245657" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="90" WEIGHT="100.0" Z="0.528665468750598">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Nemonoxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin]</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nemonoxacin 500 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin 500 mg</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5358596071148418" CI_START="0.4742273685641632" EFFECT_SIZE="0.8534322820037106" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="44" LOG_CI_END="0.18635151866297003" LOG_CI_START="-0.3240133856732993" LOG_EFFECT_SIZE="-0.06883093350516463" MODIFIED="2014-03-08 05:59:13 +1000" MODIFIED_BY="Smita Pakhale" ORDER="19" O_E="0.0" SE="0.2997908711541455" STUDY_ID="STD-van-Rensburg-2010b" TOTAL_1="89" TOTAL_2="90" VAR="0.08987456642736145" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-08-29 22:14:16 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Clarithromycin versus amoxicillin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-08-29 22:14:16 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Test-of-clinical-cure</NAME>
<GROUP_LABEL_1>Clarithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Amoxicilln</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clarithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amoxicillin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-01-30 06:18:50 +1000" MODIFIED_BY="Smita Pakhale" ORDER="10" O_E="0.0" SE="0.0" STUDY_ID="STD-Vacarezza-2010" TOTAL_1="18" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-08-29 22:14:41 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Clarithromycin versus azithromycin versus levofloxacin versus amoxicillin</NAME>
<OTHER_OUTCOME COLS="3" ID="CMP-005.01" MODIFIED="2014-08-29 22:14:27 +1000" MODIFIED_BY="[Empty name]" NO="1" ROWS_PER_STUDY="4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Test-of-clinical-cure</NAME>
<TR>
<TH>
<P>Antibiotics</P>
</TH>
<TH>
<P>Events</P>
</TH>
<TH>
<P>Total</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-03-20 12:26:52 +1000" MODIFIED_BY="Liz Dooley" ORDER="11" STUDY_ID="STD-Udupa-2011">
<TR>
<TD>
<P>Clarithromycin</P>
</TD>
<TD/>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Azithromycin</P>
</TD>
<TD/>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>Levofloxacin</P>
</TD>
<TD/>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>High-dose amoxicillin</P>
</TD>
<TD/>
<TD>
<P>9</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-005.02" MODIFIED="2014-08-29 22:14:41 +1000" MODIFIED_BY="[Empty name]" NO="2" ROWS_PER_STUDY="4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Antibiotic</P>
</TH>
<TH>
<P>Events</P>
</TH>
<TH>
<P>Total</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-08-29 22:14:41 +1000" MODIFIED_BY="[Empty name]" ORDER="12" STUDY_ID="STD-Udupa-2011">
<TR>
<TD>
<P>Clarithromycin</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Azithromycin</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>Levofloxacin</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>Amoxicillin</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>9</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2014-08-29 22:15:57 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Cethromycin versus clarithromycin</NAME>
<DICH_OUTCOME CHI2="4.250062576781388E-31" CI_END="1.221706772620954" CI_START="0.6266847472388877" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8749999999999999" ESTIMABLE="YES" EVENTS_1="430" EVENTS_2="430" I2="100.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.0869669814269861" LOG_CI_START="-0.2029508753823597" LOG_EFFECT_SIZE="-0.05799194697768681" METHOD="MH" MODIFIED="2014-08-29 22:14:54 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.432982123416091" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="518" TOTAL_2="507" WEIGHT="100.0" Z="0.7840988390333505">
<NAME>Test-of-clinical-cure</NAME>
<GROUP_LABEL_1>Cethromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Clarithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cethromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clarithromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.221706772620954" CI_START="0.6266847472388878" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="430" EVENTS_2="430" LOG_CI_END="0.0869669814269861" LOG_CI_START="-0.20295087538235965" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2014-01-30 06:56:42 +1000" MODIFIED_BY="Smita Pakhale" ORDER="22" O_E="0.0" SE="0.17029918420634618" STUDY_ID="STD-English-2012" TOTAL_1="518" TOTAL_2="507" VAR="0.029001812141347026" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5826591814081303" CI_START="0.4976029568876101" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8874321880650995" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="158" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.19938740155225596" LOG_CI_START="-0.3031170476175648" LOG_EFFECT_SIZE="-0.051864823032654425" METHOD="MH" MODIFIED="2014-08-29 22:15:28 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6857816979566105" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="184" WEIGHT="100.0" Z="0.4045862096404746">
<NAME>Bacteriological cure</NAME>
<GROUP_LABEL_1>Cethromycin 300 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Clarithromycin 250 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cethromycin 300 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clarithromycin 250 mg</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5826591814081303" CI_START="0.4976029568876101" EFFECT_SIZE="0.8874321880650995" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="158" LOG_CI_END="0.19938740155225596" LOG_CI_START="-0.3031170476175648" LOG_EFFECT_SIZE="-0.051864823032654425" MODIFIED="2014-01-30 06:59:38 +1000" MODIFIED_BY="Smita Pakhale" ORDER="23" O_E="0.0" SE="0.29517360087949296" STUDY_ID="STD-English-2012" TOTAL_1="179" TOTAL_2="184" VAR="0.0871274546561662" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.145693672876919" CI_START="1.3214694290075741" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6838849701573522" ESTIMABLE="YES" EVENTS_1="263" EVENTS_2="194" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.3315677205772172" LOG_CI_START="0.12105712057640175" LOG_EFFECT_SIZE="0.22631242057680945" METHOD="MH" MODIFIED="2014-08-29 22:15:57 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="2.5069349141342096E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="548" TOTAL_2="548" WEIGHT="100.0" Z="4.214174427158629">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Cethromycin 300 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Clarithromycin 250 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cethromycin 300 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clarithromycin 250 mg</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.145693672876919" CI_START="1.321469429007574" EFFECT_SIZE="1.6838849701573522" ESTIMABLE="YES" EVENTS_1="263" EVENTS_2="194" LOG_CI_END="0.3315677205772172" LOG_CI_START="0.12105712057640168" LOG_EFFECT_SIZE="0.22631242057680945" MODIFIED="2014-01-30 07:01:06 +1000" MODIFIED_BY="Smita Pakhale" ORDER="24" O_E="0.0" SE="0.12365496848475492" STUDY_ID="STD-English-2012" TOTAL_1="548" TOTAL_2="548" VAR="0.015290551230965734" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2014-08-29 22:16:25 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Clarithromycin versus erythromycin</NAME>
<DICH_OUTCOME CHI2="1.5323602448978" CI_END="7.800320281808088" CI_START="0.6608400648675641" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="2.2704105710240676" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="117" I2="34.74119396338852" I2_Q="100.0" ID="CMP-007.01" LOG_CI_END="0.8921124352246096" LOG_CI_START="-0.1799036348410706" LOG_EFFECT_SIZE="0.35610440019176953" METHOD="MH" MODIFIED="2014-08-29 22:16:10 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.21575899963659295" P_Q="0.0" P_Z="0.19287216837963675" Q="3.108441254541513E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="124" WEIGHT="100.0" Z="1.3021293590670604">
<NAME>Test-of-clinical-cure</NAME>
<GROUP_LABEL_1>Clarithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Erythromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clarithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours erythromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="59.93523596016516" CI_START="0.6966099093643375" EFFECT_SIZE="6.461538461538462" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="39" LOG_CI_END="1.7776822194498285" LOG_CI_START="-0.15701035193973872" LOG_EFFECT_SIZE="0.8103359337550449" MODIFIED="2014-03-28 06:04:41 +1000" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="1.1364479933169143" STUDY_ID="STD-Anderson-1991" TOTAL_1="64" TOTAL_2="43" VAR="1.2915140415140414" WEIGHT="21.22699386503067"/>
<DICH_DATA CI_END="5.8173731151037575" CI_START="0.2238019614209933" EFFECT_SIZE="1.141025641025641" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="78" LOG_CI_END="0.7647269195030335" LOG_CI_START="-0.6501361115941688" LOG_EFFECT_SIZE="0.05729540395443236" MODIFIED="2014-03-28 06:04:53 +1000" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.8310975481514545" STUDY_ID="STD-Chien-1993" TOTAL_1="92" TOTAL_2="81" VAR="0.6907231345433592" WEIGHT="78.77300613496932"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.18504039020036903" CI_END="2.570227935586031" CI_START="0.030648422463231077" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.2806660499537465" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.4099716395872069" LOG_CI_START="-1.5135918745924042" LOG_EFFECT_SIZE="-0.5518101175025987" METHOD="MH" MODIFIED="2014-08-29 22:16:15 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6670769260828462" P_Q="1.0" P_Z="0.26079906209403647" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="22" WEIGHT="99.99999999999999" Z="1.1245045444430508">
<NAME>Bacteriological cure</NAME>
<GROUP_LABEL_1>Clarithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Erythromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clarithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours erythromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.063073263066709" CI_START="0.0176179906270251" EFFECT_SIZE="0.5151515151515151" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="1.1779135884002048" LOG_CI_START="-1.754043625399432" LOG_EFFECT_SIZE="-0.2880650184996136" MODIFIED="2014-03-28 06:05:55 +1000" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="1.7222461808081844" STUDY_ID="STD-Anderson-1991" TOTAL_1="9" TOTAL_2="5" VAR="2.9661319073083776" WEIGHT="27.4745605920444"/>
<DICH_DATA CI_END="3.9590710072960364" CI_START="0.009295446510100286" EFFECT_SIZE="0.19183673469387755" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.5975932910425042" LOG_CI_START="-2.0317297439001343" LOG_EFFECT_SIZE="-0.717068226428815" MODIFIED="2014-03-28 06:06:05 +1000" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="1.5444773660842377" STUDY_ID="STD-Chien-1993" TOTAL_1="26" TOTAL_2="17" VAR="2.3854103343465045" WEIGHT="72.52543940795559"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.016140687011171446" CI_END="2.487302100451557" CI_START="0.334099426622568" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9115954177144454" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="116" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.39572853661338214" LOG_CI_START="-0.4761242696922143" LOG_EFFECT_SIZE="-0.04019786653941603" METHOD="MH" MODIFIED="2014-08-29 22:16:20 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8989039920106028" P_Q="1.0" P_Z="0.8565770037907116" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="153" TOTAL_2="123" WEIGHT="100.00000000000001" Z="0.18073319281141925">
<NAME>Radiological cure</NAME>
<GROUP_LABEL_1>Clarithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Erythromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clarithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours erythromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6520014853021556" CI_START="0.25494395694968575" EFFECT_SIZE="0.9649122807017544" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="38" LOG_CI_END="0.5625309454938054" LOG_CI_START="-0.5935552778503006" LOG_EFFECT_SIZE="-0.015512166178247553" MODIFIED="2014-03-28 06:07:10 +1000" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.6790907703114283" STUDY_ID="STD-Anderson-1991" TOTAL_1="61" TOTAL_2="42" VAR="0.46116427432216905" WEIGHT="55.10477787091367"/>
<DICH_DATA CI_END="3.8985653919948002" CI_START="0.1836512304836829" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="78" LOG_CI_END="0.5909048231903542" LOG_CI_START="-0.7360061574875777" LOG_EFFECT_SIZE="-0.07255066714861173" MODIFIED="2014-03-28 06:07:20 +1000" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.7794340783655039" STUDY_ID="STD-Chien-1993" TOTAL_1="92" TOTAL_2="81" VAR="0.6075174825174825" WEIGHT="44.89522212908634"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6196268668312608" CI_END="0.4579203866833106" CI_START="0.20115506266236452" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3035012423000201" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="113" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="-0.3392100211873575" LOG_CI_START="-0.6964690326494676" LOG_EFFECT_SIZE="-0.5178395269184125" METHOD="MH" MODIFIED="2014-08-29 22:16:25 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4311861795913695" P_Q="1.0" P_Z="1.3324216207402643E-8" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="229" TOTAL_2="247" WEIGHT="100.00000000000003" Z="5.681854284809221">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Clarithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Erythromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clarithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours erythromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7388545261560318" CI_START="0.1907096288240741" EFFECT_SIZE="0.37537537537537535" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="37" LOG_CI_END="-0.13144106188518498" LOG_CI_START="-0.7196273791113419" LOG_EFFECT_SIZE="-0.4255342204982635" MODIFIED="2014-03-28 06:08:34 +1000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.34550355430787205" STUDY_ID="STD-Anderson-1991" TOTAL_1="96" TOTAL_2="112" VAR="0.11937270603937271" WEIGHT="33.916057340042265"/>
<DICH_DATA CI_END="0.4471739618206639" CI_START="0.15895997149624097" EFFECT_SIZE="0.2666135034556087" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="76" LOG_CI_END="-0.3495234926145397" LOG_CI_START="-0.7987122237733443" LOG_EFFECT_SIZE="-0.574117858193942" MODIFIED="2014-03-28 06:08:45 +1000" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.26385568420276156" STUDY_ID="STD-Chien-1993" TOTAL_1="133" TOTAL_2="135" VAR="0.06961982208610744" WEIGHT="66.08394265995776"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2014-08-29 22:17:08 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Azithromycin microspheres versus levofloxacin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2582590747325066" CI_START="0.2743784981537089" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5875706214689266" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="177" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.09977007127028212" LOG_CI_START="-0.5616499253963347" LOG_EFFECT_SIZE="-0.23093992706302624" METHOD="MH" MODIFIED="2014-08-29 22:16:47 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.17110142483585872" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="174" TOTAL_2="189" WEIGHT="100.0" Z="1.3686732844999991">
<NAME>Test-of-clinical-cure</NAME>
<GROUP_LABEL_1>Azithromycin microspheres</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin microspheres</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2582590747325066" CI_START="0.2743784981537089" EFFECT_SIZE="0.5875706214689266" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="177" LOG_CI_END="0.09977007127028212" LOG_CI_START="-0.5616499253963347" LOG_EFFECT_SIZE="-0.23093992706302624" MODIFIED="2014-03-28 06:14:04 +1000" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.3885213801237579" STUDY_ID="STD-D_x0027_Ignazio-2005" TOTAL_1="174" TOTAL_2="189" VAR="0.15094886281326958" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.021183869086622" CI_START="0.3232772573398046" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8083333333333333" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="120" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.30560582350908644" LOG_CI_START="-0.49042484707184636" LOG_EFFECT_SIZE="-0.09240951178137997" METHOD="MH" MODIFIED="2014-08-29 22:16:56 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6490688653296212" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="107" TOTAL_2="130" WEIGHT="100.0" Z="0.45505612186589756">
<NAME>Bacteriological cure</NAME>
<GROUP_LABEL_1>Azithromycin microspheres</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin microspheres</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.021183869086622" CI_START="0.3232772573398046" EFFECT_SIZE="0.8083333333333333" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="120" LOG_CI_END="0.30560582350908644" LOG_CI_START="-0.49042484707184636" LOG_EFFECT_SIZE="-0.09240951178137997" MODIFIED="2014-03-28 06:15:03 +1000" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.46759235631460955" STUDY_ID="STD-D_x0027_Ignazio-2005" TOTAL_1="107" TOTAL_2="130" VAR="0.2186426116838488" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.702113419063948E-31" CI_END="3.025323195095523" CI_START="1.0447986119156178" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7778789258079202" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="26" I2="100.00000000000001" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.4807717771203465" LOG_CI_START="0.019032586942304176" LOG_EFFECT_SIZE="0.24990218203132533" METHOD="MH" MODIFIED="2014-08-29 22:17:08 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.03387631426677897" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="211" TOTAL_2="212" WEIGHT="100.0" Z="2.121540847552959">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Azithromycin microspheres</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin microspheres</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.025323195095522" CI_START="1.0447986119156176" EFFECT_SIZE="1.77787892580792" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="26" LOG_CI_END="0.4807717771203464" LOG_CI_START="0.019032586942304086" LOG_EFFECT_SIZE="0.24990218203132528" MODIFIED="2014-03-28 06:16:19 +1000" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.2712278859564359" STUDY_ID="STD-D_x0027_Ignazio-2005" TOTAL_1="211" TOTAL_2="212" VAR="0.07356456612039738" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2014-08-29 22:17:37 +1000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Azithromycin microspheres versus clarithromycin</NAME>
<DICH_OUTCOME CHI2="7.338017904840393E-32" CI_END="1.546462904399617" CI_START="0.31018170429400427" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6925925925925926" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="198" I2="100.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.18933950687539497" LOG_CI_START="-0.5083838221203716" LOG_EFFECT_SIZE="-0.1595221576224883" METHOD="MH" MODIFIED="2014-08-29 22:17:20 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.3701339347964453" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="202" TOTAL_2="209" WEIGHT="100.0" Z="0.8962225302863446">
<NAME>Test-of-clinical-cure</NAME>
<GROUP_LABEL_1>Azithromycin microspheres</GROUP_LABEL_1>
<GROUP_LABEL_2>Clarithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin microspheres</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clarithromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5464629043996168" CI_START="0.3101817042940042" EFFECT_SIZE="0.6925925925925925" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="198" LOG_CI_END="0.18933950687539491" LOG_CI_START="-0.5083838221203717" LOG_EFFECT_SIZE="-0.15952215762248836" MODIFIED="2014-03-28 06:18:24 +1000" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.4098461372382938" STUDY_ID="STD-Drehobl-2005" TOTAL_1="202" TOTAL_2="209" VAR="0.16797385620915034" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.611606754104293" CI_START="0.52356929975447" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1693404634581106" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="153" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.4169077831007637" LOG_CI_START="-0.2810258268617659" LOG_EFFECT_SIZE="0.0679409781194989" METHOD="MH" MODIFIED="2014-08-29 22:17:28 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.7027662964337629" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="134" TOTAL_2="169" WEIGHT="100.0" Z="0.3815889313477563">
<NAME>Bacteriological cure</NAME>
<GROUP_LABEL_1>Azithromycin microspheres</GROUP_LABEL_1>
<GROUP_LABEL_2>Clarithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin microspheres</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clarithromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.611606754104293" CI_START="0.52356929975447" EFFECT_SIZE="1.1693404634581106" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="153" LOG_CI_END="0.4169077831007637" LOG_CI_START="-0.2810258268617659" LOG_EFFECT_SIZE="0.0679409781194989" MODIFIED="2014-03-28 06:20:11 +1000" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.409969657319078" STUDY_ID="STD-Drehobl-2005" TOTAL_1="134" TOTAL_2="169" VAR="0.1680751199223222" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6376112608097362" CI_START="0.7314707161823709" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0944700460829493" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="0.21421081603129077" LOG_CI_START="-0.13580305580657906" LOG_EFFECT_SIZE="0.03920388011235586" METHOD="MH" MODIFIED="2014-08-29 22:17:37 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.660619521119514" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="247" TOTAL_2="252" WEIGHT="99.99999999999999" Z="0.43905798745048513">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Azithromycin microspheres</GROUP_LABEL_1>
<GROUP_LABEL_2>Clarithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin microspheres</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clarithromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6376112608097362" CI_START="0.7314707161823709" EFFECT_SIZE="1.0944700460829493" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="62" LOG_CI_END="0.21421081603129077" LOG_CI_START="-0.13580305580657906" LOG_EFFECT_SIZE="0.03920388011235586" MODIFIED="2014-03-28 06:21:07 +1000" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.2055998809141733" STUDY_ID="STD-Drehobl-2005" TOTAL_1="247" TOTAL_2="252" VAR="0.04227131103192224" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2014-08-29 22:18:02 +1000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Telithromycin versus clarithromycin</NAME>
<DICH_OUTCOME CHI2="1.070712527416529E-31" CI_END="1.9489784092427132" CI_START="0.49447539082312403" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9816933638443937" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="138" I2="100.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.2898070280356885" LOG_CI_START="-0.30585531760708357" LOG_EFFECT_SIZE="-0.008024144785697566" METHOD="MH" MODIFIED="2014-08-29 22:17:52 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.9578871179069511" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="162" TOTAL_2="156" WEIGHT="100.0" Z="0.05280520046883692">
<NAME>Test-of-clinical-cure</NAME>
<GROUP_LABEL_1>Telithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Clarithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours telithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clarithromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.948978409242713" CI_START="0.494475390823124" EFFECT_SIZE="0.9816933638443935" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="138" LOG_CI_END="0.2898070280356884" LOG_CI_START="-0.3058553176070836" LOG_EFFECT_SIZE="-0.008024144785697617" MODIFIED="2014-03-28 06:23:11 +1000" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.34989501040672927" STUDY_ID="STD-Mathers-Dunbar-2004" TOTAL_1="162" TOTAL_2="156" VAR="0.12242651830752517" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2947170898481133" CI_START="0.025390481345306522" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.2413793103448276" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" I2="0.0" I2_Q="100.0" ID="CMP-010.02" LOG_CI_END="0.36072915005128703" LOG_CI_START="-1.5953290658206856" LOG_EFFECT_SIZE="-0.6172999578846993" METHOD="MH" MODIFIED="2014-08-29 22:17:57 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.21606293538307964" Q="3.734579378728204E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="1.2370651091003029">
<NAME>Bacteriological cure</NAME>
<GROUP_LABEL_1>Telithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Clarithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours telithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clarithromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2947170898481133" CI_START="0.025390481345306522" EFFECT_SIZE="0.2413793103448276" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" LOG_CI_END="0.36072915005128703" LOG_CI_START="-1.5953290658206856" LOG_EFFECT_SIZE="-0.6172999578846993" MODIFIED="2014-03-28 06:24:14 +1000" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="1.148998278647525" STUDY_ID="STD-Mathers-Dunbar-2004" TOTAL_1="32" TOTAL_2="30" VAR="1.3201970443349753" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.40438666398656" CI_START="1.0819627536544176" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6129032258064515" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="62" I2="0.0" I2_Q="100.0" ID="CMP-010.03" LOG_CI_END="0.3810043104739583" LOG_CI_START="0.034212310529533996" LOG_EFFECT_SIZE="0.2076083105017461" METHOD="MH" MODIFIED="2014-08-29 22:18:02 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.018941548003760095" Q="7.42586626628096E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="222" WEIGHT="100.00000000000001" Z="2.3466793440439244">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Telithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Clarithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours telithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clarithromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.40438666398656" CI_START="1.0819627536544174" EFFECT_SIZE="1.6129032258064515" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="62" LOG_CI_END="0.3810043104739583" LOG_CI_START="0.034212310529533906" LOG_EFFECT_SIZE="0.2076083105017461" MODIFIED="2014-03-28 06:25:11 +1000" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.2037073374154403" STUDY_ID="STD-Mathers-Dunbar-2004" TOTAL_1="221" TOTAL_2="222" VAR="0.041496679316888045" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2014-08-29 22:18:29 +1000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Telithromycin versus levofloxacin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.252357118048231" CI_START="0.13631524195121797" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.7203542469538144" LOG_CI_START="-0.865455581251038" LOG_EFFECT_SIZE="-0.07255066714861173" METHOD="MH" MODIFIED="2014-08-29 22:18:13 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8576735851354711" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="54" WEIGHT="100.0" Z="0.1793363770819858">
<NAME>Test-of-clinical-cure</NAME>
<GROUP_LABEL_1>Telithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours telithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.252357118048231" CI_START="0.13631524195121797" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="52" LOG_CI_END="0.7203542469538144" LOG_CI_START="-0.865455581251038" LOG_EFFECT_SIZE="-0.07255066714861173" MODIFIED="2014-03-26 01:32:38 +1000" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.9315125429727813" STUDY_ID="STD-Kohno-2003" TOTAL_1="69" TOTAL_2="54" VAR="0.8677156177156177" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5967378571490929" CI_START="0.0019456491826282854" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.034074074074074076" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-0.22421640956762326" LOG_CI_START="-2.710935464059241" LOG_EFFECT_SIZE="-1.467575936813432" METHOD="MH" MODIFIED="2014-08-29 22:18:18 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.020700301441986958" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="40" WEIGHT="100.0" Z="2.3134064747173495">
<NAME>Bacteriological cure</NAME>
<GROUP_LABEL_1>Telithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours telithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5967378571490929" CI_START="0.0019456491826282854" EFFECT_SIZE="0.034074074074074076" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="40" LOG_CI_END="-0.22421640956762326" LOG_CI_START="-2.710935464059241" LOG_EFFECT_SIZE="-1.467575936813432" MODIFIED="2014-03-28 06:26:49 +1000" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="1.4607110820662204" STUDY_ID="STD-Kohno-2003" TOTAL_1="46" TOTAL_2="40" VAR="2.133676865271068" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="55.506977338946" CI_START="0.38376752201534103" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="4.615384615384615" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="1.7443475782459603" LOG_CI_START="-0.4159317820923466" LOG_EFFECT_SIZE="0.6642078980768068" METHOD="MH" MODIFIED="2014-08-29 22:18:25 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.2281121123009413" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="15" WEIGHT="100.0" Z="1.2052363063578246">
<NAME>Clinical efficacy against <I>H. influenzae</I>
</NAME>
<GROUP_LABEL_1>Telithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours telithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="55.506977338946" CI_START="0.38376752201534103" EFFECT_SIZE="4.615384615384615" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" LOG_CI_END="1.7443475782459603" LOG_CI_START="-0.4159317820923466" LOG_EFFECT_SIZE="0.6642078980768068" MODIFIED="2014-03-28 06:32:26 +1000" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="1.2689587898180186" STUDY_ID="STD-Kohno-2003" TOTAL_1="31" TOTAL_2="15" VAR="1.6102564102564103" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6846011877447165" CI_START="0.5772225166706725" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9860982391102873" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="0.22649710255924363" LOG_CI_START="-0.23865673600700626" LOG_EFFECT_SIZE="-0.006079816723881311" METHOD="MH" MODIFIED="2014-08-29 22:18:29 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9591377713468332" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="115" WEIGHT="100.0" Z="0.05123561636357215">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Telithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Levofloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours telithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6846011877447165" CI_START="0.5772225166706725" EFFECT_SIZE="0.9860982391102873" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="39" LOG_CI_END="0.22649710255924363" LOG_CI_START="-0.23865673600700626" LOG_EFFECT_SIZE="-0.006079816723881311" MODIFIED="2014-03-28 06:27:35 +1000" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.2732336673224511" STUDY_ID="STD-Kohno-2003" TOTAL_1="125" TOTAL_2="115" VAR="0.07465663695847588" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-08-29 23:15:28 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Cochrane Review Figure 1 2014.JPG" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2014-03-08 03:52:51 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Figure1: Antibiotic comparisons in new studies included in this review. The red arrow indicates antibiotic comparisons studied in <LINK REF="STD-Udupa-2011" TYPE="STUDY">Udupa 2011</LINK>.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Cochrane Review Figure 2 2014.JPG" FILE_TYPE="JPG" ID="FIG-02" MODIFIED="2014-08-29 22:19:14 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Figure 2. Overview of included studies and antibiotic pairs studied in 2009 review. *Indicates studies new to this review; shaded ovals indicate quinolones (gyrase inhibitors), white ovals indicate macrolides</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-08-29 23:15:28 +1000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-08-29 23:15:28 +1000" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUQAAAKCCAIAAAAm0TelAAAfwElEQVR42u3dv3IcRdvG4a2iiiJQ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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-08-29 22:20:23 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-08-29 22:20:23 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-07-11 11:36:53 +1000" MODIFIED_BY="[Empty name]">Details of previous search</TITLE>
<APPENDIX_BODY MODIFIED="2014-08-29 22:20:23 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, 2009, issue 1), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (January 1966 to February week 2, 2009) and EMBASE (January 1974 to February 2009).</P>
<P>MEDLINE and CENTRAL were searched using the search strategy shown below. We combined the MEDLINE search string with the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximising version (2008 revision) (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). The search string was adapted for EMBASE, as shown in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>
<B>MEDLINE (Ovid)</B>
</P>
<P>1 exp Anti-Bacterial Agents/<BR/>2 antibiotic$.mp.<BR/>3 or/1-2<BR/>4 exp Pneumonia/<BR/>5 exp Community-Acquired Infections/<BR/>6 and/4-5 (3356)<BR/>7 community acquired pneumonia.mp.<BR/>8 or/6-7<BR/>9 3 and 8</P>
<P>
<B>EMBASE (Elsevier)</B>
</P>
<P>#1. 'antibiotic agent'/exp AND [embase]/lim<BR/>#2. antibiotic*:ti,ab AND [embase]/lim<BR/>#3. #1 OR #2<BR/>#4. 'pneumonia'/exp AND [embase]/lim<BR/>#5. 'communicable disease'/exp AND [embase]/lim<BR/>#7. 'community acquired pneumonia'/exp AND [embase]/lim<BR/>#8. #4 AND #5<BR/>#9. 'community acquired pneumonia':ti,ab AND [embase]/lim<BR/>#10. #7 OR #8 OR #9<BR/>#11. #3 AND #10<BR/>#12. 'randomized controlled trial'/exp OR 'double blind procedure'/exp OR 'single blind procedure'/exp OR<BR/>'crossover procedure'/exp AND [embase]/lim<BR/>#13. random*:ti,ab OR factorial*:ti,ab OR crossover*:ti,ab OR 'cross over':ti,ab OR assign*:ti,ab OR allocat*:ti,ab OR volunteer*:ti,ab OR 'single blind':ti,ab OR 'single blinding':ti,ab OR 'single blinded':ti,ab OR 'double blind':ti,ab OR 'double blinded':ti,ab OR 'double blinding':ti,ab AND [embase]/lim<BR/>#14. #12 OR #13<BR/>#15. #11 AND #14</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-07-11 12:08:09 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-02-20 15:44:20 +1000" MODIFIED_BY="[Empty name]">Embase.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-11 12:08:09 +1000" MODIFIED_BY="[Empty name]">
<P>#32 #23 AND #31 <BR/>#31 #26 NOT #30 <BR/>#30 #27 NOT #29 <BR/>#29 #27 AND #28 <BR/>#28 'human'/de <BR/>#27 'animal'/de OR 'nonhuman'/de OR 'animal experiment'/de <BR/>#26 #24 OR #25 <BR/>#25 random*:ab,ti OR placebo*:ab,ti OR trial:ti OR allocat*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR (doubl* NEXT/1 blind*):ab,ti <BR/>#24 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp <BR/>#23 #14 AND #229264<BR/>#22 #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 <BR/>#21 macrolide*:ab,ti OR makrolide*:ab,ti OR quinolone*:ab,ti OR tetracycline*:ab,ti OR aciclovir:ab,ti OR amikacin:ab,ti OR amoxicillin:ab,ti OR amoxycillin:ab,ti OR ampicillin:ab,ti OR<BR/>azithromycin:ab,ti OR cefepim:ab,ti OR cefotaxim*:ab,ti OR ceftarolin:ab,ti OR ceftazidim*:ab,ti OR ceftibuten:ab,ti OR ceftriaxon*:ab,ti OR cefuroxim*:ab,ti OR cethromycin:ab,ti OR<BR/>ciprofloxacin:ab,ti OR clarithromycin:ab,ti OR 'clavulanic acid':ab,ti OR clindamycin:ab,ti OR doxycyclin*:ab,ti OR ertapenem:ab,ti OR erythromycin:ab,ti OR fluoroquinolon*:ab,ti OR fluorchinolon*:ab,ti OR gemifloxacin:ab,ti OR gentamicin:ab,ti OR imipenem:ab,ti OR levofloxacin:ab,ti OR linezolide:ab,ti OR meropenem:ab,ti OR moxifloxacin:ab,ti OR penicillin*:ab,ti OR piperacillin:ab,ti OR roxithromycin:ab,ti OR sultamicillin:ab,ti OR tazobactam:ab,ti OR tobramycin:ab,ti OR 'beta-lactam':ab,ti OR 'beta-lactams':ab,ti OR 'co-amoxiclav':ab,ti OR 'co-trimoxacol':ab,ti <BR/>#20 'tetracycline derivative'/exp <BR/>#19 'quinolone derivative'/de <BR/>#18 'beta lactam'/de <BR/>#17 'macrolide'/exp <BR/>#16 antibiotic*:ab,ti <BR/>#15 'antibiotic agent'/exp <BR/>#14 #1 OR #2 OR #13 <BR/>#13 #5 AND #12 <BR/>#12 #6 OR #7 OR #8 OR #9 OR #10 OR #11 <BR/>#11 (ambulat* NEAR/2 (care OR patient*)):ab,ti <BR/>#10 'ambulatory care'/exp <BR/>#9 outpatient*:ab,ti OR 'out-patient':ab,ti OR 'out-patients':ab,ti <BR/>#8 'outpatient'/de <BR/>#7 'community acquired':ab,ti <BR/>#6 'communicable disease'/de <BR/>#5 #3 OR #4 <BR/>#4 pneumon*:ab,ti <BR/>#3 'pneumonia'/exp <BR/>#2 'community acquired pneumonia':ab,ti OR cap:ab,ti <BR/>#1 'community acquired pneumonia'/de <BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-07-11 12:15:32 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-07-11 12:09:17 +1000" MODIFIED_BY="[Empty name]">CINAHL (EBSCO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-11 12:15:32 +1000" MODIFIED_BY="[Empty name]">
<P>S34 S23 and S33 <BR/>S33 S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 <BR/>S32 (MH "Random Assignment") <BR/>S31 (MH "Quantitative Studies") <BR/>S30 TI placebo* OR AB placebo* <BR/>S29 (MH "Placebos")<BR/>S28 TI random* OR AB random* <BR/>S27 TI ( (singl* or doubl* or tripl* or trebl*) W1 (blind* or mask*)) OR AB ((singl* or doubl* or tripl* or trebl*) W1 (blind* or mask*)) <BR/>S26 TI clinical* trial* OR AB clinical* trial* <BR/>S25 PT clinical trial <BR/>S24 (MH "Clinical Trials+") <BR/>S23 S14 and S22 <BR/>S22 S15 or S16 or S17 or S18 or S19 or S20 or S21 <BR/>S21 TI (beta-lactam* or macrolide* or makrolide* or quinolone* or tetracycline* or aciclovir or amikacin or amoxicillin or amoxycillin or ampicillin or azithromycin or cefepim or cefotaxim* or ceftarolin or<BR/>ceftazidim* or ceftibuten or ceftriaxon* or cefuroxim* or cethromycin or ciprofloxacin or clarithromycin or clavulanic acid or clindamycin or co-amoxiclav or co-trimoxacol or doxycyclin* or ertapenem or erythromycin or fluoroquinolon* or fluorchinolon* or gemifloxacin or gentamicin or imipenem or levofloxacin or linezolide or meropenem or moxifloxacin or penicillin* or piperacillin or roxithromycin or sultamicillin or tazobactam or telithromycin or tetracyclin* or ticarcillin or tobramycin) OR AB (beta-lactam* or macrolide* or makrolide* or quinolone* or tetracycline* or aciclovir or amikacin or amoxicillin or amoxycillin or ampicillin or azithromycin or cefepim or cefotaxim* or ceftarolin or ceftazidim* or ceftibuten or ceftriaxon* or cefuroxim* or cethromycin or ciprofloxacin or clarithromycin or clavulanic acid or clindamycin or co-amoxiclav or co-trimoxacol or doxycyclin* or ertapenem or erythromycin or fluoroquinolon* or fluorchinolon* or gemifloxacin or gentamicin or imipenem or levofloxacin or linezolide or meropenem or moxifloxacin or penicillin* or piperacillin or roxithromycin or sultamicillin or tazobactam or telithromycin or tetracyclin* or ticarcillin or tobramycin)<BR/>S20 (MH "Antibiotics, Lactam+") <BR/>S19 (MH "Tetracyclines+") S<BR/>S18 (MH "Antiinfective Agents, Quinolone+") <BR/>S17 (MH "Antibiotics, Macrolide+") <BR/>S16 TI antibiotic* OR AB antibiotic* <BR/>S15 (MH "Antibiotics+") <BR/>S14 S11 or S12 or S13 <BR/>S13 TI (community acquired pneumon* or cap) OR AB (community acquired pneumon* or cap) <BR/>S12 (MH "Community-Acquired Pneumonia") <BR/>S11 S3 and S10 <BR/>S10 S4 or S5 or S6 or S7 or S8 or S9 S<BR/>S9 TI (ambulat* N1 (care or patient*)) OR AB (ambulat* N1 (care or patient*)) <BR/>S8 (MH "Ambulatory Care") <BR/>S7 TI (outpatient* or out patient*) OR AB (outpatient* or out patient*) <BR/>S6 (MH "Outpatients") <BR/>S5 TI community acquired OR AB community acquired <BR/>S4 (MH "Community-Acquired Infections+") <BR/>S3 S1 or S2 <BR/>S2 TI pneumon* OR AB pneumon* <BR/>S1 (MH "Pneumonia+") </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-07-11 12:17:05 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2012-07-11 12:16:21 +1000" MODIFIED_BY="[Empty name]">Web of Science (Thomson Reuters) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-11 12:17:05 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="17">
<TR>
<TD VALIGN="TOP">
<P># 9</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=18&amp;SID=Q1HLLL2I4mmNe7ip71H&amp;search_mode=Refine">204</A>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>#7 AND #6</P>
<P>Refined by: Publication Years=( 2011 OR 2009 OR 2010 OR 2012 )</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=1985-2012</I>
</P>
<P>
<I>Lemmatization=On   </I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 8</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=17&amp;SID=Q1HLLL2I4mmNe7ip71H&amp;search_mode=CombineSearches">755</A>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>#7 AND #6</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=1985-2012</I>
</P>
<P>
<I>Lemmatization=On   </I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 7</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=16&amp;SID=Q1HLLL2I4mmNe7ip71H&amp;search_mode=GeneralSearch">1,077,429</A>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>Title=(trial) OR Topic=(random* or placebo* or ((singl* or doubl*) NEAR/1 blind*))</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=1985-2012</I>
</P>
<P>
<I>Lemmatization=On   </I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 6</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=15&amp;SID=Q1HLLL2I4mmNe7ip71H&amp;search_mode=CombineSearches">4,075</A>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>#5 AND #4</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=1985-2012</I>
</P>
<P>
<I>Lemmatization=On   </I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 5</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=14&amp;SID=Q1HLLL2I4mmNe7ip71H&amp;search_mode=GeneralSearch">266,150</A>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>Topic=(antibiotic* or beta-lactam* or macrolide* or makrolide* or quinolone* or tetracycline* or aciclovir or amikacin or amoxicillin or amoxycillin or ampicillin or azithromycin or cefepim or cefotaxim* or ceftarolin or ceftazidim* or ceftibuten or ceftriaxon* or cefuroxim* or cethromycin or ciprofloxacin or clarithromycin or clavulanic acid or clindamycin or co-amoxiclav or co-trimoxacol or doxycyclin* or ertapenem or erythromycin or fluoroquinolon* or fluorchinolon* or gemifloxacin or gentamicin or imipenem or levofloxacin or linezolide or meropenem or moxifloxacin or penicillin* or piperacillin or roxithromycin or sultamicillin or tazobactam or telithromycin or tetracyclin* or ticarcillin or tobramycin)</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=1985-2012</I>
</P>
<P>
<I>Lemmatization=On   </I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 4</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=13&amp;SID=Q1HLLL2I4mmNe7ip71H&amp;search_mode=CombineSearches">9,196</A>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>#3 OR #2 OR #1</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=1985-2012</I>
</P>
<P>
<I>Lemmatization=On   </I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 3</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=12&amp;SID=Q1HLLL2I4mmNe7ip71H&amp;search_mode=GeneralSearch">44</A>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>Topic=((ambulat* NEAR/2 (care or patient* or setting)) NEAR/3 pneumon*)</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=1985-2012</I>
</P>
<P>
<I>Lemmatization=On   </I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 2</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=9&amp;SID=Q1HLLL2I4mmNe7ip71H&amp;search_mode=GeneralSearch">194</A>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>Topic=((outpatient* or "out patient" or "out patients") NEAR/3 pneumon*)</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=1985-2012</I>
</P>
<P>
<I>Lemmatization=On   </I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 1</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=8&amp;SID=Q1HLLL2I4mmNe7ip71H&amp;search_mode=GeneralSearch">9,089</A>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>Topic=(community acquired*) AND Topic=(pneumonia)</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=1985-2012</I>
</P>
<P>
<I>Lemmatization=On   </I>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2012-07-11 12:23:28 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2012-07-11 12:22:06 +1000" MODIFIED_BY="[Empty name]">LILACS (BIREME) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-11 12:23:28 +1000" MODIFIED_BY="[Empty name]">
<P>Search &gt; ("community-acquired pneumonia" OR ((MH:pneumonia OR pneumon$ OR Neumonía OR MH:C08.381.677$ OR MH:C08.730.610$) AND (MH:"Community-Acquired Infections" OR "Community-Acquired Infections" OR<BR/>"Infecciones Comunitarias Adquiridas" OR "Infecções Comunitárias Adquiridas" OR MH:Outpatients OR outpatient$ OR "out patient" OR "out patients" OR "Pacientes Ambulatorios" OR "Pacientes<BR/>Ambulatoriais" OR MH:"Ambulatory Care" OR "ambulatory care" OR "Atención Ambulatoria" OR "Assistência Ambulatorial" OR "Cuidados Ambulatorios" OR "Cuidados de Pacientes Externos" OR "Cuidados<BR/>ambulatoriais"))) AND (MH:"Anti-Bacterial Agents" OR antibiot$ OR antibacteria$ OR MH:macrolides OR Macrólidos OR Macrolídeos OR MH:D02.540.505$ OR MH:"beta-Lactams" OR "beta-Lactamas" OR<BR/>MH:D02.065.589.099$ OR MH:D02.886.108$ OR MH:D04.075.080.875.099.221$ OR MH:Quinolones OR Quinolonas OR Quinolinones OR Ketoquinolines OR Oxoquinolines OR MH:D03.438.810.835$ OR MH:Tetracyclines OR<BR/>tetraciclinas OR tetraciclinas OR MH:D02.455.426.559.847.562.900$ OR MH:D04.615.562.900$ OR "beta-lactam" OR "beta-lactams" OR macrolide$ OR makrolide$ OR quinolone$ OR tetracycline$ OR aciclovir OR<BR/>amikacin OR amoxicillin OR amoxycillin OR ampicillin OR azithromycin OR cefepim OR cefotaxim$ OR ceftarolin OR ceftazidim$ OR ceftibuten OR ceftriaxon$ OR cefuroxim$ OR cethromycin OR ciprofloxacin OR<BR/>clarithromycin OR "clavulanic acid" OR clindamycin OR "co-amoxiclav" OR "co-trimoxacol" OR doxycyclin$ OR ertapenem OR erythromycin OR fluoroquinolon$ OR fluorchinolon$ OR gemifloxacin OR gentamicin<BR/>OR imipenem OR levofloxacin OR linezolide OR meropenem OR moxifloxacin OR penicillin$ OR piperacillin OR roxithromycin OR sultamicillin OR tazobactam OR telithromycin OR tetracyclin$ OR ticarcillin OR<BR/>tobramycin) &gt; clinical_trials</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="AFF_69155329214877133743120328025730_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="69155329214877133743120328025730"><ADDRESS><ORGANISATION>CAPNETZ STIFTUNG</ORGANISATION><CITY>Hannover</CITY><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>